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Cancer is a well-known disease with a significant impact in society not only due to its incidence, 
more evident in more developed countries, but also due to the expenses related to medical treat-
ments. Cancer research is considered an increasingly logical science with great potential for the 
development of new treatment options. Advances in nanomedicine have resulted in rapid devel-
opment of nanomaterials with considerable potential in cancer diagnostics and treatment. The 
combination of diagnosis and treatment in a single nano-platform is named theranostic. In this 
PhD thesis a theranostic system for osteosarcoma was proposed, composed by a magnetic core, a 
polymeric coating, and a chemotherapeutic drug. The presence of a specific targeting agent, in 
this case a monoclonal antibody, provides high specificity to the proposed theranostic system.  
For the core of the proposed theranostic system, stable aqueous suspensions of superparamagnetic 
iron oxide nanoparticles with an average diameter of 9 nm were produced. Chitosan-based poly-
meric nanoparticles with a hydrodynamic diameter around 150 nm were successfully produced. 
Incorporation of iron oxide nanoparticles into the polymeric ones increased their hydrodynamic 
diameter to at least 250 nm. A monoclonal antibody specific for a transmembranar protein (car-
bonic anhydrase IX) present in solid tumors was developed by hybridoma technology. Functional 
hybridomas producing the desired monoclonal antibodies were obtained. 
The proposed theranostic system functionality was evaluated in separated parts of its components. 
Uncoated and coated iron oxide nanoparticles with chitosan-based polymers generated heat under 
the application of an external alternating magnetic field. Uncoated iron oxide nanoparticles sta-
bilized with oleic acid were able to enhance contrast in magnetic resonance imaging. Drug deliv-
ery studies were conducted in chitosan-based polymeric nanoparticles without and with the in-
corporation of iron oxide nanoparticles, demonstrating to be an effective drug delivery platform 
for doxorubicin. 
The theranostic system proposed in this PhD thesis is very promising for cancer theranostic, 
demonstrating to be applicable in solid tumors such as osteosarcoma. 
 























O cancro é uma doença bem conhecida a nível mundial e com um elevado impacto na sociedade, 
não só pela sua elevada incidência mas também devido aos custos médicos que acarreta. Como 
consequência, a investigação científica nesta área é considerada bastante promissora para o 
desenvolvimento de novas opções terapêuticas. Por outro lado, o avanço na nano-medicina tem 
permitido o rápido desenvolvimento de nano-materiais com grande potencial para o diagnóstico 
e tratamento de cancro. A combinação de diagnóstico e tratamento num único nano-dispositivo 
chama-se teragnóstico. Nesta tese de doutoramento foi proposto o desenvolvimento de um 
sistema de teragnóstico para o osteossarcoma composto por um núcleo magnético, um 
revestimento polimérico e um fármaco quimioterapêutico. A presença de um anticorpo 
monoclonal torna o sistema altamente específico. 
Para o núcleo do dispositivo de teragnóstico proposto foram desenvolvidas nanopartículas de 
óxido de ferro superparamagnéticas estáveis em suspensões aquosas, com um diâmetro médio de 
9 nm. Foram também produzidas nanopartículas poliméricas à base de quitosano com um 
diâmetro hidrodinâmico de 150 nm. A incorporação de nanopartículas de óxido de ferro nas 
nanopartículas poliméricas aumentou o diâmetro hidrodinâmico destas últimas para 250 nm. Por 
último, foi produzido um anticorpo monoclonal específico para uma proteína transmembranar 
(anidrase carbónica IX) presente em tumores sólidos usando a tecnologia do hibridoma. Foram 
obtidos hibridomas funcionais capazes de produzir os anticorpos desejados. 
A funcionalidade do dispositivo de teragnóstico proposto foi testada em cada uma das suas partes 
isoladamente. As nanopartículas de óxido de ferro com e sem o revestimento polimérico foram 
capazes de gerar calor sob a aplicação de um campo magnético externo alternado. As mesmas 
nanopartículas de óxido de ferro estabilizadas com ácido oleico melhoraram o contraste da 
ressonância magnética de imagem. Os estudos de libertação de fármaco foram feitos usando 
nanopartículas poliméricas com e sem óxido de ferro, tendo demonstrado a sua eficácia na 
libertação controlada de doxorubicina. 
O sistema de teragnóstico desenvolvido nesta tese de doutoramento é bastante promissor para o 
teragnóstico do cancro, podendo ser aplicado em tumores sólidos como o osteossarcoma. 
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The present chapter introduces the cancer problem around the world and the need for new treat-
ment options. Nanotechnology is presented as a reliable solution for this problem. The thesis’ 
objectives are subsequently presented as a result of nanotechnology development and its applica-
tion in cancer treatment and diagnostic. At the end of this chapter, the outline of the thesis is 
presented, followed by the scientific contributions that resulted from this PhD. 
1.1. Scientific context 
Cancer is a devastating disease of the present days with a huge incidence and related deaths. 
Everyone knows someone that had, have or will have cancer. It is estimated that each year more 
than 11 million new cases of cancer are diagnosed, and more than 7 million people die from this 
devastating disease. If current trends continue, in 2020 new cancer cases will increase to 17 mil-
lion, an increase of 30% compared to 2009.  
In the past 20 years, the total medical costs of cancer have nearly doubled as a direct consequence 
of the increasing number of cancer cases. The dramatic increase in the number of cancer cases is 
because of new cases diagnosed among the aging population base, as well as increasing cancer 
prevalence [1].  
Current cancer treatments, such as radiotherapy and chemotherapy, although effective for some 
cases, did no cover all of them. In addition, cancer treatment is exhaustive and expensive because 
of the multi-therapeutic approaches and constant admissions for treatments and side effects man-
agement. The majority of cancer treatments are not specific for the type of cancer and for the 
patient, and treatment monitoring is not accurate. 
Osteosarcoma is a relatively uncommon malignancy, with an overall incidence of five cases per 
million persons per year. However, among childhood malignancies, osteosarcoma is the eighth 
most common. Only leukemia, lymphomas, and neurological malignancies are more common. 




Osteosarcoma accounts for 8-9% of cancer-related deaths in children and carries an overall 5-
year survival rate of 60–70% [2]. Current chemotherapy regimens comprise a group of chemo-
therapeutic agents in which doxorubicin are included. However, tumor resistance to anthracy-
clines and cardiotoxicity are limiting factors for its usage. Liposomal formulations of doxorubicin 
improve its anti-cancer effects but are still insufficient. 
Consequently, a method that possesses enough versatility to be adapted to the cancer type within 
a group of cancer types but that, when is applied, has a high specificity for cancer cells, dramati-
cally decreasing the side effects, is required. Moreover, if this method allows cancer diagnose and 
treatment monitoring, although may seem ambitious and expensive at a first glance, will become 
economically favorable for the patient and for the medical institution. By reducing the side effects, 
reduces the number of hospital admissions and the costs of side effects management. By increas-
ing treatment effectiveness, reduces the number of treatments required and improves patients’ 
quality of life. 
Nanotechnology is a recent technology with a huge potential for medicine, among other applica-
tions. Properties like increased surface area, optical, electronic, magnetic, and structural proper-
ties at nanometer scale are not available for bulk solids or individual molecules, making these 
materials unique. The development of new materials based on multi-functional magnetic nano-
particles can open a window of opportunity for a new therapeutic approach to osteosarcoma treat-
ment. There is currently significant interest in designing new drug delivery systems with the ob-
jective of achieving targeted drug delivery. 
1.2. Objective 
The main objective of this PhD thesis is to obtain chitosan-based magnetic nanoparticles for os-
teosarcoma treatment (drug delivery and magnetic hyperthermia) and monitoring (contrast agents 
for targeted magnetic resonance imaging). These nanoparticles are composed of a magnetic core 
and a chitosan-based coating that will encapsulate a chemotherapeutic drug. In addition, a highly 
specific monoclonal antibody is attached to the nanoparticle surface conferring specificity to the 
whole system. It is expected that these highly specific nanoparticles promote specifically tumor 
cell death, opening a new therapeutic approach for osteosarcoma treatment and monitoring. The 
therapeutic effectiveness of these nanoparticles is achieved by: specificity for tumor cells due to 
the presence of a monoclonal antibody specific for CA IX, a transmembranar protein present in 
several tumor cells; specific drug delivery, using the produced nanoparticles as a carrier; and 




sensitization or death of tumor cells by magnetic hyperthermia. In addition, the magnetic core 
provides the basis for the treatment monitoring through magnetic resonance imaging. 
To achieve this objective, several tasks were developed: 
1. Production and characterization of superparamagnetic iron oxide nanoparticles with diameters 
in the nanometric range, stable in physiological conditions and able to generate heat by the appli-
cation of an alternating external magnetic field. 
2. Production and characterization of chitosan and O-HTCC nanoparticles with diameters in the 
nanometric range, stable in physiological conditions. Further, both polymers were used to coat 
iron oxide nanoparticles produced in task 1. 
3. Production of a highly specific monoclonal antibody for CA IX (a glycoprotein over expressed 
in osteosarcoma). 
4. Study the suitability of the produced nanoparticles for application in magnetic hyperthermia, 
as a contrast agent for magnetic resonance image, and as a drug delivery system for doxorubicin. 
1.3. Thesis outline 
The following section is an outline of the chapters in this thesis: 
Chapter 1: Motivation – This chapter presents the motivation and the objectives of the present 
PhD thesis. 
Chapter 2: General Introduction – This chapter reviews some of cancer’ bullet points, such as 
current treatments and statistics. A brief insight on osteosarcoma is also given. Finally, nanotech-
nology is presented as an alternative for cancer treatment and diagnosis. 
Chapter 3: Iron oxide nanoparticles – This chapter starts with an introduction to iron oxide 
nanoparticles synthesis, colloidal stability, and properties. The detailed methodology for the pro-
duction and characterization of the studied iron oxide nanoparticles is provided, and the main 
results obtained are presented and discussed. 
Chapter 4: Chitosan-based coating – Chitosan and chitosan’s derivatives properties and appli-
cations are summarized in this chapter. Methods for producing chitosan nanoparticles are re-
viewed and a detailed methodology for the production and characterization of chitosan and O-
HTCC nanoparticles is presented. Moreover, are provided in this chapter the main results and 
discussion of the coated iron oxide nanoparticles with both polymers. 




Chapter 5: Monoclonal antibody production – A summary of state of the art concerning mon-
oclonal antibodies’ properties and their production is provided in the beginning of this chapter, 
that also includes a detailed methodology for production and evaluation of monoclonal antibodies 
anti-CA IX, and the obtained results are presented and discussed. 
Chapter 6: Theranostic part I: Magnetic hyperthermia, MRI, and cytotoxicity – This chapter 
contains a brief overview on magnetic hyperthermia and magnetic resonance imaging, presents 
and discuss the results obtained in both techniques, and the cytotoxic behavior of the produced 
nanoparticles. 
Chapter 7: Theranostic part II: Drug release studies – This chapter is related to doxorubicin 
as a model drug, giving an insight on its usage and drawbacks. Moreover, the potential of chitosan 
as a drug delivery system and the mathematical models used are reviewed. Drug delivery studies 
are presented and discussed, and mathematical models are fitted to the experimental data to eval-
uate the release behavior of the produced nanoparticles. 
Chapter 8: Conclusions and Perspectives – In this final chapter are presented the main conclu-
sions of this PhD thesis and provides new perspectives for future work. 
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The main contributions of this PhD thesis were published in peer-reviewed journals, as book 
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istry, 12 (12): 1239-1249, 2012. 
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 General introduction 
The present chapter gives a brief overview of the cancer problem, illustrating the gaps in its treat-
ment options. Some cancer statistics are shown for better understanding of the global burden of 
cancer. Theranostic systems are a reliable alternative for management of cancer in men. As such, 
the basic structure of a theranostic system is presented and discussed. Finally, the most recent 
applications of both magnetic nanoparticles and chitosan nanoparticles in cancer treatment and 
diagnostic are reviewed. 
2.1. Cancer 
Cancer is a generic term used for a group of more than 100 diseases that can affect any part of the 
body. It is defined as a disease in which a group of abnormal cells grows uncontrollably, disre-
garding the signals that regulate cell cycle of normal cells. In some cases, cancer cells become 
able to invade other tissues, a process referred to as metastasis [1, 2]. 
Cancer can be caused by either genetic factors or environmental factors. Environmental factors 
include not only carcinogens such as tobacco smoke, alcohol, and infectious diseases, but also 
age, diet, excess body weight, among others. Carcinogens are by definition any substance, radio-
nuclide, or radiation that is an agent directly involved in the promotion of cancer or in the facili-
tation of its propagation. These substances have the ability to damage the genome or to disrupt 
cellular metabolic processes after prolonged or excessive exposure [1]. 
On the other hand, cancer can also be caused by the inclusion of mutations in certain genes that 
are responsible for proliferation, maturation, and apoptosis of the cells (tumor suppressor genes 
or oncogenes). A small proportion of many cancers are due to inherited mutations in genes, which 
result in a high risk to the individual of developing specific cancers. However, familiar clustering 
of cancer is relatively common. This is likely to occur due to a combination of environmental 
factors, rare gene mutations with high penetrance, and common lower penetrance gene variants 




acting together to change disease susceptibility. These usually occur at a young age and are fre-
quently aggressive [2, 3]. 
Certain viruses can also cause cancer by persistent mucosal or epithelial cell colonization, which 
leads to chronic inflammation. Hepatitis B and C can cause hepatocellular cancer, human papil-
loma viruses can cause cervical cancer, and the bacterium Helicobacter pylori is responsible for 
gastric cancer. The combined effects of increased inflammation and epithelial cell turnover can 
promote the phenotypic and genotypic changes that may ultimately progress to malignant trans-
formation. In the inflammatory process, some mediators are release, such as cytokines, chemo-
kines and free radicals, which play an important role in carcinogenesis [4]. 
 The hallmarks of cancer 
Although there are several factors that can lead to tumor development, all cancer cells have de-
fects in the regulatory circuits that govern normal cell proliferation and homeostasis. The dereg-
ulation of the production and release of growth-promoting signals, cancer cells become masters 
of their own destinies [5]. Taking the basic teachings of cell biology into account in which all 
mammalian cells carry a similar machinery to regulate their proliferation, differentiation and 
death, Hanahan and Weinberg [5] defined rules that govern the transformation of normal human 
cells into malignant cancers. These six essential alterations in cell physiology are manifested as 
different cancer genotypes, although they are shared in common by most or even all human tu-
mors. The six hallmarks of cancer defined by these authors in 2000 are the following: 
 Self-sufficiency in growth signals: tumor cells are able to stimulate their own growth; 
 Insensitivity to anti-growth signals: the inhibitory signals that normally govern normal cells 
proliferation and homeostasis do not have affect tumor cells; 
 Evasion of programmed cell death (apoptosis): tumor cells are able to evade apoptosis and 
survive; 
 Limitless replicative potential: contrary to normal cells, tumor cells are able to replicate indef-
initely; 
 Sustained angiogenesis: tumors are able to stimulate the growth of blood vessels to supply 
nutrient to their own cells; 
 Tissue invasion and metastasis: tumor cells are able to invade local tissues and spread to distant 
sites. 
The acquisition of each of these hallmarks capabilities explain the evolution of normal cells to 
progressively become tumoral cells. With the combination of these traits, tumor cells are able to 




survive, proliferate, and disseminate. However, a decade of research later led to a change in the 
notion that tumor development was exclusively dependent on the tumor cells. Instead, to a better 
understanding of the biology of tumors, one must consider the contribution of the tumor micro-
environment. Tumors are complex tissues composed of multiple distinct cell types that participate 
in heterotypic interactions with one another [6]. 
 Tumor microenvironment 
In the last decade, the tumor microenvironment was recognized to be of critical importance for 
the understanding of fundamental cancer biology. Nowadays, cancer is known to be composed 
not only by a mass of malignant cells, but also by other cells that are recruited and that can be 
corrupted by the transformed cells. The close interaction between malignant and non-transformed 
cells create the tumor microenvironment [7, 8]. 
The non-malignant component of the tumor microenvironment often has a dynamic and tumor-
promoting function at all stages of cancer development. For example, intracellular communica-
tion is achieved by a complex and dynamic network of cytokines, chemokines, growth factors, 
and inflammatory and matrix remodeling enzymes. The evolution, structure and activities of the 
tumor microenvironment has many similarities with the wound healing and inflammation process 
[8]. In fact it is well demonstrated that human tumors are generally infiltrated by inflammatory 
cells, which demonstrates that the host is not ignorant of the developing tumor; instead, the host 
tries to interfere with tumor progression, a process referred as immune surveillance [9]. 
The tumor microenvironment of a developing tumor is composed of proliferating tumor cells, the 
tumor stroma, blood vessels, infiltrating inflammatory cells and a variety of associated tissue cells 
[9]. The non-malignant cells of the tumor microenvironment can comprise over 50% of the mass 
of primary tumors and their metastasis, although in some cases their biology and function is still 
unclear. However, it is clear that in both hematological cancers and solid tumors there is a Dar-
winian evolution of malignant cells, leading to heterogeneous mutations within single tumors and 
at different sites of metastasis [8]. 
 The next generation of cancer hallmarks 
The above-described hallmarks of cancer are acquired functional capabilities that allow cancer 
cells to survive, proliferate, and disseminate. These functions are acquired in different tumor types 
via distinct mechanisms and at various times during the course of multistep tumorigenesis. The 
acquisition of such characteristics is made possible by two enabling characteristics: 




 Genomic instability and mutation in cancer cells; 
 Inflammatory state of premalignant and frankly malignant lesions. 
In addition, two other attributes of cancer cells have been proposed to be functionally important 
for the development of cancer and were therefore added to the list of core hallmarks: 
 Deregulating cellular energetics; 
 Avoiding immune destruction. 
The first attribute is a consequence of the need to support continuous cell growth and prolifera-
tion, which involves a major reprogramming of cellular energy metabolism. In this case, the met-
abolic program that operates in most normal tissues and fuels the physiological operations of the 
associated cells is replaced. The second attribute is related to an active evasion by cancer cells 
from attack and elimination by immune cells. In both cases, these two attributes may facilitate the 
development and progression of many forms of human cancers [6]. 
The six core hallmarks defined in 2000 provide a solid framework for understanding the complex 
biology of cancer. Nevertheless, the extended concept of cancer hallmarks and the definition of 
the emerging hallmark capabilities and enabling characteristics have provided the basis for the 
development of new means to treat human cancer. The understanding of the tumor microenviron-
ment functionality and importance during tumorigenesis is crucial for the development of new 
and more effective cancer treatments. 
 Current treatments 
There are several treatments available for cancer including surgery, i.e., removal of tumor cells, 
radiotherapy that uses radiation to kill tumor cells, chemotherapy with cytotoxic drugs and bio-
therapy that is usually targeted therapy. 
 Surgery 
The majority of long-term cancer survivors have been treated largely because of the surgical re-
moval of their solid tumor. Even in the disseminated stages of disease, the surgical removal of 
isolated organ metastases may offer a realistic chance for cure, for example, following resection 
of liver or lung metastases in patients with colorectal or other types of cancer [10]. 
The spectrum of cancer surgery ranges from very minor procedures (polypectomy, lumpectomy) 
to ‘mega-operations' such as regional pancreatectomy, pelvic exenterating, or liver transplanta-
tion. The type of surgery performed depends on the biology and natural history of the tumor, the 




expected functional and cosmetic outcome, the skill of the individual surgeon, the efficacy and 
availability of other treatment modalities, the morbidity and mortality of the operation itself, and 
the patient's willingness to accept the associated risk(s) [10]. 
 Radiotherapy 
Radiation therapy (RT) is based upon use of ionizing radiation as part of cancer treatment to 
control malignant cells. Radiotherapy may be used for curative or adjuvant cancer treatment. To-
day, more than 50% of newly diagnosed cancer patients receive radiation therapy, typically as a 
part of curative combined modality treatment with surgery and/or chemotherapy. Additionally, a 
majority of patients who present with metastatic disease or who develop metastases following 
initial cancer treatment require palliative radiation therapy [11]. 
The interaction of ionizing radiation with various types of biologic materials or media (e.g., air, 
soft tissue, bone) is a random process, with frequency and density of energy deposition. As human 
cells and tissues (as well as tumors) are mainly considered dilute aqueous solutions containing 
biomolecules, the localized but randomly distributed energy depositions from ionizing radiation 
can have either direct effects on important biomolecules such as DNA or indirect effects produced 
by intermediate radiation products resulting from interactions with water. This interactions pro-
duce highly reactive species like the hydroxyl radical (•OH) among many other types of free 
radicals produced by ionizing radiation, including DNA free radicals resulting from direct ioni-
zations that cause chemical damage to DNA [11]. 
Radiation side effects can be divided into acute and chronic. Acute radiation sequel such as skin 
desquamation, mucositis, and diarrhea, occur during or immediately following treatment. Such 
side effects are believed to be due to the interruption of repopulation of rapidly proliferating tis-
sues. The type of reaction is dependent on the site irradiated. Chronic reactions, such as, fibrosis, 
fistula, and necrosis, occur months to years following treatment and are due, in part, to damage 
in slowly proliferating tissues. Chronic reactions, like acute ones, are dependent upon the irradi-
ated site; chronic reactions, however, are often permanent. Overall, the risk of a second malig-
nancy following RT is low. The notable exception is osteosarcoma arising in irradiated bones in 
children treated for retinoblastoma, particularly the hereditary type [12]. 
 Chemotherapy 
Chemotherapy uses chemical drugs to destroy cancer cells, keep them from growing, and spread-
ing, shrink the size of a tumor or relieve cancer symptoms. Cancer chemotherapy has mainly been 
used in the management of advanced or metastatic disease, following failed local therapies, or in 




disease for which no alternative therapy is effective [13]. In the majority of patients with cancer, 
chemotherapy will be considered for use at some time during the course of their illness, either 
aiming at cure, prolongation of life, and/or palliation [10]. 
Chemotherapy is curative for several advanced human cancers, such as gestational trophoblastic 
disease, certain hematologic malignancies, or germ cell testicular cancer. However, most common 
solid tumors are not curable with current chemotherapeutic regimens when metastatic [13]. 
Chemotherapy can be used as a primary therapy or as adjuvant. Induction chemotherapy denotes 
its use as primary therapy when there is no alternative treatment available or subsequently suitable 
even with tumor response, such as in hematologic malignancies, where disease is systemic. On 
the other hand, chemotherapy as an adjunct in combined modality therapy is applied after the 
tumor has been controlled by an alternative modality, such as surgery and/or radiotherapy, or 
neoadjuvant (primary) chemotherapy [13]. 
Conventional chemotherapy, although directed toward certain macromolecules or enzymes, typ-
ically does not discriminate effectively between rapidly dividing normal cells and tumor cells, 
thus leading to several toxic side effects. Important common side effects include (dependent on 
the agent): nausea and vomiting, hair loss, immunosuppression and mielossupression, among oth-
ers. Tumor responses from cytotoxic chemotherapy are usual partial, brief, and unpredictable 
[14]. Recently, chemotherapy has been combined with targeted therapies that interfere with mo-
lecular targets that have a role in tumor growth or progression. 
 Cancer statistics 
Cancer is a leading cause of death worldwide in both more and less developed countries. The 
most concerning part is that the burden is expected to grow worldwide due to the growth and 
aging of the population, mainly in less developed countries, which accounts for around 82% of 
the world’s population. Changes in the lifestyle behaviors such as smoking, poor diet, physical 
inactivity, and reproductive changes have further increased the cancer burden in less economi-
cally developed countries. GLOBOCAN 2012 worldwide estimates cancer incidence and mortal-
ity using data produced by the International Agency for Research on Cancer (IARC) for 2012. 
According to this, an estimated 14.1 million of new cancer cases and 8.2 million cancer deaths 
occurred in 2012 worldwide. The most frequently diagnosed cancers and the leading causes of 
death in men and women are lung and breast, respectively, in less developed countries. In more 
developed countries, the number of prostate cancers in men is superior than lung ones, thus being 
the leading cause of death in men. The most frequent cancers in more developed countries are 




prostate, colorectal, female breast, and lung cancer. On the other hand, in less developed countries 
the most frequently diagnosed cancers are liver, stomach, and cervical cancers, which are pre-
dominantly attributed to infection, which accounts for 77%, 75%, and 100% of cases worldwide, 
respectively. Although the majority of the world’s population is in less developed countries, only 
57% of cases and 65% of cancer deaths worldwide occur in these countries. The main reasons for 
this is the younger age structure, immaturity of the tobacco epidemic, and competing causes of 
death, such as infection. However, changes in lifestyle behaviors in less developed countries will 
continue to shift the global cancer burden [15]. 
Breast cancer is the most frequent diagnosed cancer and the leading cause of death in women 
worldwide, with an estimated 1.7 million cases and 521,900 deaths in 2012. Breast cancer alone 
causes 15% of cancer deaths in women. The main risk factors for breast cancer are reproductive 
and hormonal factors such as a long menstrual history, recent use of oral contraceptives, and never 
having children, among others. Potentially modifiable risk factors include overweight, physical 
inactivity, use of menopausal hormone therapy (combined estrogen and progestin), and alcohol 
consumption [15, 16].  
Prostate cancer is the second most frequently diagnosed cancer in men worldwide, with estimated 
1.1 million new cases in 2012. It is the most frequently diagnosed cancer among men in more 
developed countries, and is the fifth leading cause of death worldwide. Death rates due to prostate 
cancer have been decreasing in more developed countries mainly due to improved treatment 
and/or early detection. On the other hand, death rates have been increasing in less developed 
countries, mostly due to associated risk factors such as consumption of animal fat, obesity, and 
physical inactivity [15, 17]. 
Lung cancer was the most frequently diagnosed and the leading cause of death in men in 2012, 
accounting for an estimated 1.8 million new lung cancer cases, about 13% of total cancer diagno-
ses. Lung cancer is the leading cause of death in women in more developed countries, and the 
secondary cause of death in less developed countries. The risk factors for lung cancer include 
exposition to air pollution, exposure to occupational and environmental carcinogens such as as-
bestos, arsenic, radon, and polycyclic aromatic hydrocarbons, and outdoor pollution [15, 18]. 
Lung cancer is one of the most prevalent cancers, and most of them can be avoided by eliminating 
smoking initiation and increasing smoking cessation among current smokers [15]. 
Colorectal cancer is the third most commonly diagnosed cancer in men and the second in women, 
with an estimated 1.4 million cases and 693,900 deaths occurring in 2012. The decrease of inci-
dence in more developed countries such as the United States in the last five decades is related to 
increase in screening and removal of precancerous adenomas. Moreover, increase incidence in 




several Asian and Eastern European countries may reflect an increased prevalence of risk factors 
for colorectal cancer such as unhealthy diet, obesity, and smoking [15, 19, 20]. Preventive meas-
urements for colorectal cancer include maintaining a healthy body weight, being physically ac-
tive, minimizing consumption of red and processed meat and alcohol, and avoidance of smoking 
[21, 22]. 
 Cancer statistics in Portugal 
According to GLOBOCAN, an estimated 49,000 new cases of cancer in Portugal occurred in 
2012. Moreover, around 24,100 cancer deaths occurred in 2012, for both sexes. The main causes 
of cancer deaths include colorectal, prostate, and breast cancers (Figure 2.1). Similarly, to more 
developed countries, prostate, colorectal and lung cancer are the most frequently diagnosed can-
cers in men in Portugal, in 2012. In women, the most diagnosed cancer in 2012 was breast, colo-
rectal and corpus uteri cancers [23]. 
 
Figure 2.1. Estimated number of new cases (incidence) and deaths (mortality) of cancer for both sexes in 
Portugal in 2012 (adapted from [23]). 
 Osteosarcoma 
Osteosarcoma is the most common primary malignant bone tumor and has a high incidence in 
children and adolescents, since it accounts for approximately 60% of primary malignant bone 
tumors diagnosed in the first two decades of life. It is characterized by an extremely aggressive 




clinical route with rapid development of metastases in 40-50% of patients, occurring mainly in 
lung [24, 25]. Conventional therapies for osteosarcoma include surgery (frequently amputation), 
chemotherapy and radiotherapy [12]. Current neoadjuvant chemotherapy protocols for high-grade 
osteosarcoma are based on doxorubicin (DOX), high-dose methotrexate (MTX), and cis-dichloro-
diamine platinum (CDDP), with the addition of ifosfamide in the post-operative phase, increasing 
the 5-year disease free survival rate to 70%, in patients without metastasis [25]. However, current 
treatments for osteosarcoma have not resulted in improved prognosis during the last decade 
providing incentive for the development of new treatment options [26]. 
The major cause of failure of chemotherapeutic regimens is multidrug resistance (MDR). MDR 
has been correlated with multi-factorial processes such as: enhanced detoxification of the drugs 
through increased metabolism; decreased drug uptake; a reaction with increased levels of intra-
cellular nucleophiles; enhanced repair of the drug-induced damage to DNA; or through overex-
pression of membrane-bound drug transporter proteins, such as P-glycoprotein (Pgp, ABCB1), 
multidrug resistance-associated proteins (MRP1, ABCC1 and MRP2, ABCC2) and the breast 
cancer resistance protein (BCRP, ABCG2) [24, 27]. 
Solid tumors such as osteosarcoma, breast cancer, and prostate cancer, among others, consist of 
a heterogeneous population of cells that differ in their relative states of differentiation [28]. Dur-
ing the last years, the cancer stem cells (CSC) theory emerged as a model to account for the 
heterogeneity and renewal capacity of tumor cells. The CSC theory postulates that the greater part 
of a tumor mass contains more differentiated cells that are susceptible to radiation and chemo-
therapy because of their close vicinity to non-tumorigenic tissues and sufficient blood flow due 
to induced angiogenesis, or blood vessel growth [28]. In contrast, a small subset of cells with 
stem-like properties that is responsible for initiating and sustaining tumor growth were termed 
cancer stem cells because of the properties they share with normal stem cells, including their 
ability to self-renew and undergo differentiation [29]. Similar to the normal tissue stem cells, in 
some tumors, the CSCs are believed to reside in less oxygenated areas in a quiescent state. In fact, 
CSCs have several features that make them naturally resistant to conventional therapies. Most of 
the drugs used in cancer treatment target DNA and induce irreversible damage leading to cell 
death. CSCs seem to have enhanced DNA repair mechanisms allowing them to resist do damage 
induced by conventional therapies [30]. The multidrug resistance trait of CSCs is associated with 
an overexpression of proteins from the BCL-2 family, which protects CSCs from apoptosis and 
leads to an increase in expression of membrane proteins responsible for drug resistance [31]. In 
addition, an increased expression of transporting proteins such as MDR1 and ABC transporters 
is an important factor in chemotherapy resistance [32]. 




Recent studies have successfully identified the presence of CSCs in osteosarcoma. Gibbs et al. 
[33] have successfully isolated the CSCs subpopulation from nine established cultures from un-
treated osteosarcoma biopsies and an osteosarcoma cell line (MG 63) through sphere formation 
assay. Sarcospheres-derived cells expressed the MSC surface markers Stro-1, CD105 and CD44 
and over-expressed embryonic stem cells pluripotency markers (OCT4 and Nanog). Wang et al. 
[34] observed similar results in four more human osteosarcoma cell lines. Murase et al. [35] also 
reported the existence of a subset of CSCs in human osteosarcoma cell lines identified through 
the extrusion of Hoechst 33324. These cells revealed higher tumorigenic potential in vivo and in 
vitro. These findings strongly suggest that osteosarcoma is enriched in cells with stem-like prop-
erties, and that these cells may be responsible for drug resistance. 
The high incidence of MDR in osteosarcoma and the difficulties in its treatment suggest the need 
for new treatment options. 
2.2. The basis of a theranostic system 
The latest advances in cancer nanotechnology aims at the design and engineering of targeted con-
trast agents that improve the resolution of cancer cells to the single cell level, and nano-devices 
that are capable of addressing the biological and evolutionary diversity of the multiple cancer 
cells that make up a tumor within an individual [36]. 
NP development is highly focused on the development of both therapeutic and diagnostic agents. 
Ideally, these two approaches should be combined in a single nano-agent, because of its potential 
ability to simultaneously image and treat disease at the cellular level. The term theranostics is 
used to define ongoing efforts to develop more specific, individualized therapies for various dis-
eases and to combine diagnostic and therapy capabilities into a single agent. These nanostructures 
may present differences in size, shape, functionality, targeting mechanism, and imaging modality; 
however, some components are common between them (Figure 2.2):  
 Detection component for noninvasive imaging: can be metallic or magnetic compounds for 
MRI, fluorescent compounds for optical imaging, and radioisotopes for positron emission to-
mography (PET) and single-photon emission computed tomography (SPECT). 
 Polymer coating: this component is essential for colloidal stability and to provide functional 
groups for bioconjugation. 




 Drug loading capabilities: this may be achieved by physical encapsulation in the polymeric 
matrix and electrostatic interaction with the other components of the nanostructure or by co-
valent biding.  
The rationale for theranostics arose from the fact that diseases, such as cancer, are very heteroge-
neous and the existing treatments are effective only in a small part of the patient population and 
at selective stages of disease development. The theranostic approach is expected to provide ther-
apeutic protocols that are more specific to individuals and, therefore, more likely to improve 
prognostics [37]. This integration of diagnostic imaging capabilities with therapeutic intervention 
is crucial to overcome cancer challenges. 
 
Figure 2.2. Basic components of a theranostic nanostructure. 
Recent advances on cancer research have shown a huge heterogeneity among the different type, 
between the primary tumor and its metastasis foci, and even differences between cells that con-
stitute individual tumors [38]. That said cancer has become one of the major applications of 
theranostic nanostructures. 
Due to the exciting potential of these theranostic nanostructures, many researchers have focused 
on this issue. Theranostic nanostructures can be roughly divided by their detection and therapeutic 
component (Figure 2.2). 
 Detection Component 
The detection component through molecular imaging allows the characterization of biological 
processes at cellular and subcellular level, without any damage to the living tissues. As so, by 
selecting a specific probe or a contrast agent, it is possible to create a powerful tool to both detect 




and characterize early stage disease and monitor the treatment progress. There are vast possibili-
ties for the detection component; however, two materials are the most used in theranostic 
nanostructures: iron oxide NPs and quantum dots. 
 Iron oxide NPs 
Iron oxide NPs have been used clinically as MRI contrast agents mainly in the liver (e.g., Reso-
vist, Feridex), due to the high magnetic moments that make them efficient in reduction T2 relax-
ation time, leading to signal attenuation on a T2 or T2*-weighted map. 
The idea of using magnetic micro- or nanoparticles as drug carriers for cancer treatment dates 
back to the late 1970s [39], when magnetic micro- and nanoparticles attached to cytotoxic drugs 
were developed. Since then, several authors tried to improve this technique. For example, some 
authors have proposed nanocomposites based on the inclusion of magnetite nanocrystals into NPs 
constructed by self-assembling molecules of squalenoyl gemcitabine (SQgem) bioconjugate. 
These nanocomposites, after subcutaneous injection on mice tumor model, were magnetically 
guided to the target site showing high anticancer activity. The superior therapeutic activity and 
enhanced tumor accumulation were successfully visualized using T2-weighted imaging in MRI. 
This method was further actualized by the design of squalene-based NPs containing the T1 Gd3+ 
contrast agent instead of magnetite and by using different chemotherapeutic drugs such as DOX, 
cisplatin, and paclitaxel. 
The use of MRI contrast agents has another advantage, treatment monitoring. By using oleic acid–
coated iron oxide and pluronic-stabilized magnetic NPs loaded with DOX and paclitaxel, highly 
synergetic anti-proliferative activity in breast cancer cells was demonstrated [40], the NP accu-
mulation and time of circulation in blood being monitored by MRI. Thus, that work showed that 
the incorporation of cytotoxic agents in magnetic NPs does not affect its physical (size and sur-
face) properties or magnetization characteristics. 
 Quantum dots 
Quantum dots are nanostructures with favorable characteristics for theranostic applications as a 
detector component, to identify disease via targeting ligands. However, their innate toxicity limits 
the applications in biomedical field [41, 42]. To overcome quantum-dot toxicity, hydrophobic 
quantum dots and iron oxide NPs were co-encapsulated along with DOX, into micelles formed 
with PEGylated phospholipid [43]. The conjugates were further coupled to a tumor-homing pep-
tide F3 and injected into an MDA-MB-435 xenograft model. The results showed successful tumor 
targeting by both optical and MRI modalities. 




The use of quantum dots in biomedical applications is very promising owing to their unique phys-
icochemical properties such as broad absorption spectra, size-dependent narrow and stable emis-
sion spectra, and photostability. However, the inherent toxicity is a large limitation of their appli-
cation. Moreover, there is a need to understand the quantum dot faith once they enter the body 
[41]. 
 Coating Component 
As seen by the given examples, the diagnostic component must be coated with a biocompatible 
material in order to be used as a theranostic agent. In the case of iron oxide NPs, these are gener-
ally coated with a biocompatible material (e.g., polysaccharide, synthetic polymer, lipid protein), 
creating a composite morphology often referred as core-shell structure. An ideal coating bio-
material for iron oxide NPs is the one that satisfies the following requirements [44]: 
 Prevent opsonization and, consequently, increase the blood half-life of the iron oxide NPs in 
circulation; 
 Avoid agglomeration of the NPs in physiological conditions; 
 Achieve the desired surface charge for NPs’ function; 
 Preserve the functionalities of the NPs; 
 Ensure the biocompatibility of the iron oxide NPs; 
 Serve as a platform for NPs’ surface functionality. 
Several organic and inorganic coatings that meet these requirements have been used on the iron 
oxide NP surface. One example of a polysaccharide-based coating is given by chitosan. Chitosan 
is the N-deacetylated product of chitin, the second most abundant polysaccharide in nature, and 
possesses favorable characteristics: nontoxicity, biocompatibility, biodegradability, cationic, and 
hydrophilic. In addition, chitosan possesses amine and hydroxyl groups, suitable for NP function-
alization with targeting, imaging, and therapeutic agents. 
On the other hand, if the polymeric component is composed of a “smart” polymer, the theranostic 
nanostructure will only become activated when an external stimulus (temperature, pH, redox po-
tential, or specific biomolecules) is present. For example, a theranostic nanostructure for a spe-
cific solid tumor composed by a polymer sensitive to a pH variation is capable of only releasing 
the therapeutic drug in the tumor microenvironment, which is characteristically more acidic than 
physiological conditions. This pH variation will induce changes in physical conformation (swell-
ing or deswelling) of the polymeric coating, leading to drug release [45]. 




Liposomes are also used as coating, with promising results as a part of a theranostic agent. Lipo-
somes are very versatile structures because of its capacity to incorporate pharmaceutical drugs, 
water-soluble macromolecules (hydrophilic), or lipid macromolecules (hydrophobic). Conse-
quently, liposomes are a promising approach as theranostic agents [46]. Liposome application as 
theranostic agents was achieved by combining delivery and MRI of DOX-loaded liposomes in a 
Kaposi’s sarcoma in vivo [47]. MRI was used both to determine liposome tissue distribution and 
to monitor DOX delivery and release. The results showed that Cd3 (high-affinity neural cell ad-
hesion molecule [NCAM] binding ligand)-coated liposomes loaded with both DOX and gadolin-
ium-DOTAMA(C18) were internalized and induced apoptosis of Kaposi’s cells and tumor endo-
thelial cells significantly more efficiently than did with uncoated PEG liposomes. In addition, the 
incorporation of DOX in PEG-coated liposomes reduced its cardiotoxicity while increasing its 
therapeutic efficacy. Furthermore, the use of gadolinium-labeled liposomes allowed the concom-
itant MRI visualization of the drug delivery in the tumor region. 
Similarly, to liposomes, dendrimers are versatile structures capable of acting as drug and imaging 
agents with applications in tumor regression, gene delivery, and molecular imaging. However, 
their toxicity is a current barrier to its usage in this field [48]. To overcome this, several research-
ers have focused on chemical modification of dendrimers. For example, new dendrimer was de-
signed and synthesized as based building block that is water soluble and can be functionalized in 
a highly controllable and orthogonal fashion [49]. This dendrimer was functionalized with an 
NIR-cyanine dye. The results showed fluorescence in the NIR region with a large Stokes shift 
and relatively high quantum yields. In addition, dendrimers showed no toxicity toward T98G 
human cells being promising agents for theranostic applications. 
 Target Component 
After the detection component and coating of the theranostic nanostructure, another important 
issue is the target component. Although passive targeting is possible due to the NPs’ small di-
mensions, it is not suitable for all diseases. As so, specific targeting is generally required. The 
specific targeting may be achieved using numerous biomarkers, specifically overexpressed by the 
target cells. Monoclonal antibodies were the first targeting agents to exploit molecular recognition 
to deliver magnetic NPs [50]. Magnetic nanocrystals conjugated to Herceptin were used as can-
cer-targeting monoclonal antibody for breast cancer treatment and successfully monitored in vivo 
selective targeting events of human cancer cells implanted in live mice [51].  
Depending on NP characteristic, all types of NPs previously described may be applied for 
theranostics as a component of the theranostic nanostructure. Concerning this matter, iron oxide 




NPs are among the most used NPs as theranostic agents. As such, iron oxide NPs may have two 
main functions: MRI contrast agents and hyperthermia agents. 
2.3. Theranostic systems: state of the art 
The proposed theranostic system is composed of magnetic nanoparticles with a polymeric coating 
based on chitosan. Iron oxide nanoparticles were chosen as the magnetic core of this theranostic 
system. In this section, the most recent developments for cancer treatment and/or diagnostic using 
both magnetic nanoparticles, especially iron oxide ones, and chitosan-based systems are re-
viewed. 
 Magnetic nanoparticles 
Iron oxide NPs may form ideal platform for imaging of biological materials. Their mode of action 
is noninvasive and can be controlled remotely for drug release and cell signaling in the therapeutic 
field. Their superior magnetic properties allow for targeted imaging of specific receptors in dis-
ease processes and for monitoring treatment efficiency. The development of theranostic agents 
based on iron oxide NPs is a relatively recent approach but very promising application of these 
NPs. If by one hand is too early to predict its success the interest in this field has led to a larger 
investment in this technology, expecting consistent results soon. 
Cell labeling/cell separation, magnetofection to facilitate drug delivery, as contrast agents for 
MRI or as drug delivery agents [39, 40, 52-55] are some of the possible applications of magnetic 
NPs, in particularly iron oxide nanoparticles have already been employed in clinical practice as 
MRI agents (e.g. Feridex®) and as magnetic hyperthermia agents (NanoTherm®). NanoTherm® is 
still in clinical trials for three types of tumors: glioblastoma multiform, prostate carcinoma [56-
58] and pancreatic carcinoma [59]. 
The use of magnetic NPs as drug delivery agents for chemotherapeutic drugs is possible and 
promising. However, the major problems of chemotherapeutic drugs are their non-specificity and 
cell resistance; but with a drug carrier it is possible to overcome these problems [60]. For that, 
size, charge and surface chemistry of the magnetic NPs are crucial because they affect the time 
of circulation on the blood and the bioavailability of magnetic NPs [52]. Akiyoshi et al. [61] 
produced cholesterol-bearing pullulan hydrogel nanoparticles incorporated with doxorubicin 
(DOX) and, despite the loading levels were very low, encapsulated DOX-mediated cytotoxicity 




was lower than with free DOX. Other authors associated DOX to polyalkylcyanoacrylate nano-
particles demonstrating reduced cardio toxicity after intravenous administration in mice [62] and 
increased cytotoxicity against multidrug resistance cell lines in vitro [63]. Janes et al. [64] demon-
strated the viability of using chitosan nanoparticles as colloidal carriers to DOX delivery, incor-
porated with dextran sulfate. These particles have demonstrated a minimal burst release and the 
cytotoxic activity of DOX in vitro was retained. Sun et al. [65] developed iron oxide nanoparticles 
conjugated with chlorotoxin, a specific target for glioma and medulloblastoma cells, which are 
capable of delivering methotrexate to the tumor cells. They obtained improved specificity, ex-
tended particle retention and increased cytotoxicity in tumor cells. In order to improve these meth-
ods some authors used tumor-targeted magnetic NPs, e.g., DeNardo et al. [66] used dextran-
coated magnetic nanoparticles conjugated to breast cancer targeting chimeric L6 monoclonal an-
tibody and demonstrated its specificity in targeting cancer cells. 
Another application of magnetic NPs is MRI, which is a powerful imaging tool due to its non-
invasive nature, high spatial resolution, and tomographic capabilities [67]. The use of superpara-
magnetic iron oxide nanoparticles provides a better differentiation between healthy and patholog-
ical tissues and specifically allows for cancer cell targeting [68]. For example, some authors have 
used magnetic NPs to detect apoptosis, an active process of cellular self-destruction present in 
many disorders, such as neurodegenerative diseases (e.g. Alzheimer, Parkinson), by MRI [69-
71].  
The use of nanotechnology in biomedicine, particularly in cancer treatment, is becoming a real 
treatment option as more investigation is made in this area. Nanoparticles potential has been ex-
plored in several areas showing its advantages as adjuvant agents for chemo- and radiotherapy; 
moreover, magnetic NPs are already used as contrast agents for cancer detection, diagnosis, and 
treatment monitoring. 
 Polymeric nanoparticles 
Park et al. [72] surveyed the use of chitosan in the area of targeted delivery of low molecular 
weight drugs, a category of major importance in therapeutics. This review is divided in two sec-
tions: the first related to organ-specific delivery and the subsequent one with recent developments 
of drug delivery carriers for cancer therapy. In colon, targeting the issue was how to protect the 
drug/chitosan combination as it transited the stomach and upper gastrointestinal tract to arrive the 
colon. Several strategies include coating, microspheres, and polyanionic micelles. Other target 
sites mentioned included the liver, kidney, and lung. In the second part of the review, the drug 




delivery of cancer drugs using chitosan was presented. Passive targeting adopting the EPR (en-
hanced permeation and retention) effect included methods such as cross-linking of chitosan and 
polyelectrolyte complexes. Active targeting with receptor-mediated endocytosis and physical 
methods such as the use of chitosan-based stimuli-sensitive formulations and magnetic particles 
were explained. 
Akbuğa et al. [73] prepared cisplatin loaded chitosan microspheres using a w/o emulsion system 
with an efficiency of about 30%. Pharmacokinetics, targeting, embolization effects, and alteration 
of liver function using cisplatin chitosan microspheres were evaluated after hepatic arterial em-
bolization in dogs. A remarkable decrease in the number of arterioles in liver, necrosis of nodules 
and hepatic cell degeneration in the embolized region was found. Wei et al. [74] encapsulated 
paclitaxel in salicylic acid-graft chitosan oligosaccharide nanoparticle. 
Chitosan structures have been used for the delivery of proteins/peptides, antibiotics, anti-inflam-
matory drugs and vaccines, among other molecules [75]. 
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 Iron oxide nanoparticles 
This chapter starts with the most important concepts related to iron oxide nanoparticles, their 
magnetic properties, synthesis, colloidal stability, and toxicity. The used methodology for the 
production of iron oxide nanoparticles as well as the detailed characterization are further de-
scribed and discussed in this chapter. At the end of this chapter, the produced iron oxide nanopar-
ticles are suitable to compose the core of the theranostic system developed during this PhD thesis. 
3.1. Introduction 
In a general approach, nanostructures have at least one dimension in a range of 1–100 nm and can 
be classified according to their dimension. Further, these nanostructures exhibit new or enhanced 
size-dependent properties compared with larger particles of the same material. Some regulatory 
agencies have tried to standard the definitions of nanoparticle (NP). The first published standard 
to provide this definition was given by an International Organization of Standardization (ISO) 
standard, ISO/TS 27687:2008 “Nanotechnologies - Terminology and definitions for nano-objects 
- nanoparticle, nanofiber and nanoplate” [1]. According to this standard, a NP is defined as a 
“nano-object with all three dimensions in the nanoscale” being the nanoscale a “size range from 
approximately 1 nm to 100 nm.” Two notes accompany this nanoscale definition: “Properties that 
are not extrapolations from a larger size will typically, but not exclusively, be exhibited in this 
size range. For such properties the size limits are considered approximate” and “The lower limit 
in this definition (approximately 1 nm) is introduced to avoid single and small groups of atoms 
from being designated as nano-objects or elements of nanostructures, which might be implied by 
the absence of a lower limit.” 




 Magnetic nanoparticles 
Within the last decades, magnetic NPs have been extensively investigated for biomedical appli-
cations (Figure 3.1). These applications include magnetic resonance image (MRI) contrast agents 
for diagnosis [2] and magnetic hyperthermia agents for cancer treatment [3, 4]. In general, all 
materials respond to applied magnetic fields. However, those that have a strong response to mag-
netic fields are called magnetic. Magnetic nanoparticles are a class of nanoparticles that can be 
manipulated using a magnetic field. These NPs possess unique physical properties and ability to 
function at cellular and molecular level of biological interactions [2]. 
 
Figure 3.1. Evolution in the number of scientific papers published related to magnetic nanoparticles, iron 
oxide nanoparticles and magnetite nanoparticles. (Source: ISI Web of Knowledge © the Thompson Corpo-
ration. Search terms: ‘magnetic nanoparticles’, ‘iron oxide nanoparticles’, and ‘magnetite nanoparticles’. 
Date of search: June 2015). 
Magnetic NPs are generally composed of pure metals, metal alloys or metal oxides [5]. Metallic 
NPs have larger magnetization compared to metal oxides but they are not stable in air and are 
easily oxidized. Metal NPs may be composed of iron, cobalt, or nickel, and due to their instability 
are typically protected by coating such as gold or silica, forming a core-shell structure. Despite 
the difficulty in synthetize these types of magnetic NPs, research continues due to the unique 
advantages some of these NPs can offer. For example, iron NPs have a high magnetic moment 
density and are able to maintain their superparamagnetism at larger particle sizes, when compared 
to their oxides [2, 5]. Metal alloy NPs or bimetallic NPs are usually composed of one metallic 




material and platinum or of two metallic materials. These nanoparticles can also exhibit super-
paramagnetic behavior and have shown extremely high saturation magnetization values [2, 6]. 
 Iron oxide nanoparticles 
Iron oxides are compounds available in nature and easily synthetize in laboratory. Iron oxide NPs 
are superior to other metal oxide NPs for their biocompatibility and stability and are the most 
commonly employed magnetic NPs for biomedical applications [7]. From all the iron oxides, 
Fe3O4 (magnetite) has the most interesting magnetic properties due to the presence of iron cations 
in two valence states, Fe2+ and Fe3+ [5]. In the bulk form, this material is ferromagnetic due to the 
antiferromagnetic coupling among Fe (III) in its inverse spinel structure. However, at nanoscale 
(< 20 nm), iron oxide NPs are superparamagnetic at room temperature, that is, when the size of 
the particle is reduced enough, magnetite NPs become a single magnetic dipole and therefore 
maintain one large magnetic moment. Consequently, these NPs are easily magnetized under the 
application of an external magnetic field and unmagnetized once the field is removed. Another 
interesting property of iron oxide NPs is their ability to generate heat when subjected to an alter-
nating magnetic field (AMF). This thermal phenomenon may be due to energy losses during the 
demagnetization process (specific loss power). This property is crucial for hyperthermia applica-
tions [2, 8, 9]. 
The need to improve magnetic properties of these materials has generated the development of 
metal-doped iron oxides. These materials with a composition of MFe2O4, where M may be Mn, 
Fe, Co or Ni, have a remarkably similar spinel structure to magnetite [2, 10]. 
 Magnetic properties 
Macroscopic objects possess a large number of atoms (> 1023 particles) and therefore their mag-
netic properties should be calculated using methods of solid-state physics. On the other hand, 
nanoparticles are composed of several hundred up to ≈ 105 atoms and consequently their magnetic 
properties can be determined by methods common to quantum chemistry and solid state physics 
[5]. 
The magnetic effects are caused by particles with both mass and electric charges such as electrons, 
holes, protons, positive and negative ions. The spinning of an electric-charged particle causes a 
magnetic dipole – a magneton. A ferromagnetic material is composed of magnetic domains, i.e., 
a magnetic domain is a portion of the ferromagnetic material in which all magnetic dipoles are 




aligned in the same direction by the exchange forces [11]. Bulk ferromagnetic materials are com-
posed of thousands of magnetic domains separated by boundaries called domain walls, forming 
the so-called grains. This domain wall is a defect in the material that takes energy to form, and 
have significant width, generally in the tens to hundreds of nanometers. In these cases the reversal 
of the magnetization is controlled by the nucleation and motion of domain walls through the ma-
terial [12]. When the size of the particles is reduced, the state of lowest energy has uniform mag-
netization and the particle is composed of a single domain. The critical size of the single domain 
is affected by several factors, such as the value of the saturation magnetization (Ms), the strength 
of the crystal anisotropy and exchange forces, the surface or domain-wall energy, and the shape 
of the particles [11]. 
 
Figure 3.2. Schematic representation of hysteresis loops (magnetization versus applied magnetic field) for 
ferromagnetic, superparamagnetic, diamagnetic, and paramagnetic nanoparticles. (Hc – Coercivity; Mr – 
Remanent magnetization; Ms – Saturation magnetization) (Adapted from [12, 13]). 
The properties of magnetic materials are classified according to the magnetic susceptibility (χ), 
which is defined by the ratio of the induced magnetization (M) to the applied magnetic field (H) 
[2, 14]. This ratio is well described by a hysteresis loop (Figure 3.2), which is characterized by 
two main parameters: remanence (Mr) and coercivity (Hc). The remanence or remanent magneti-
zation is the magnetization that remains after an applied field has been removed. The coercivity 
or coercive field is related to the ‘thickness’ of the curve and is the applied magnetic field required 




for reduction of a saturated magnetic material to zero magnetization. The coercivity has been 
found to be size-dependent for small particles, i.e., as the size of the particle is reduced, the coer-
civity increases to a maximum and then decreases toward zero (Figure 3.3) [11, 12]. 
 
Figure 3.3. Schematic illustration of the relationship between coercivity, nanoparticles size, and magnetic 
domain structures. The blue and red arrows represent the magnetic dipoles (adapted from [11]). 
When the size of single domain particles decreases and the coercivity becomes zero such particles 
become superparamagnetic. Superparamagnetic NPs have such strong thermal fluctuations to de-
magnetize a previously saturated assembly, i.e., these NPs become magnetic when an external 
magnetic field is applied; however, they are able to revert to a nonmagnetic state once the applied 
magnetic field is removed. Therefore, superparamagnetic nanoparticles have zero coercivity and 
no hysteresis [11]. The transition temperature in which the NPs become superparamagnetic is 






Where K is the magnetic anisotropy constant, kB is the Boltzmann constant, and V is the volume 
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Where M is the magnetization, MS is the saturation magnetization and α is the ratio of magnetic 




 Equation 3.3 
Where H is the magnetic field, m is the magnetic moment, µ0 is the permeability of free space, kB 
is the Boltzmann constant, and T is the absolute temperature. At very low magnetic fields, α << 
1 and the Langevin equation becomes 𝑀/𝑀𝑆 = (𝜇0𝑚𝐻)/(𝑘𝐵𝑇) where the relationship between 
the magnetization and the magnetic field is linear. With the increase of the magnetic field, mag-
netic saturation occurs due to the very high magnetic moment of the magnetic nanoparticles (α 
>> 1) [15].  
Magnetic materials may be classified according the type of response to an applied magnetic field. 
All materials exhibit diamagnetism, a very weak repulsion to an applied magnetic field. These 
materials have negative susceptibility (χ < 0) because the current loops created by the orbital 
motion of electrons respond to oppose the applied magnetic field. The effects of these atomic 
current loops are overcome if the material displays a net magnetic moment or has a long-range 
ordering of its magnetic moments. The other types of magnetic behaviors occur in materials that 
have at least partially unpaired electrons in their atomic shells, often in the 3d or 4f shells of each 
atom [11]. 
Paramagnetic materials possess atomic uncoupled magnetic moments and consequently their 
magnetic moments have no long-range order and are permanent. Therefore these materials have 
a small positive magnetic susceptibility (χ ≈ 0) [11]. Ferromagnetism occurs in particles whose 
unpaired electron spins align themselves spontaneously and subsequently the material can exhibit 
magnetization in the absence of an applied magnetic field [11, 16]. Similarly, antiferromagnetism 
occurs in materials with atomic magnetic moments of equal magnitude but arranged in an anti-
parallel fashion. Above the Néel temperature (temperature above which an antiferromagnetic ma-
terial becomes paramagnetic), thermal energy is sufficient to cause the equal and oppositely 
aligned atomic moments to randomly fluctuate, leading to a disappearance of their long-range 
order, becoming a paramagnetic material [11, 12]. 
Ferrimagnetic materials consist of antiparallel arrangements of the magnetic moments in a zero 
applied field below at the Néel temperature (TN), yet the material maintains a net magnetization. 
This magnetic behavior occurs due to either the number of magnetic moments being different in 
each direction, or the size of the magnetic moments in alternating directions being different, or 
both. At sufficient high temperature (above the Currie temperature, Tc), the material becomes 




paramagnetic [11, 12]. It should be noted that the Currie temperature is the critical point where a 
material's intrinsic magnetic moments change direction. The Néel temperature is similar to Curie 
temperature but for antiferromagnetic materials. 
 Synthesis 
The synthesis of NPs can be performed by different methods, although when choosing one it is 
important to consider the application, because their properties are highly dependent on the syn-
thesis method. 
 Chemical co-precipitation 
The co-precipitation method is probably the simplest method to produce iron oxide NPs. It is 
possible to use harmless and biocompatible materials and chemical agents and thus suitable for 
biomedical applications. A careful control of the reaction parameters, allows obtaining a fine sus-
pension of NPs with sizes as small as 5 nm. For magnetite preparation, a strong base is added to 
a mixture of Fe2+ and Fe3+ solution (usually with molar ratio of 1:2) under an inert atmosphere 





(𝑎𝑞) → 𝐹𝑒3𝑂4(𝑠) + 4𝐻2𝑂(𝑙) Equation 3.4 
The controlling of particles size, distribution, and morphology is the main difficulty of this 
method. Although, an oxygen-free atmosphere is required to avoid oxidation of ferrous ion in the 
solution [10, 14], Fe3O4 NPs can be utilized to prepare the Fe2O3 NPs by oxidation or anneal 
treatment under oxygen atmosphere [17]. 
The size and shape of the obtained NPs depend on the type of salt used (such as chlorides, sulfates, 
nitrates, perchlorates, etc.), the ferric and ferrous ions ratio, the reaction temperature, the pH 
value, ionic strength of the media, and the other reaction parameters (e.g. stirring rate, dropping 
speed of basic solution) [17]. Gnanaprakash and coworkers [18] have studied the effect of diges-
tion time and alkali addition rate on the size and magnetic properties of magnetite NPs produced 
by chemical precipitation. The MS of the obtained NPs decreases from 60 to 46 emu.g-1 as the 
particle size decreases. More recently other authors found similar behavior but influenced by 
temperature, stirring rate and time, pH and concentration of precursors [19]. In general, the ex-
perimental value for MS obtained by this method is around 30-80 emu.g-1 [17]. 
Despite the difficulty in controlling the properties of the NPs, several authors have obtained low 
size and narrow dispersed NPs [20-22], even without stabilizers [23-25]. 




 Thermal decomposition 
The synthesis of NPs by thermal decomposition is based on the decomposition of metal oxysalts 
(e.g., nitrates, carbonates, and acetates) when heated. The decomposition is made on controlled 
environment and so the reactions are more controlled, leading to a better size control, narrow size 
distribution, and crystallinity of grains. Thermolysis of Fe(acac)3 in diphenyl ether in the presence 
of small amounts of hexadecane-1,2-diol gives very fine Fe3O4 NPs (around 1 nm), which can be 
enlarged by adding excess Fe(acac)3 into the reaction mixture [5]. However, usually it is required 
relatively high temperature and a complicated operation [14, 17] and the NPs are generally only 
dissolved in nonpolar solvents [26]. However, Maity and coworkers [27, 28] have synthetized 
water-soluble magnetite NPs by thermal decomposition of iron (III) acetylacetonate in tri(eth-
ylene glycol) (TREG) alone and a mixture of TREG and triethanol amine (TREM). In both cases, 
the obtained NPs have a MS of 65 and 68 emu.g-1, respectively, are biocompatible and have po-
tential applicability for magnetic hyperthermia application. 
 Microemulsion method 
Microemulsion is a thermodynamically stable isotropic dispersion of two immiscible phases (wa-
ter and oil) under the surfactant present. Iron oxide NPs may be produced also through water-in-
oil (w/o) microemulsion systems that are composed of fine microdroplets of the aqueous phase 
trapped within assemblies of surfactant molecules dispersed in a continuous oil phase. The sur-
factant-stabilized microcavities (of approximately 10 nm range) provide the necessary confine-
ment to limit particle nucleation, growth, and agglomeration [14].  
 Hydrothermal synthesis 
Hydrothermal synthesis includes various wet chemical technologies of crystalizing substance in 
a sealed container from the high temperature aqueous solution (usually above 100 ºC) at high 
vapor pressure (usually above 1 atm). This technique is prone to obtain highly crystalline iron 
oxide NPs, and the unusual iron oxide nanostructures such as nanocubes or iron oxide hollow 
spheres. The advantages of this technique include low-temperature synthesis, simple reactions, 
cost effectiveness, and good water dispersibility of the obtained NPs [17, 29, 30]. 
Several other techniques are available for the preparation of iron oxide NPs, including sonochem-
ical synthesis [31], electrochemical synthesis [32, 33], laser pyrolysis techniques [34], microor-
ganism or bacterial synthesis [35, 36]. 




 Colloidal stability and coating 
Colloidal stability of magnetic nanoparticles is crucial to obtain magnetic colloidal ferrofluids 
that are stable against aggregation in both a biological medium and a magnetic field [37]. 
When nanoparticles are in aqueous medium they may agglomerate or aggregate, forming large 
particles that may settle out due to gravity. This event may change the superparamagnetic prop-
erties to ferromagnetic ones due to particle size increase [16, 38].  
The colloidal stability is strongly influenced by the interactions between nanoparticles and be-
tween NPs and its surrounding medium. The particle surface charges are balanced by an equal 
but oppositely charged region of counter-ions. Each particle has electrical charge that is respon-
sible by the mutual electrostatic repulsion/attraction force between adjacent particles. The coun-
ter-ions form a double layer at the interface of the NPs with the medium. The double layer theory 
(Figure 3.4 A) describes the formation and the extension of the ionic neighborhood of a charged 
colloid [39, 40]. If one considers a negative charged particle in an aqueous medium, this particle 
would be surrounded by a layer of positive ions (counter-ions) also known as the Stern layer. 
Surrounding the Stern layer are positive ions that form a second layer called diffuse layer. The 
Stern layer together with the charged region of the diffuse layer is the so-called double layer. The 
presence of the double layer not only neutralizes the charged particle, but also creates an electro-
kinetic potential between the surface of the colloid and any point in the mass of the solution, 
called surface potential (Figure 3.4 B). On the other hand, the diffuse layer, or part of it, can move 
under the influence of tangential stress. Therefore, a slipping plane is introduced to separate the 
mobile fluid from fluid that remains attached to the surface. The electric potential at this plane is 
called the zeta potential (ζ). A value of 25-30 mV (in modulus) can be taken as a reference of the 
minimum potential to form a stable colloid, since it separates low charged surfaces from highly 
charged surfaces [39, 40]. 
Colloidal stability of magnetic NPs in aqueous media results from the equilibrium established 
between attractive and repulsive forces. Theoretically, the attractive ones are van der Waals 
forces, dipolar, and magnetic dipolar forces while repulsive forces come from electrostatic and 
steric repulsion. Van der Waals forces induce strong short-range isotropic attractions. The elec-
trostatic repulsive forces can be partially screened by adding salt to the suspension. These repul-
sive forces become significant when two particles approach each other and their double layers 
begin to interfere. When discussing colloidal stability of magnetic nanoparticles another force 
must be considered, the magnetic dipolar force. This force induces anisotropic interactions, which 
result in globally attractive forces if the anisotropic interparticle potential is integrated over all 




directions. Finally, when the nanoparticles are coated with a surfactant, a polymer, or any other 
type of coating, steric repulsion has to be taken into account [37, 39]. 
 
Figure 3.4. A) Schematic representation of the double layer of a nanoparticle in aqueous medium; B) Re-
lationship between zeta potential and surface potential; C) Schematic representation of the free energy pro-
file interaction between two superparamagnetic particles in the presence and absence of a strong magnetic 
field according to a generalized theory including magnetic interactions. The particles are assumed to be 
stabilized electrostatically (adapted from [40-42]). 
A good stabilization can be achieved by controlling the strength of one or both repulsive forces 
(electrostatic and steric repulsion). While steric repulsion is difficult to predict and quantify, since 
it depends on the coating, electrostatic forces can be followed through the knowledge of the zeta 
potential and the Debye-Huckel length (depend upon the ionic strength and pH of the solution) 
[37]. 




Stabilization means that the particles do not aggregate at a significant rate. The rate of aggregation 
is generally determined by the frequency of collisions and the probability of cohesion during 
collision. Taking these facts into account, the Derjaguin-Landau-Verwey-Overbeek (DLVO) the-
ory explains the tendency of colloids to agglomerate or not. The DLVO theory suggests that the 
stability of a particle in aqueous medium is determined by the sum of van der Waals attractive 
and electrical double layer repulsive forces that exist between particles. By combining the van 
der Waals attraction curve with the electrostatic repulsion, the DLVO theory forms a net interac-
tion energy curve. At each distance, the smaller value is subtracted from the larger to obtain the 
net energy. The net value is then plotted – above if repulsive and below if attractive – and a net 
magnetization curve is formed. The maximum repulsive energy is called the energy barrier (Fig-
ure 3.4 C) [37, 38, 41]. 
When dealing with superparamagnetic nanoparticles in aqueous medium, magnetic interaction 
must be added. Figure 3.4 C shows a typical shape of interaction energy between two electrostat-
ically stabilized superparamagnetic NPs in a magnetic field. When the NPs are very close from 
each other, there is a primary minimum due to the van der Waals attractive forces. The energy 
barrier created by electrostatic repulsion prevents the particles from achieving this minimum 
(electrostatic stabilization). A secondary minimum is present, which is responsible for the reversi-
ble aggregation of particles in the presence of the magnetic field. If the energy barrier is large 
enough, a NP captured in the second minimum will remain there, thus preventing irreversible 
aggregation. Once the magnetic field is removed, the second minimum disappears, and the parti-
cles captured in the second minimum redisperse again without adding energy to the system (e.g. 
sonication) [42]. 
Iron oxide NPs surface is covered by iron atoms that act as Lewis acids and coordinate with 
molecules that donate lone-pair electrons. When iron oxide NPs are placed in aqueous medium, 
water dissociates and the iron oxide surface gets hydroxyl functionalized. These hydroxyl groups 
are amphoteric and therefore may react with either acids or bases. The surface of the iron oxide 
NPs may be positive or negative, depending upon the pH of the solution. The isoelectric point for 
magnetite is around pH 6.8. Around this point of zero charge (PZC) the surface charge density is 
too small and the particles are no longer stable in water and flocculate. Accordingly, to obtain 
stable iron oxide nanoparticles it is necessary to play on both electrostatic and steric stabilization 
[37, 39]. 
Surfactants and polymers can form a single or double layer around magnetic NPs by either chem-
ical anchoring or physical adsorption. This coating creates repulsive (mainly as steric repulsion) 




forces to balance the magnetic and the van der Waals attractive forces. As a consequence, the NPs 
are stabilized in suspension by steric repulsion [43]. 
The purpose of coating iron oxide NPs is not only to stabilize the NPs, but also to provide chem-
ical handles for the conjugation of drug molecules, targeting ligands, and reporter moieties. Fur-
thermore, polymer coating have been engineered to enhance iron oxide NPs pharmacokinetics, 
endosomal release, and tailored drug loading and release behaviors [43]. 
 Coating with inorganic materials 
Iron oxide nanoparticles can be coated with silica [44-48], gold [49-52] or gadolinium (III) [37, 
53].  
Inert silica coating on the surface of magnetite NPs prevents their aggregation in liquid, improves 
their chemical stability, and provides better protection against toxicity. Silica coating stabilizes 
magnetite NPs through shielding the magnetic dipole interaction with the silica shell [13, 54]. 
Coating of magnetite NPs is difficult since its amorphous structure prohibits silica from forming 
a homogenous layer on the surface of magnetite NPs. The result is the formation of silica spherical 
particles upon the iron oxide surface with size comparable to the iron oxide NP [10]. Additionally, 
silica NPs are negatively charged leading to an enhancement of the Coulomb repulsion of mag-
netic NPs [37]. Moreover, the internal porosity of silica can be used to host a specific drug, avoid-
ing unwanted adsorption of larger molecules [13]. One of the great advantages of using silica as 
a coating for iron oxide NPs is the presence of surface silanol groups that can easily react with 
various coupling agents to covalently attach specific ligands to these magnetic NPs [37]. Further-
more, silica and other microporous inorganic materials are heat resistant, with high surface areas 
and good mechanical strength [13].  
Gold as a coating for magnetic NPs has the advantages of having low chemical reactivity and 
unique ability to form self-assembled monolayers (SAMs) on their surface using alkanethiols. 
Nevertheless, the chemical inertness of gold may difficult the formation of gold shells over NPs 
with an adequate thickness to prevent aggregation [2, 16]. 
The incorporation of gadolinium in magnetic NPs can help surpass the hurdle for molecular im-
aging with paramagnetic NPs. The problem relays on the sparseness of the molecular epitope on 
targeted cell surfaces (e.g. nanomolar concentration) concerning the modest signal intensity from 
conventional paramagnetic agents, which may result in insufficient contrast-to-noise ratio. Para-
magnetic particles carrying high payloads of gadolinium enables to quantify molecular epitopes 
present in picomolar concentration in single cells with routines magnetic resonance imaging [16]. 




 Coating with monomeric materials 
As above stated, iron oxide surface act as a Lewis acid therefore coordinates with molecules that 
donate lone-pair electrons. For that reason, functional groups such as carboxylates, phosphates, 
and sulfates can easily bind to the surface of iron oxide NPs. This stabilization can be tailored for 
dispersibility into oil/hydrocarbon carrier fluids or aqueous medium.  
Carboxylates such as citric acid stabilizes iron oxide NPs in aqueous dispersions. This molecule 
coordinates one or two of its carboxylate functionalities, depending upon the steric necessity and 
the curvature of the surface. This way, at least one carboxylic acid group is exposed to the solvent. 
This functional group is responsible for making the surface negatively charged and hydrophilic 
[37]. Long chain surfactants such as oleic acid are composed of a long hydrocarbon chain with a 
carboxylic acid at the end. These molecules are usually suitable for stabilization in oil medium 
(hexadecane) [16]. However, above a certain concentration oleic acid is suitable for stabilization 
in aqueous medium [55-57]. 
Phosphates [58] such as alkanesulphonic and alkanephosphoric acid are suitable to obtain ther-
modynamically stable dispersions of iron oxide NPs, maybe due to a quasi-bilayer structure 
formed by the ligands [37]. 
Liposomes [59] are phospholipid bilayer membrane vesicles that can range from 100 nm to 5 µm 
in size. These structures are very used to delivery of small molecules, proteins and peptides, DNA 
and MRI contrast agents (e.g. iron oxide NPs). The great advantage of using these structures is 
that the in vivo behavior has been well established with processes such as PEGylation, resulting 
in long circulation times. Furthermore, these structures have the ability to encapsulate a large 
number of magnetic NPs cores and deliver them together to a target site [2]. 
 Coating with polymeric materials 
Coating with polymeric materials provides a steric barrier to prevent NP agglomeration and avoid 
opsonization. Furthermore, polymeric coatings provide a means to tailor the surface properties of 
magnetic NPs such as surface charge and chemical functionality. The nature of the chemical 
structure of the polymer, the length or molecular weight and the conformation of the polymer, the 
type of anchoring, and the degree of particle surface coverage are critical factors that may affect 
the performance of the magnetic NP [2]. 
Natural polymers which include carbohydrates and proteins have the inherent advantage of being 
biocompatibility [10]. Dextran is a neutral polysaccharide composed exclusively of α-D-gluco-
pyranosyl units with varying degrees of chain length and branching [60]. Dextran chains have a 




favorable size enabling optimum polar interactions (mainly chelation and hydrogen bounding) 
with iron oxide surfaces. Although hydrogen bonds are relatively weak, the total bonding energy 
of hydrogen bonds over the length of a polysaccharide molecule can be very high because of the 
large number of hydroxyl groups per molecule [37, 61]. Alginate is another natural polymer also 
classified as an electrolytic polysaccharide. This polymer has many carboxylic groups. It is a non-
immunogenic and biocompatible polymer. Moreover, it is able to dissolve and degrade under 
physiological conditions [9]. Chitosan is an alkaline, non-toxic, hydrophilic, biocompatible, and 
biodegradable natural polymer [37]. The presence of reactive groups of –OH and –NH2 allows 
the formation of hydrogen bounds with substrates by inter- or intramolecular hydrogen bounding 
[9]. This particular natural polymer will be further analyzed in Chapter 4. 
Besides natural polymers, synthetic polymers can also be used as coating for iron oxide NPs. One 
of the most studied is polyethylene glycol (PEG) [62, 63], which is hydrophilic, water soluble, 
and biocompatible polymer. The presence of PEG into the surface of iron oxide NPs increase 
their biocompatibility and blood circulating times, and minimizes or eliminates protein adsorption 
onto the particle surface, thus evading the reticuloendothelial system (RES) [37, 61]. Poly (eth-
ylene oxide) (PEO) is also widely used as a surface coating of iron oxide NPs due to its biocom-
patibility and non-biodegradability [61]. Polyvinyl alcohol (PVA) is a hydrophilic and biocom-
patible polymer that prevents coagulation, originating monodisperse particles. 61]. 
Only a few polymers were described in this section. However, there is an enormous list of poly-
mers used as coating for magnetic nanoparticles. Some of them were reviewed in references [9], 
[37] and [64]. 
 Pharmacokinetics, biodistribution and clearance 
Typically, once the iron oxide NPs are administrated within the body, they are internalized by 
cells via endocytosis where, clustered in lysosomes, the NPs are degraded into iron ions by an 
array of hydrolyzing enzymes at low pH according to endogenous iron metabolism pathways. A 
critical factor for their success is increasing the magnetic NPs blood circulating times thus evad-
ing RES. RES is the primary physiological mechanism responsible for NPs clearance from circu-
lation, being determinant for plasma lifetime. During RES clearance the circulating opsonin pro-
teins adsorb to NPs surface, are recognized, and removed from the bloodstream by circulating 
macrophages [2, 65]. 
NPs physical characteristics (hydrodynamic size, surface charge, morphology, surface chemistry) 
determine their biodistribution in the body. Large NPs (> 200 nm) are usually retained in the 




spleen via mechanical filtration followed by phagocytosis, while small NPs (< 10 nm) are rapidly 
removed through extravasation and renal clearance. Therefore, particles within a range diameter 
of 10–100 nm are optimal for intravenous administration [2, 7]. Related to surface charge, posi-
tively charged polymers and particles tend to stick to cells nonspecifically, decreasing their blood 
half-life. On the other hand, negatively charged particles tend to increase liver uptake. Conse-
quently, neutral particles are optimal for extended blood circulating times [2]. 
 Passive targeting 
Passive targeting is a non-specific accumulation that occurs mainly through the enhanced perme-
ability and retention (EPR) effect. This effect is based on the mechanism that damaged tissues 
(tumor, inflammation, infection) possess “leaky” vasculature, allowing macromolecules and NPs 
to extravasate and accumulate in these tissues. For this non-specific accumulation to occur parti-
cles must have a diameter within the range of 10 to 500 nm [2]. 
Passive targeting can be useful to deliver contrast agents and drug carriers to organs related to 
RES by the uptake of magnetic NPs by phagocytic cells (bone marrow progenitors, blood mono-
cytes, and tissue macrophages) [2].  
 Active targeting 
Active targeting is achieved through targeting molecules with high affinity toward unique molec-
ular signatures found on tumor cells. The receptor-ligand or antigen-antibody interactions provide 
effective strategy to improve the residence time in tumoral tissues [2].  
The targeting molecules may be proteins, peptides, aptamers, and small molecules. The specific 
binding of these molecules can facilitate internalization of the NPs by receptor mediated endocy-
tosis [2]. However, active targeting often requires a costly synthetic production and/or compli-
cated chemistries for their attachments to the NPs [65]. 
Monoclonal antibodies (mAbs) are high affinity molecules that were the first targeting agents to 
exploit molecular recognition to deliver magnetic NPs. The disadvantage of using these molecules 
is their large size and inherent immunogenicity that can cause conjugated NPs to diffuse poorly 
through biological barriers [2].  




 Active targeting with applied magnetic fields 
The active targeting with applied magnetic fields, or magnetic targeting, can be very useful to 
deliver magnetic NPs to a specific site. The gradient (∇B) produced by an externally applied mag-
netic field (B) to a tumor region exerts attractive forces on magnetic NPs delivered via the circu-





 Equation 3.5 
Where χ is the magnetic susceptibility of the magnetic core, Vc is the volume of the magnetic 
core, and µ0 is the magnetic permeability of free space. According to the above equation, magnetic 
NPs are retained when the magnetic force is sufficient to overcome hydrodynamic drag forces 
exerted on the particles by blood flow. Optimal magnetic NPs for magnetic targeting must have 
a large core (> 100 nm in diameter) and be superparamagnetic. Nevertheless, for larger cores the 
magnetic forces are greater but the clearance is faster, limiting the availability for interaction with 
the applied field [65]. 
 Biodistribution 
An optimal biodistribution is crucial for the success of targeting and for the determination of the 
off-target toxicity. The majority of the administrated NPs often distribute in tissues of the RES, 
mostly in liver and spleen [7, 65]. 
After intravenous administration of magnetic NPs, the NPs enter the bloodstream and opsoniza-
tion activates RES. Consequently, mononuclear phagocytes (monocytes) clear the NPs to the 
liver, sleep and bone marrow. The NPs retained in the liver are uptaken by Kupffer macrophage 
cells located in sinusoids. Some of the NPs present in the lysosomal vesicles of the Kupffer cells 
may incorporate bile and be removed by feces. Smaller particles are filtered in the kidneys and 
incorporated into urine. Finally, if NPs are biodegradable, the decomposition products can be 
taken by any cell by means of pinocytosis [13, 65]. 
Local subcutaneous injection of small particles allows them to infiltrate into the interstitial spaces 
and be gradually absorbed by the lymphatic capillary system. Lymphatic targeting may be useful 
for lymphatic tumors. However, the used particles must be small (below 60 nm). In addition this 
process can be limited by intra tumoral pressure caused by the fast proliferation in solid tumors 
[13]. 




Oral administration for delivery in the gastrointestinal tract has the drawbacks of particles (mainly 
organic ones) being degraded in gastrointestinal acid, have low absorption, being eliminated by 
the first-pass metabolism by the liver, and a significant initial increase in drug concentration [13]. 
 Toxicity 
Uncoated iron oxide NPs have shown some toxic effects, while coated iron oxide NPs have been 
found to be relatively nontoxic. Poly(ethylene glycol) (PEG)-coated NPs have shown biocompat-
ibility since exposed cells remained more than 99% viable relative to control at an upper concen-
tration of 1 mg.ml-1 [63]. On the other hand, bare iron oxide NPs induced 25%–50% loss in fi-
broblast viability at 250 μg.ml-1. In a more extensive study, the same group [16] found that iron 
oxide NPs toxicity is dose dependent. Iron oxide NPs caused a 20% reduction in cell viability at 
the lowest concentration tested (0.05 mg.ml-1). Further reductions were seen at higher concentra-
tions, with the highest concentration tested (2.0 mg.ml-1), resulting in about 60% loss of cell via-
bility. 
The increase of body contact with magnetic NPs arouses serious concerns about their pharmaco-
kinetics, metabolism, and toxicity. The major contributions of magnetic iron oxide NPs are usu-
ally the generation of reactive oxygen species (ROS) via Fenton reaction [66]: 
𝐻2𝑂2 + 𝐹𝑒
2+ → 𝐹𝑒3+ + 𝐻𝑂− + 𝐻𝑂∗ Equation 3.6 
This reaction is the most prevalent source of ROS in biological systems [7]. The high chemical 
reactivity of NPs may produce oxidative stress via four primary sources: 1) generation of ROS 
from the NPs surface; 2) leaching of the NPs, causing the generation of ROS; 3) altering organelle 
functions (mitochondrial or other); 4) induction of cell signaling [67]. Although some authors 
consider that uncoated iron oxide NPs are biocompatible in vitro, there are several studies report-
ing in vitro cytotoxicity of iron oxide NPs with and without coating [68-71]. 
The in vivo toxicity assessment of magnetic iron oxide NPs is difficult due to the complexity of 
the biological systems. Nevertheless, iron oxide NPs are considered biocompatible in vivo be-
cause iron is a natural component of the human body. Nevertheless, high concentrations of Fe 
(above 60 mg per kg) may lead to severe side effects. Contrast agents (for example, EndoremTM) 
are used in a concentration of 1 mg of Fe per kg [72] and in vivo toxicity studies show no long-
term implications when administrated at clinically relevant concentrations via relevant routes. For 




example, although iron oxide NPs deposits were detected in the prostates of prostate cancer pa-
tients after one year of magnetic hyperthermia therapy in phase I clinical trials, there were no 
evidences of toxic effects due to this accumulation [73]. 
3.2. Materials and methods 
All the chemical reagents used in this research work were of analytical grade and used without 
further purification.  
 Iron oxide nanoparticles synthesis 
 Chemical precipitation 
Iron oxide nanoparticles were synthesized by chemical co-precipitation using an adapted method 
of Gnanaprakash and coworkers [18]. Ferrous and ferric chlorides (Sigma-Aldrich) were dis-
solved in deionized water to achieve a concentration of 1 M. An appropriate amount of the above-
mentioned solutions was mixed in order to obtain a molar ratio of 1:2 (Fe2+:Fe3+) and diluted to 
100 ml of deionized water with deaeration of O2 with bubbling N2. Further, 10 ml of NH4OH 25% 
(Panreac) was rapidly added under vigorous stirring and kept for a fixed period of time (5, 10 or 
30 min). Deionized water was added to stop the reaction, the precipitate was left to settle, and the 
top water layer was discarded. The magnetic NPs were washed three times with deionized water, 
and pH of the final suspension was adjusted to 7 with diluted HCl. A part of the suspension was 
freeze-dried (Vaco 2, Zirbus) in order to obtain dry nanoparticles for further characterization. 
These samples without further modification will be designated as “Pristine Fe3O4 NPs” from 
now on. 
 Stabilization of pristine Fe3O4 NPs 
Pristine Fe3O4 NPs obtained from chemical precipitation technique form instable colloidal sus-
pensions in water. Due to the positive charge, the NPs tend to aggregate and sediment when in an 
aqueous suspension. This is a crucial issue for biomedical application. One of the most effective 
way to stabilize these NPs is by using surfactants (surface active agents) that neutralize the su-
perficial charge of the NPs and promote their stabilization in an aqueous medium [74]. In this 
work three stabilizing agents were studied: tri-sodium citrate (TC), oleic acid (OA) and triton X-
100 (TX). 




Tri-sodium citrate (Figure 3.5) is a carboxylate such as citric acid used in the synthesis of silver, 
gold and alumina nanoparticles due to its high solubility in several solvents and because it has a 
high degree of stabilization of the nanoparticles. Its chemical structure has three negative charged 
groups which facilitate the attachment to negative nanoparticles such as Fe3O4, enhancing the 
particles dispersion and stabilization in suspensions. 
 
Figure 3.5. Chemical structure of tri-sodium citrate. 
The chemical structure of oleic acid (Figure 3.6) makes it a very good surfactant for magnetite 
nanoparticles since the oleic acid chain possesses a terminal carboxylic acid with negative charge 
that has high affinity to magnetite nanoparticles surface due to their positive charge [56]. This 
compound is a monounsaturated fatty acid that can be found naturally in many plant or animal 
products. 
 
Figure 3.6. Chemical structure of oleic acid. 
Triton X-100 (Figure 3.7) is a non-ionic surfactant from the class of the alkyl phenyl polyethox-
ylate (PEO) surfactants, composed of a PEO hydrophilic chain and a hydrophobic aromatic group. 
It is compatible with other surfactants non-ionic, anionic and cationic. This surfactant is utilized 
in the production of detergents, emulsifiers, wetting agents, solubilizers and dispersants [75]. 





Figure 3.7. Chemical structure of triton X-100. 
For the stabilization of the iron oxide nanoparticles, an appropriate amount of tri-sodium citrate, 
oleic acid or triton X-100 was added to a known volume of the magnetite suspension. The mixture 
was allowed to react for 1 h under stirring. Finally, the samples were sonicated for 5 min. These 
different surfactants were used in the iron colloidal solutions with the concentrations indicated in 
Table 3.1. 
Table 3.1. Tested concentrations of the three stabilizing agents used (tri-sodium citrate, oleic acid and triton 
X-100). 






















 Thermal decomposition 
Iron oxide nanoparticles synthesis using thermal decomposition (TD) technique was based on the 
work of Maity and his coworkers [28, 76]. This technique is based on the thermal decomposition 
of an iron precursor, Fe(acac)3 in tri-ethylene glycol (TREG) at high temperature without the use 
of further stabilizers. Typically, 2 mmol of Fe(acac)3 (Sigma Aldrich) are dissolved in 20 ml of 
TREG (Alfa aesar) and magnetically stirred under a flow of nitrogen. There are two heating stages 
in this synthesis method: the first stage is related to the dehydration of the solution; the second 




stage is the one that leads to the decomposition of the iron source at the solvent boiling tempera-
ture. Therefore, the first stage of temperature was fixed at 120 ºC for either 30 or 60 minutes. The 
second stage (around 280 ºC, i.e. TREG boiling temperature) was kept for 30 min, 1 h, or 2 h. A 
condenser was used to prevent the high-boiling temperature solvent from evaporation. The result-
ant black solution was cooled to room temperature overnight by removing the heat source. The 
obtained nanoparticles were precipitated by addition of 20 ml of ethyl acetate (Sigma Aldrich), 
and then isolated by centrifugation (Heraeus Multifuge X1R Centrifuge) for 20 minutes at 10000 
rpm. The washing process was repeated three times and finally the obtained nanoparticles were 
dispersed in ultrapure water. A part of the suspension was freeze-dried (VaCo 2, Zirbus) in order 
to obtain dry nanoparticles for further characterization. These samples will be designated as 
“Fe3O4 TD”. 
 Iron content determination 
The iron content of the samples was determined using the 1,10-phenantroline colorimetric method 
[77]. Briefly, 40 µl of diluted sample was placed into an Eppendorf, followed by the addition of 
20 µl of hydrochloric acid 37% (v/v) (Panreac). The mixture was incubated for 1 h at room tem-
perature to dissolve all the iron oxide NPs and obtain ferrous and ferric chloride. Next, to reduce 
Fe (III) to Fe (II), 100 µl of hydroxylamine hydrochloride (Alfa aesar) solution 100 mg.ml-1 was 
added to the mixture, followed by 500 µl of phenanthroline (Applichem) 3 mg.ml-1 to form the 
orange-red complex of tris(1,10-phenantroline) iron (II). Lastly, the samples were diluted to 1800 
µl by adding ammonium acetate (Sigma Aldrich) 500 mM pH 4 buffer. The absorbance of the 
samples was measured at 510 nm using a UV-VIS spectrophotometer (T90+ UV/VIS Spectrom-
eter PG Instruments Ltd). The concentration of iron (II) was calculated by a calibration curve 
obtained using Mohr’s salt solution in HCl 0.01 N in a concentration range of 10 to 1000 µg.ml-
1. 
To obtain the nanoparticles concentration the formula [Fe] = 0.7 x [NPs] was used. The ratio was 
obtained from control experiments. 
 Characterization 
 X-ray diffraction (XRD) 
The crystalline phases of the samples were verified using powder X-ray diffraction. X’Pert PRO 
PANAlytical X-ray diffractometer was used to obtain X-ray diffraction patterns of the iron oxide 




nanoparticles previously freeze-dried. The 2θ values were taken from 15º to 80º using a Cu-Kα 
radiation (k = 1.54060 Å) with a step size of 0.033. The Scherrer`s equation was used to measure 
the average crystallite size. 
 Fourier Transform Infrared (FTIR) spectrometry 
FTIR spectra of the samples were obtained using a Nicolet 6700 – Thermo Electron Corporation 
Attenuated Total Reflectance-Fourier Transform Infrared spectrometer (ATR-FTIR). The spectra 
were acquired with a 45° incident angle in the range of 4000 – 480 cm−1 and with a 2 cm−1 reso-
lution. 
 Scanning electron microscopy (SEM) 
Morphology and size of the NPs was obtained using a scanning electron microscope of high res-
olution, Zeiss DSM-962. A drop of the diluted sample was placed into the sample holder using a 
carbon tape. The solvent was left to evaporate overnight. 
 UV-VIS spectrophotometry 
UV–VIS spectrophotometer (PG Instruments model T90+) was used to perform the absorbance 
spectra of colloidal solutions containing iron oxide nanoparticles coated with different surfac-
tants: oleic acid, tri-sodium citrate, and triton X-100. The measurements were acquired using a 
quartz cuvette with high purity water. The colloidal solutions were prepared in a dilution of 1:100 
with respected to the initial concentration, where the concentration of surfactant was changed 
keeping the dilution constant to ensure that the absorbance spectra do not saturate. Measurements 
were performed at different times after sonication of the samples, using a single cuvette for each 
sample. Spectra were acquired using the same concentration of the surfactant used in the samples 
in the reference cuvette. 
 Transmission electron microscopy (TEM) 
Transmission electron microscopy images were obtained using a Hitachi H-8100 II with thermo-
ionic emission LaB6. TEM analysis was performed in a little quantity of nanoparticles suspended 
in pure water that were placed in a Kevlar 25 mesh grid. 




 Thermogravimetric analysis (TGA) 
Thermogravimetric analysis and differential thermal analysis (DTA) studies were carried out us-
ing a Thermal Analyzer NETZSCH STA 449 F3 Jupiter® at a rate of 10 ºC.min-1 in a N2 atmos-
phere. 
 Superconducting quantum Interference device (SQUID) 
The DC magnetic properties were performed using a 7T SQUID magnetometer (S700X; Cryo-
genic Ltd.). The zero-field cooled (ZFC) and field-cooled (FC) measurements were performed by 
cooling the sample to 5 K at zero field or in the presence of an external field of 100 Oe, respec-
tively. All the magnetic measurements were carried out in increasing temperature range 5–320 K. 
Isothermal magnetization curves were obtained for fields up to 5 T for temperatures of 10 and 
320 K. 
 Dynamic light scattering (DLS) 
Hydrodynamic diameter (DH) of the nanoparticles was measured by means of dynamic light scat-
tering equipment (Avid Nano) using the blade cell at 20 ºC.  
Dynamic light scattering and zeta potential measurements were performed using a SZ-100 nano-
partica series (Horiba, Lda) with a laser of 532 nm and controlling temperature with a Peltier 
system (25 ºC). DLS measurements were carried out for diluted NPs suspensions in triplicates 
using a disposable cell with a scattering angle equal to 90º. Data analysis was performed using 
cumulative statistics to measure hydrodynamic size and polydispersity unless stated otherwise. 
Zeta potential measurements were performed with a scattering angle equal to 173º, in a graphite 
electrode cell. 
3.3. Results and discussion 
The results section of this chapter is divided into three sub-sections: the first one shows the char-
acterization and optimization of iron oxide nanoparticles obtained from chemical precipitation 
technique. The second one refers to the influence of surfactants; and the third section is related to 
the characterization of iron oxide nanoparticles obtained from thermal decomposition technique. 




 NPs obtained from chemical precipitation 
The structure of the samples was analyzed by XRD spectra while their morphology was observed 
through TEM images. These characterizations were performed before and after functionalization 
with the stabilizers. 
 Structural and physical characterization 
Figure 3.8 shows the XRD patterns obtained for pristine iron oxide NPs. The six characteristic 2θ 
peaks occurred at 30.1, 35.5, 43.2, 53.5, 57.0 and 62.8, which correspond to the diffraction planes 
(220), (311), (400), (422), (511) and (440), respectively. Compared to standard XRD patterns for 
magnetite and maghemite powders (JCPDS 00-019-0629 for magnetite and JCPDS 00-039-1346 
for maghemite) the synthesized NPs have a crystalline cubic magnetite structure. The average 




 Equation 3.7 
Where τ is equivalent of particles average core diameter; K is the grain shape factor (K = 0.94); 
λ is the incident X-ray wavelength; β denotes the full width at half-maximum (in radians) of the 
highest intensity, and θ is the corresponding diffraction angle (2θ = 35.6141).  
  
Figure 3.8. X-ray patterns of (a) pristine iron oxide nanoparticles produced by chemical precipitation tech-
nique (b) Tri-sodium citrate 5 mM coated Fe3O4 nanoparticles; (c) Oleic acid 64 mM coated Fe3O4 nano-
particles; (d) Triton X-100 17 mM coated Fe3O4 nanoparticles. 
The iron oxide NPs stabilized with surfactants retained the crystal structure of pristine Fe3O4, as 
can be seen in Figure 3.8 (B) where pristine and coated nanoparticles XRD patterns are similar, 
denoting that the surfactant does not change the Fe3O4 nanoparticles crystalline structure. 




The obtained FTIR spectrum for pristine Fe3O4 NPs is shown in Figure 3.9 (A). The strong ab-
sorbance band at 560 cm-1 is attributed to the Fe-O stretching vibration mode while the band at 
1630 cm-1 is related to the O-H stretching vibration modes, and the broad band between 3000 cm-
1 and 3500 cm-1 is related to the O-H stretching vibration mode due to water vapor [18].  
The influence of surfactants in FTIR spectra is shown in Figure 3.9 (B), (C) and (D) for tri-sodium 
citrate, oleic acid, and triton X-100 coated Fe3O4 NPs, respectively. It is possible to observe the 
presence of the above-referred bands of Fe3O4 in all the spectra. By increasing the surfactants 




Figure 3.9. FTIR spectra of (A) pristine Fe3O4 nanoparticles, (B) tri-sodium citrate coated Fe3O4 NPs, (C), 
oleic acid coated Fe3O4 NPs (D) triton X-100 coated Fe3O4 NPs. 
In oleic acid coated nanoparticles (Figure 3.9 (C)), the difference between the minimum and max-
imum concentration used is much evident. In the sample with 8 mM of oleic acid, it is possible 
to identify the following bands: bands at 2910 and 2840 cm-1 are attributed to the symmetric and 
asymmetric CH2 stretch in the oleic acid molecule, respectively. The bands at 1506 and 1415 cm-
1 are respectively due to the symmetric and asymmetric –COO- stretching vibration modes; the 




band at 1398 cm-1 corresponding to the CH3 umbrella mode of oleic acid. For a concentration 
above 32 mM of oleic acid, a sharp band at 1704 cm-1 appears, which corresponds to the stretching 
vibration of C=O in oleic acid, while the bands between 1550 and 1450 cm-1 tend to disappear. 
The differences between oleic acid samples are due to the formation of a bilayer above a concen-
tration of 32 mM. Considering that the oleic acid molecule links to the Fe3O4 nanoparticle surface 
through the carboxylic group, when oleic acid forms a monolayer, only the COO- group appears 
on FTIR spectra, since none of the COOH groups are present. However, with the addition of more 
oleic acid, the COOH group starts to become visible in the FTIR spectra, thus justifying the for-
mation of the bilayer. This bilayer formed by the oleic acid molecules turns the magnetite nano-
particles hydrophilic making them more stable in aqueous solutions [56]. 
In the tri-sodium citrate Fe3O4 NPs (Figure 3.9 (B)) the absorptions bands at 1369 and 1568 cm-1 
are characteristic of the COO-Fe bond that may be due to the reaction of hydroxide radical groups 
on the surface of Fe3O4 with carboxylate anion of tri-sodium citrate [78]. These characteristic 
bands prove that the tri-sodium citrate molecule is linked to the nanoparticle surface, thus provid-
ing stability in aqueous solutions. 
In the FTIR spectrum of triton X-100 Fe3O4 NPs (Figure 3.9 (D)) the broad absorption band at 
3320 cm-1 corresponding to the stretching vibration of hydroxyl groups (O-H). The sharp bands 
at 2933 and 2852 cm-1 are owed to the asymmetric and symmetric CH2 stretch, respectively. The 
bands at 1604 and 1508 cm-1 are due to the stretching vibration of the benzenoid group while the 
peaks at 1242 and 1147 cm-1 are associated with the asymmetric stretch of the aromatic ether [79]. 
Comparing to the characteristic bands of triton X-100 [80], a shift of the characteristic bands to a 
lower frequency region can be observed. These could indicate that triton X-100 molecules are 
attached to the Fe3O4 NPs surface.  
 Morphological characterization  
Chemical precipitation technique is a very versatile way to synthetize iron oxide nanoparticles 
since it allows controlling the properties of the obtained nanoparticles by changing the synthesis 
parameters. In this work, the time of reaction was evaluated to access if the size of the nanoparti-
cles changed. To determine the appropriate time of reaction, SEM images were taken in samples 
with 5, 10 and 30 minutes of reaction. Figure 3.10 show the differences obtained for tri-sodium 
citrate and oleic acid Fe3O4 nanoparticles. 
The obtained images do not allow to clearly identifying differences between samples. The size 
distribution graphs show mean diameters around 30-40 nm, with a high standard deviation. The 
obtained data may reflect that the time of reaction does not promote differences between samples. 




Based on an exhaustive study published by Gnanaprakash [18], further on all samples produced 
by chemical precipitation had a reaction time of 5 minutes.  


















Figure 3.10. Size distribution graphs with SEM images insets of Fe3O4 stabilized with either tri-sodium 
citrate (TC) or oleic acid (OA) with 5, 10 and 30 minutes of reaction time.  
Keeping the reaction time constant, a new set of samples was produced to investigate the influ-
ence of the surfactants in the nanoparticles size by TEM. Figure 3.11 (A) shows TEM image of 
pristine Fe3O4 NPs with an average diameter of 8.5 nm and a narrow size distribution. This is very 
interesting considering that for biomedical applications the nanoparticles must have a size below 
100 nm and a narrow size distribution. In addition, for these nanoparticles to be superparamag-
netic their size cannot exceed a few tens of nanometers [37]. However, the NPs show a high 




aggregation state, due to the absence of stabilizers. The remaining TEM images and size distri-
butions are relative to Fe3O4 NPs stabilized with the chosen molecules. In all cases, there is a 
common conclusion: the used stabilizers in the tested concentrations do not change the Fe3O4 core 




Figure 3.11. TEM image of pristine Fe3O4 NPs (A) and their respective size distribution graph. Size distri-
bution graphs with TEM image inset of Fe3O4 NPs obtained from chemical precipitation technique and 
further stabilized with TC 30 mM (C), TX 26 mM (D), OA 8 mM (E) and OA 96 mM (F). 
A 




Figure 3.11 (C) and (D) are relative to Fe3O4 NPs stabilized with tri-sodium citrate and triton X-
100, respectively. The aggregation state of the NPs seems to decrease for tri-sodium citrate, i.e., 
the samples seem to have fewer aggregates. The same is not observed for triton X-100. Regarding 
oleic acid, when a low concentration is used (8mM, Figure 3.11 E) aggregation of the NPs is 
observed. However, if this concentration is increased to 96 mM (Figure 3.11 F), oleic acid is the 
most effective stabilizer, since isolated nanoparticles are visible as well as the absence of aggre-
gates. 
 Colloidal stability  
The colloidal stability of Fe3O4 NPs with surfactants was performed using two techniques: eval-
uation of the UV/VIS absorbance along the time after sonication of the samples to a maximum of 
24h; and evaluation of the sedimentation rate of the samples over a period of 8 weeks. Both studies 
were performed for concentrations that do not saturate the values of absorption. All the samples 
were diluted in a factor of 1:100 for pristine, TC and OA Fe3O4 NPs and 1:200 for TX Fe3O4 NPs. 
The hydrodynamic diameter was measured through dynamic light scattering at 0 h and 24 h after 
sonication.  
To perform the absorbance test, the colloidal solutions with different concentrations of surfactant 
were placed on a quartz cuvette and the absorbance spectra was acquired immediately after the 
suspension preparation (t = 0 h) and after a period (t = x), keeping the suspension unruffled. 
Figure 3.12 shows the obtained UV-VIS spectra for pristine Fe3O4 NPs in ultrapure water. The 
absorbance spectra of as-prepared colloids do not present a specific peak of absorbance in the 
UV–VIS wavelength range. However, as time passes the absorbance of the samples decreases 
because of the sedimentation of NPs, leading to a more transparent suspension. 
The UV–VIS spectrum of pristine Fe3O4 nanoparticles (Figure 3.12) demonstrates that the sedi-
mentation occurs faster within the first hours after sonication. This effect was expected due to the 
absence of a stabilizer in the suspension. Thus, the NPs tend to agglomerate and consequently 
their size increases leading to fast sedimentation. The use of a stabilizer not only avoids the nu-
cleation of the iron oxide NPs but also prevents its growth and agglomeration. 
The Fe3O4 nanoparticles coated with surfactants show a specific absorbance peak that follows the 
observed peak of surfactant. 





Figure 3.12. UV-VIS spectra of pristine Fe3O4 NPs immediately after sonication and after different periods 
up to 24 h. 
3.3.1.3.1. Tri-sodium citrate 
Figure 3.13 shows the UV-VIS spectra of tri-sodium citrate Fe3O4 NPs in the range of tested 
concentrations of tri-sodium citrate, immediately and 24 h after sonication. In each case, the ab-
sorbance of a tri-sodium citrate solution with the same concentration was also measured. The 
maximum absorbance is observed in the wavelength from 200 to 300 nm, and from 300 to 400 
nm a hump is observed, which may be attributed to NPs with bigger size. Considering the stabi-
lizer concentration, for tri-sodium citrate with concentrations below 5 mM, the nanoparticles are 
not well stabilized and a remarkable decrease in the intensity of the hump occurs after 24 h, prob-
ably due to the amount of surfactant that is insufficient to prevent agglomeration of the nanopar-
ticles in suspension. Moreover, above a concentration of 5 mM no significant differences can be 
found. 
To better identify the differences between samples with different stabilizer concentration, the 
maximum absorbance at 300 nm was taken at 0 h and 24 h after sonication. Figure 3.14 shows 
the obtained values. It is clear that for lower tri-sodium citrate concentrations, the NPs settle and 
the absorbance drastically decreases. However, for concentrations above 5 mM, no significant 
difference exists between the absorbance at 0 h and 24 h after sonication. Taking into account the 
data in Figure 3.14 it seems that the best concentration to stabilize the Fe3O4 NPs is between 5 
and 10 mM of tri-sodium citrate. 





Figure 3.13. UV-VIS spectra of tri-sodium citrate Fe3O4 NPs immediately and after 24 h of sonication, at 
different tri-sodium citrate concentrations.  
 
Figure 3.14. UV-Vis absorbance at 300 nm of tri-sodium citrate and Fe3O4 TC immediately and 24 h after 
sonication for different concentrations of tri-sodium citrate. 




Figure 3.15 represents the sedimentation test performed for tri-sodium citrate Fe3O4 NPs. This 
test was performed for 8 weeks by weighting the sediment obtained over time. The high standard 
deviation observed in the graph was caused by experimental errors (small sample size and lack 
of precision of the balance). In the obtained results, two groups of samples are seen: the first group 
containing the lower concentrations of tri-sodium citrate and the second group with the three 
higher concentrations of tri-sodium citrate. 
In UV-VIS, absorbance test the tri-sodium citrate concentration that better stabilizes Fe3O4 NPs 
in an aqueous suspension was between 5 and 10 mM. In the sedimentation test, the tri-sodium 
citrate concentrations that achieve a higher mass of nanoparticles in suspension along 8 weeks 
are above 10 mM. Therefore, the better concentration of tri-sodium citrate to stabilize iron oxide 
nanoparticles in an aqueous suspension is 10 mM, within the tested conditions. 
 
Figure 3.15. Mass of Fe3O4 TC NPs in suspension (%) along time for the tested tri-sodium citrate concen-
trations. 
3.3.1.3.2. Oleic Acid 
Figure 3.16 shows the UV-VIS spectra of oleic acid Fe3O4 NPs within the tested range of con-
centrations, immediately and 24 h after sonication. Similarly, to tri-sodium citrate, each graph has 
the equivalent oleic acid concentration absorbance spectrum without Fe3O4 NPs. For oleic acid 
Fe3O4 NPs spectra, a maximum absorbance peak is at 224 nm. Considering oleic acid concentra-
tion it is visible that below an oleic acid concentration of 32 mM the absorbance is very low, 




leading to the conclusion that almost none of the NPs are in suspension. However, above the same 
concentration, oleic acid maximum absorbance peak is clearer and has a higher value, which may 
be associated to a higher mass of NPs in suspension. Moreover, in the OA 64 mM sample a hump 
is visible at 280 nm, which similarly to tri-sodium citrate case may be attributed to the presence 
of larges particles, possibly agglomerates of NPs. However, this hump decreases after 24 h of 
sonication, which reveal that the NPs agglomerates fall down, being in suspension only the small 
ones. 
 
Figure 3.16. UV-VIS spectra of oleic acid Fe3O4 NPs immediately and after 24 h of sonication, at different 
oleic acid concentrations. 
Figure 3.17 shows the absorbance at 224 nm taken 0 h and 24 h after sonication, for each concen-
tration of oleic acid. Except for the lowest concentration, the tested concentrations show differ-
ences in the absorption values between 0 h and 24 h after sonication, which is attributed to the 
NPs settling due to agglomeration. However, the trend with the concentration is similar for both, 
and OA of 64 mM and above lead to the most stable suspensions. 
Figure 3.18 represents the sedimentation test performed for oleic acid Fe3O4 NPs. Comparing to 
tri-sodium citrate, oleic acid is not so effective stabilizer of Fe3O4 NPs, leading to a complete 
sedimentation after four weeks, in all the tested surfactant concentrations.  




Thus, the results show that any concentration above 64 mM (including) is appropriate to stabilize 
the Fe3O4 NPs in an aqueous suspension. However, this stabilization is only effective for short 
periods. 
 
Figure 3.17. UV-VIS absorbance at 224 nm of oleic acid and Fe3O4 OA immediately and 24 h after soni-
cation for different concentrations of oleic acid. 
 
Figure 3.18. Mass of Fe3O4 OA NPs in suspension (%) along time for the tested oleic acid concentrations. 




3.3.1.3.3. Triton X-100 
The UV-VIS spectrum of triton X-100 Fe3O4 NPs within the tested range of concentrations, im-
mediately and 24 h after sonication is depicted in Figure 3.19. Similarly, to tri-sodium citrate, 
each graph has the equivalent triton X-100 concentration absorbance spectrum without Fe3O4 
NPs. When triton X-100 is added to the NPs, the maximum absorbance peak is at 222 nm. In this 
case, as the surfactant concentration increases, the absorbance at 222 nm also increases (Figure 
3.20), without further changes in the curves, similarly to oleic acid case. As such, the most prob-
able explanation is that the tested range of concentration was small and the ideal concentration 
was not found. 
Figure 3.21 shows the UV-VIS spectra for suspensions of Fe3O4 NPs with different concentrations 
of triton X-100 along the time. Comparing to tri-sodium citrate and oleic acid samples, in triton 
X-100 only after 6 weeks is verified a complete sedimentation of the NPs. However, for this study 
the range of concentrations used for triton X-100 was not enough to found an ideal concentration. 
Further increase in concentration is needed. 
 
Figure 3.19. UV-VIS spectra of triton X-100 Fe3O4 NPs immediately and after 24 h of sonication, at dif-
ferent triton X-100 concentrations. 





Figure 3.20. UV-VIS absorbance at 222 nm of triton X-100 and Fe3O4 TX, immediately and 24 h after 
sonication for different concentrations of triton X-100. 
 
Figure 3.21. Mass of Fe3O4 TX NPs in suspension (%) along time for the tested triton X-100 concentrations. 
In order to complement the previous study, the hydrodynamic diameter of NPs was measured at 
0 h and 24 h after sonication, for all the tested concentrations of the three surfactants (Figure 
3.22). Hydrodynamic measurements are important to optimize suspensions and extrapolate the 
biodistribution of the NPs in the body. It allows the prediction of the nanoparticles behavior in 




the blood vessel, the mechanism of clearance, and the permeability of the nanoparticles out of the 
vasculature [81]. 
The average hydrodynamic diameter increases after 24 h of sonication for suspensions with tri-
sodium citrate. Since tri-sodium citrate is a salt, it reduces the surface energy and dipolar attrac-
tion. As such, there is some aggregation after 24 h but the hydrodynamic diameter of the nano-
particles is not greatly increased, allowing the nanoparticles to remain in suspension. 
 
Figure 3.22. Hydrodynamic diameter of coated magnetic nanoparticles with six concentrations of each 
tested surfactant, 0 h and 24 h after sonication. 
The average hydrodynamic diameter of the nanoparticles decreases after 24 h of sonication for 
concentrations of oleic acid above 16 mM. This is in agreement with the absorbance results shown 
previously and can be correlated with the sedimentation of the bigger agglomerates of NPs, leav-
ing in suspension only the smaller particles. Indeed the figure shows that immediately after soni-
cation the hydrodynamic diameter almost duplicates in OA concentrations above 64 mM. On the 




other hand, for those concentrations the nanoparticles colloids are stable as the hydrodynamic 
diameter is constant. This behavior may be correlated with the formation of the oleic acid double 
layer. 
The hydrodynamic diameter after 24 h sonication is much higher in suspensions made with triton 
X-100. Therefore, within the tested conditions, it is the surfactant with the lowest performance. 
 Magnetic characterization 
The influence of surfactants in the magnetic properties of Fe3O4 NPs was evaluated by magne-
tometry, using a superconducting quantum interference device. The magnetization, represented 
as emu per gram of the whole particle (including magnetic and non-magnetic material), was eval-
uated in samples with and without surfactants. 
Figure 3.23 (A) shows the temperature dependence of the zero-field cooled and field cooled mag-
netization curves of pristine Fe3O4 NPs measured by SQUID under an applied filed of 100 Oe. 
The blocking temperature (TB) was determined as the maximum value of ZFC curve. The hyste-
resis loops measured at temperatures 10 and 320 K for the pristine Fe3O4 nanoparticles are shown 
in Figure 3.23 (B). 
  
Figure 3.23. Magnetic characterization of pristine Fe3O4 nanoparticles: (A) Zero-field cooled and field 
cooled results; (B) Magnetization vs. applied magnetic field at 320 and 10 K. 
The temperature dependence of magnetization of pristine Fe3O4 NPs exhibits a TB around 172 K, 
which indicates that at room temperature the produced NPs have a superparamagnetic behavior, 
confirmed by the absence of coercivity and remanence at 320 K. For pristine NPs at 10 K, the 
saturation magnetization reaches 67 emu.g-1 with a coercivity of 270 Oe.  
For the tri-sodium citrate, Fe3O4 NPs magnetic characterization was performed for the lowest and 
higher concentrations used. Figure 3.24 shows (A) the ZFC-FC curves obtained under an applied 




field of 100 Oe and (B) the hysteresis loops measured at 320 K for both concentrations. The 
obtained results show that a higher concentration of tri-sodium citrate has a higher influence in 
blocking temperature (152 K for TC 1.25 mM and 147 K for TC 30 mM). However, in both cases, 
the superparamagnetic behavior above TB remains constant. Moreover a little influence of the 
surfactant is observed, resulting in saturation magnetization around 60 emu.g-1 for both concen-
trations tested. 
  
Figure 3.24. Magnetic characterization of tri-sodium citrate Fe3O4 nanoparticles: (A) Zero-field cooled  and 
field cooled results for TC 1.25 mM and TC 30 mM; (B) Magnetization vs. applied magnetic field at 320 
K for TC 1.25 mM and TC 30 mM. 
Figure 3.25 shows the influence of oleic acid on the Fe3O4 NPs for concentrations of 8 and 64 
mM. The influence in the TB is small but the saturation magnetization decreases from 60 emu.g-1 
(OA 8 mM) to 45 emu.g-1 (OA 64 mM). This suggests that a concentration of 8 mM of OA is so 
small that do not influence the magnetic properties of Fe3O4 NPs. When OA concentration in-
creases the surfactant is reducing the magnetic moments at the surface of the nanoparticles prob-
ably due to the diamagnetic contribution of the surfactant volume [21]. In addition, the formation 
of the oleic acid bilayer must have a lower influence in the magnetic properties of the nanoparti-
cles. 
Fe3O4 NPs stabilized with triton X-100 (Figure 3.26) show a magnetic behavior quite similar to 
tri-sodium citrate, meaning that this surfactant has also very small influence over the Fe3O4 NPs 
magnetic properties.  
Table 3.2 resumes the obtained data from magnetic characterization of pristine Fe3O4 NPs and 
Fe3O4 NP stabilized with tri-sodium citrate, oleic acid and triton X-100. 
The results confirm that pristine Fe3O4 NPs have a superparamagnetic behavior above the block-
ing temperature, given by the absence of coercivity and remanence at 320 K. Moreover, for the 




tested concentrations of the three surfactants, the superparamagnetic behavior is not affected, 
since at 320K the absence of coercivity and remanence remains. In all cases, the magnetic do-
mains are not separate by domain walls (multi-domain state). Instead, each particle represents a 
single magnetic domain [82]. For magnetite the critical size is 30 nm at room temperature [83]. 
This observation confirms the superparamagnetic behavior of our samples. The loop areas for all 
samples are narrow, demonstrating very low heat generations due to hysteresis, which also cor-
relates with the literature values [82, 84]. 
  
Figure 3.25. Magnetic characterization of oleic acid Fe3O4 nanoparticles: (A) Zero-field cooled and field 
cooled results for OA 8 mM and OA 64 mM; (B) Magnetization vs. applied magnetic field at 320 K for 
OA 8 mM and OA 64 mM. 
  
Figure 3.26. Magnetic characterization of triton X-100 Fe3O4 nanoparticles: (A) Zero-field cooled and field 
cooled results for TX 17 mM and TX 61 mM; (B) Magnetization vs. applied magnetic field at 320 K for 
TX 17 mM and TX 61 mM. 
The characterizations performed confirm that triton X-100 has the worst performance as surfac-
tant, both related to the aggregation and stability of the particles in suspension. Both tri-sodium 
citrate and oleic acid were very effective in stabilizing the iron oxide nanoparticles. Their negative 




nature promotes the ideal environment for the stabilization of the iron oxide nanoparticles whose 
surface is usually positively charged [56, 85, 86]. Further, coating of NPs is possible with any of 
these surfactants since it allows obtaining a high number of small NPs stabilized in the suspen-
sions. Furthermore, the tested surfactants do not significantly change the physicochemical and 
magnetic properties of the NPs except for higher concentration of oleic acid due to the formation 
of a bilayer. 
Table 3.2. Magnetic properties of pristine Fe3O4 NPs and Fe3O4 NPs coated with a lower and higher con-
centration of the used stabilizers: tri-sodium citrate (TC), oleic acid (OA) and triton X-100 (TX). The mag-
netic properties shown are blocking temperature (TB) obtained from the maximum value of the ZFC curve, 
saturation magnetization (MS) at 10 K and 320 K, and coercivity (Hc) at 10 K (at 320 K there was an absence 




MS 10 K  
(emu.g-1) 
Hc (10 K) 
(Oe) 
MS (320 K) 
(emu.g-1) 
Pristine Fe3O4 172 67 270 58 
Fe3O4 TC 
1.25 mM 152 76 180 64 
30 mM 147 71 145 61 
Fe3O4 OA 
8 mM 152 71 188 60 
64 mM 147 52 157 45 
Fe3O4 TX 
17 mM 152 75 175 63 
61mM 152 71 186 60 
 Oleic acid double layer study 
Oleic acid is commonly used as a surfactant to modify the surface of magnetite nanoparticles due 
to its high affinity to the magnetite surface. Although oleic acid is only soluble in non-polar sol-
vents, bilayer oleic acid-coated magnetite nanoparticles can be dispersed in polar carrier liquids 
with the proper adjustment of pH. Though several works have been reported with oleic acid as a 
surfactant for magnetite nanoparticles [77, 87, 88], only few authors have reported the presence 
of an oleic acid bilayer that turns the iron oxide NPs soluble in aqueous solvents [56, 82, 89]. 
Maity el al. [76] have prepared iron oxide NPs coated with either a monolayer or a bilayer of 
oleic acid and found that they are either stable in kerosene and dodecane or water, respectively. 




This is important as per their biomedical use in MRI as contrast agents and for magnetic hyper-
thermia as treatment agents. 
Lan et al. [90] have synthetized bilayer surfactant stabilized nanoparticles with an average size 
of about 12 nm by using oleic acid as the primary and secondary layer of surfactant. In addition, 
the author found that the prepared NPs are applicable in preparing Pickering emulsions with con-
trollable stability due to their sensitivity to pH and ionic strength. Other authors have found that 
oleic acid coated Fe3O4 NPs are effective to enhance hyperthermic killing ability under an AC 
magnetic field in mice fibrosarcoma tumoral cells. 
Yang et al. [56] have performed an extensive study to distinguish between the monolayer and the 
bilayer. Based on the assumption that the amount of oleic acid necessary to form a bilayer is 20 
% with respect to the Fe3O4 NP mass, the authors have characterized both types of samples. In 
the present study, the formation of the oleic acid bilayer was also studied and its influence on iron 
oxide nanoparticles properties was accessed. 
 FTIR spectroscopy and DSC/TGA 
The presence of oleic acid bonded to the NPs was evaluated by FTIR spectroscopy. Figure 3.27 
shows the FTIR spectra of pristine Fe3O4 NPs and the same particles with different percentages 
of oleic acid. The typical bands of pristine Fe3O4 NPs are present, as previously demonstrated. 
For low concentrations of oleic acid (below 20%) which are assumed to form a monolayer, the 
FTIR spectra show some characteristic bands of the surfactant. 
The presence of oleic acid covering the nanoparticles was also evaluated by thermal analysis. The 
TGA/DTA curves of Fe3O4 NPs coated with oleic acid are shown in Figure 3.28. In the analyzed 
temperature range pristine Fe3O4 NPs shows only a slight decrease in the mass percentage which 
is related to the conversion of Fe3O4 to γ-Fe2O3 and FeO, which are the stable phase of diagram 
of Fe-O system above 570 ºC [91]. Fe3O4 NPs with 8% and 96% of oleic acid show three deriva-
tive peaks in the DTA curve corresponding to mass losses in the TGA curve. The first peak at 
214ºC is close to the boiling temperature of oleic acid (b.p. 94-195 ºC/1.2 mmHg) and is common 
to both oleic acid samples, OA 8% and 96%, where a mass loss of about 2.3% and 7.5%, respec-
tively, is obtained and can be correlated to the removal of free oleic acid on the Fe3O4 NPs. The 
second peak is at about 338 ºC with a mass loss of 10.6% for OA 96% and less than 2% for OA 
8% and corresponds to the removal of oleic acid molecules that are bonded to Fe3O4 NPs surface. 
This peak adsorption temperature confirms stronger binding energy between the oleic acid mole-
cules and Fe3O4 NPs, and happens when a bilayer is formed [58]. The third peak at 617 ºC and 
712 ºC is common to both OA samples and the mass loss is of 6.8% and 32% for OA 8% and OA 




96%, respectively. Above 600 ºC the carbon from the oleic acid is oxidized to CO and CO2 during 
the annealing and the reduction mechanism may be as follows [92]: 
𝐹𝑒3𝑂4 + 𝐶𝑂 → 3𝐹𝑒𝑂 + 𝐶𝑂2 Equation 3.8 




𝑂2 → 𝐶𝑂2 Equation 3.10 
 
Figure 3.27. FTIR spectra of pristine Fe3O4 nanoparticles coated with 0% (black line), 8% (red line) 32% 
(green line) and 96% (blue line) of oleic acid. 
  
Figure 3.28. TGA (A) and DTA (B) of pristine Fe3O4 NPs and coated with 8% and 96% of oleic acid. 




 Zeta potential and DLS 
The effect of the oleic acid bilayer on the stability of the Fe3O4 NPs suspended in water was 
evaluated by zeta potential and DLS. The samples with different percentages of oleic acid were 
prepared at different pH and measured the zeta potential of these samples in order to evaluate 
their stability (given by a zeta potential value above +/- 30 mV) as a function of pH. Figure 3.29 
shows the variation of zeta potential as a function of pH for each NPs suspension.  
 
Figure 3.29. Graphical representation of zeta potential of oleic acid coated iron oxide nanoparticles as a 
function of pH for an iron concentration of 1.25 mM. 
At neutral pH (pH = 7), the NPs have a zeta potential of around -32 mV. Moreover at basic pH 
(above 9) the NPs are stable in aqueous suspension for an iron concentration of 1.25 mM. When 
oleic acid is added to the NPs suspension, for a low concentration (8%), the zeta potential of the 
NPs at pH 7 shifted to positive values of zeta potential (around 17 mV). Above the critical con-
centration for the formation of the bilayer, the zeta potential at pH 7 shifts to more negative values, 
around -120 mV for 96% of oleic acid. Therefore, it is possible to achieve a stable NPs suspension 
at physiological pH using oleic acid as a stabilizer. 
Dynamic light scattering measurements allow the probing of the diffusion dynamics of the NPs 
in a number of conditions and compare them with the zeta potential results. Autocorrelation func-
tions (ACF) of pristine NPs show clearly two relaxation modes (Figure 3.30 A). Indeed a slow 
relaxation mode is present, here attributed to very large NPs aggregates, and contributes largely 




to the overall measurement despite its zeta potential value being clearly negative at pH=9 (Figure 
3.29). 
Comparison between OA 8% and OA 96% at the same pH and NPs concentration shows the 
disappearance of the slow relaxation mode with the increase of OA concentration. Indeed, with 
96% of oleic acid, it is completely absent and the ACF shows a typical single-exponential relax-
ation. The DLS experiments show that although the zeta potential is clearly favorable at pH=9 
even without oleic acid, large aggregates persist which may compromise the long-term colloidal 
stability of the dispersions. 
  
Figure 3.30. Comparison of measured (dots) and adjusted (lines) correlation curves of dynamic light scat-
tering measurements between (A) pristine Fe3O4, OA 8% Fe3O4 and OA 96% Fe3O4 at pH9, and (B) OA 
96% Fe3O4 at different pH: 3, 5, 7, 9, 11 and 12. 
Using 96% of oleic acid as an optimal condition to attain stable colloidal dispersions the pH was 
changed in order to understand its effect on the NPs stability (Figure 3.30 B). Again, when zeta 
potential values approach zero (pH=3) a very slow relaxation mode is observed. However, in the 
range between pH=5 and 11 all ACF overlap, showing that within experimental error the system 
is independent of pH in this region. This includes the physiological pH. A single relaxation is 
obtained, which may be fitted with a single-exponential function. 
In order to analyze the obtained data from dynamic light scattering measurements the method of 
cumulants expansion was used for every measurement described above. This method is based on 
the expansion in Taylor series of the expression that relates the autocorrelation curve with the 
experimental curve, given by Equation 3.11: 
𝐶(𝜏) = 1 + 𝛽exp (−2Γ𝜏) 
Equation 3.11 




Where τ is the delay time (µsec), C is the autocorrelation, β is a pre-exponential factor, and Γ is 
the decay constant, giving the average value 〈Γ〉. In a first order expansion: 〈Γ〉 = Γ and  
𝛤 = 𝐷𝑞2 Equation 3.12 







) Equation 3.13 
Where n is the refractive index, λ is the wavelength (532 nm) and θ is the scattering angle (90º). 
Finally, the hydrodynamic diameter of the samples can be calculated using the Stokes-Einstein 




 Equation 3.14 
Where kB is the Boltzmann constant, T is the absolute temperature and η is the fluid viscosity. 
Under non-optimal conditions, i.e., when ACF has more than one relaxation, this type of analysis 
is not valid.  
Figure 3.31 shows the relation between the measured hydrodynamic diameters and the iron con-
centration. For each case and using the method of the cumulants expansion the hydrodynamic 
diameters were calculated through the ACF curves. Although this type of analysis is not valid, it 
is possible to see that for the cases where the ACF curve has more than one relaxation, there are 
two calculated diameters, probably representing the isolated NPs (smallest diameter, around 200 
nm) and the larger aggregates, since these suspensions are not stable enough to prevent NPs ag-
gregation. 
Figure 3.32 shows the relation between the measured and calculated hydrodynamic diameters in 
the range of pH. According to ACF curves, at pH 3 and 12, the most instable ones, the measured 
and calculated hydrodynamic diameters are different. However, when all ACF measurements 
overlap the method of the cumulants is valid. For these the hydrodynamic diameter is constant 
over a wide range of pH and NPs concentration of 96% oleic acid. The determined size at pH 7 
(physiological pH) is 164  3 nm and polydispersity is 0.20  0.06, indicating a fairly monodis-
persed suspension. 






Figure 3.31. Measured vs calculated hydrodynamic diameter for pristine Fe3O4 NPs, OA 8% Fe3O4 NPs, 
and OA 96% Fe3O4 NPs at pH 9. The calculated hydrodynamic diameters were obtained using the above-
described method of the cumulants expansion. 
 
Figure 3.32. Measured vs calculated hydrodynamic diameter in the range of pH measured for OA 96% 
Fe3O4 NPs. 




A difference between the size of NPs obtained by TEM and the Dh is observed. In TEM image, 
the oleic acid coating is not visible; therefore, the measured diameters correspond to the single 
core of the NP. When the NPs are in suspension with oleic acid, the hydrodynamic diameter was 
measured with DLS, which incorporates also the oleic acid bilayer. Still accounting with the bi-
layer leads to a discrepancy of one order of magnitude between the two experiments. The most 
plausible explanation is that even at very low concentrations, the Fe3O4 NPs are agglomerated in 
larger particles with a size of about 164 nm. Interestingly, this effect is pH independent between 
5 and 11. At pH=12 this size increases to about 390 nm and becomes again dependent of NPs 
concentration. Therefore, the structure of the agglomerates is dependent of the ionization degree 
of the oleic acid. 
 Magnetic characterization 
DC magnetic measurements were performed to access the influence of oleic acid in pristine iron 
oxide NPs magnetic properties. Magnetic saturation values are presented in emu per gram of the 
whole particle (magnetic and non-magnetic material). Pristine iron oxide NPs exhibit a saturation 
magnetization of around 59 emu.g-1 at 320 K. When oleic acid is incorporated, MS of the nano-
particles is greatly reduced (around 27 emu.g-1 for OA 96%). The reduction of Fe3O4 MS is de-
pendent upon oleic acid’ percentage. 
Figure 3.33 represents the hysteresis loops of pristine NPs and Fe3O4 NPs coated with oleic acid 
8%, 64%, and 96%, measured at 320 K. Inset corresponds to the magnification of the same hys-
teresis loops. For all samples it is evident the absence of coercivity and remanence at 320 K, 
which confirms superparamagnetic behavior of all samples above the blocking temperature. Ac-
cordingly, it is possible to conclude that oleic acid does not change the superparamagnetic behav-
ior of the Fe3O4 NP. However, with the increase in the oleic acid concentration the magnetic 
saturation of the NPs decreases, which may be attributed to surface effects. Larger oleic acid 
concentration decreases aggregation of NPs, the surface atoms to volume ratio in NPs increases 
and consequently reduces the saturation of magnetization [4, 93]. 
The formation of a bilayer of oleic acid on the surface of Fe3O4 NPs was studied and its influence 
on the NPs properties was assessed. Using FTIR and TGA/DTA analysis, the presence of an oleic 
acid bilayer was confirmed. This bilayer formation is a major factor for the Fe3O4 NPs stabiliza-
tion in physiological conditions. An oleic acid concentration of 96% is able to prevent the for-
mation of larger aggregates at physiological pH, as demonstrated by TEM and DLS measure-
ments. The average size of the Fe3O4 cores is around 9 nm while the average hydrodynamic di-
ameter is around 170 nm, not only due to the presence of oleic acid but also probably because the 




oleic acid bilayer incorporated small aggregates of Fe3O4 NPs. Furthermore zeta potential meas-
urements confirmed that at physiological conditions (pH = 7) OA 96% Fe3O4 NPs are stable (~ -
120 mV). 
The magnetic studies confirmed the presence of oleic acid bilayer since the magnetic saturation 
of the NPs is inferior to the values obtained when a bilayer is not present. Additionally, this sur-
factant does not change the superparamagnetic nature of the Fe3O4 NPs, as shown by the absence 
of coercivity and remanence magnetization at 320 K. 
 
Figure 3.33. Magnetization vs. applied magnetic field of oleic acid coated iron oxide NPs, for different 
surfactant concentration: 8%, 64%, and 96%. 
 NPs obtained from thermal decomposition 
The structure of the NPs synthetized by thermal decomposition method is shown in Figure 3.34. 
The XRD patterns obtained for pristine iron oxide nanoparticles have the 2θ six characteristic 
peaks at 30.1, 35.4, 43.2, 53.6, 57.2, and 62.8, which correspond to (220), (311), (400), (422), 
(511) and (440), diffraction planes, respectively. Comparison of XRD pattern of NPs with stand-
ard diffraction spectrum for magnetite and maghemite powders (JCPDS 00-019-0629 for mag-
netite and JCPDS 00-039-1346 for maghemite) for the synthesized product we clearly identify 
the diffraction peaks of crystalline cubic magnetite structure. The average crystallite size was 
calculated to be 9.74 nm using the Scherrer’s equation (Equation 3.7). 




FTIR measurements were performed to identify the main chemical bonds of Fe3O4 TD NPs. The 
obtained spectrum for Fe3O4 TD NPs is shown in Figure 3.35 that shows the presence of specific 
absorbance bands. A strong absorbance band at 538 cm-1 is attributed to the Fe-O stretching vi-
bration mode. The bands at 1421 cm-1 and 1626 cm-1 are related to the C-H bending and O-H 
stretching vibration modes, respectively. The broad band between 3000 cm-1 and 3500 cm-1 is 
related to the O-H stretching vibration mode due to water vapor [18]. 
 
Figure 3.34. X-ray patterns of iron oxide nanoparticles produced thermal decomposition technique. 
 
Figure 3.35. FTIR spectra of Fe3O4 nanoparticles produced by thermal decomposition technique. 




The average diameter of the Fe3O4 TD nanoparticles was obtained from TEM images (Figure 
3.36). The synthetized NPs show an average diameter of 8 nm with a narrow size distribution, 
which is similar to the average diameter obtained for pristine Fe3O4 NPs. 
  
Figure 3.36. TEM image of pristine Fe3O4 TD NPs and their respective size distribution graph. 
Figure 3.37 shows the temperature dependence of the zero-field cooled and field cooled magnet-
ization curves of Fe3O4 TD NPs measured by SQUID under an applied field of 100 Oe. The 
blocking temperature (TB) was determined as the maximum value of ZFC curve. The hysteresis 
loops measured at temperatures 10 and 320 K for the pristine Fe3O4 nanoparticles are shown in 
Figure 3.37. 
The temperature dependence of magnetization of Fe3O4 TD NPs exhibits a TB around 182 K, 
confirming that the produced NPs have a superparamagnetic behavior, due to the absence of co-
ercivity and remanence at 320 K. For Fe3O4 TD NPs at 10 K, the saturation magnetization reaches 
72 emu.g-1 with a coercivity of 250 Oe and at 320 K the saturation magnetization is around 61 
emu.g-1. 
  
Figure 3.37. Magnetic characterization of Fe3O4 TD NPs: (A) Zero-field cooled and field cooled results; 
(B) Magnetization vs. applied magnetic field at 320 and 10 K. 




The obtained results of Fe3O4 TD NPs characterization are very similar to the ones obtained for 
Fe3O4 NPs produced by chemical precipitation method. As such, both techniques allow obtaining 
superparamagnetic NPs suitable for biomedical applications. 
3.4. Summary 
Magnetic nanoparticles have been extensively investigated for biomedical applications in the last 
decades. Among the different types of magnetic nanoparticles, iron oxides are the most interesting 
due to their biocompatibility and stability. Their superparamagnetic properties provide them ad-
vantage face to ferromagnetic materials due to the absence of magnetization once an externally 
applied magnetic field is removed. Colloidal stability of iron oxide NPs in aqueous medium is 
crucial for biomedical applications. The stabilization of colloids can be achieved by controlling 
the strength of one or both repulsive forces (electrostatic and steric repulsion). In most cases, 
stabilizing agents such as surfactants or polymers are used to control these forces and obtain 
highly stable colloids. 
In this chapter the core of the theranostic system developed in this PhD thesis was studied. Syn-
thesis and characterization of iron oxide colloids produced by either chemical precipitation or 
thermal decomposition technique was described and discussed. The characterization of the pro-
duced iron oxide colloids evolves the most significant properties for biomedical applications. 
Morphology of the produced Fe3O4 NPs was evaluated by TEM and SEM, while crystalline 
phases and chemical composition was evaluated by XRD and FTIR, respectively. The stability of 
iron oxide colloids in aqueous medium was also evaluated and the magnetic properties of the 
produced NPs were accessed. 
The iron oxide NPs produced by either chemical precipitation or thermal decomposition were 
identified to be magnetite due to its characteristic crystalline cubic structure. Using Scherrer’s 
equation, the average crystallite size was found to be 9.75 and 9.74 nm for chemical precipitation 
and thermal decomposition, respectively. The obtained size correlates with TEM diameter that 
was found to be 8.5 ± 2.0 nm and 8.0 ± 1.8 nm, respectively. FTIR spectra demonstrated the 
presence of typical absorbance bands for iron oxides.  
Iron oxide NPs produced by chemical precipitation are typical hydrophilic but not very stable in 
aqueous medium, having a tendency to agglomerate. Therefore, the particles obtained by this 
technique were stabilized using three different agents: tri-sodium citrate, oleic acid, and triton X-
100. The three of them possess at least one negative charge that is attracted to the positively 




charged magnetite surface. In order to evaluate the influence of the stabilizers upon the properties 
of the NPs, XDR, FTIR and TEM were again performed. XDR showed that the presence of the 
surfactant do not change the crystalline phase of the compound, while FTIR, although show the 
presence of the typical absorbance bands for each stabilizer also show the presence of the iron 
oxide. Morphology analysis demonstrated that the average size of the iron oxide core is not altered 
by the presence of surfactants; however, in some cases, the agglomeration of the NPs decreases 
significantly. 
The colloidal stability of the iron oxide colloids in aqueous medium was evaluated by UV-VIS 
absorbance through time dependence and by sedimentation rate, using different stabilizer con-
centration. An optimal concentration was found for tri-sodium citrate and oleic acid stabilized 
NPs. Tri-sodium citrate appears to have the best performance for long-term stability (up to 8 
weeks), while oleic acid is better for short-term stability (24 hours). Triton X-100 showed the 
worst performance in both stability tests performed. 
Magnetic characterization tests were performed in pristine Fe3O4 NPs and Fe3O4 NPs stabilized 
with the three tested stabilizers. In all cases, the NPs are superparamagnetic at room temperature, 
confirmed by the absence of coercivity and remanence at this temperature. The saturation mag-
netization of pristine Fe3O4 NPs at 320 K (58 emu.g-1) decreases when the surfactant is present. 
The surfactant that mostly affects the saturation magnetization is oleic acid. 
Oleic acid is a particular surfactant that has high affinity to the magnetite surface. Although oleic 
acid is only soluble in non-polar solvents, bilayer oleic acid-coated magnetite NPs can be dis-
persed in polar carrier liquids with the proper adjustment of pH. The presence of the mono- and 
bilayer of oleic acid was studied using FTIR, DSC/TGA, zeta potential, and DLS. Finally the 
influence on the magnetic properties of the iron oxide core was evaluated. FTIR spectra demon-
strated the presence of the typical bands for the monolayer and the bilayer, which was confirmed 
by DSC/TGA measurements. An oleic acid concentration of 96% is able to prevent the formation 
of larger aggregates at physiological pH, as demonstrated by TEM and DLS measurements. The 
average diameter of the Fe3O4 cores is around 9 nm while the average hydrodynamic diameter is 
around 170 nm, not only due to the presence of oleic acid but also probably because the oleic acid 
bilayer incorporated small agglomerates of Fe3O4 NPs. Furthermore zeta potential measurements 
confirmed that at physiological conditions (pH = 7) OA 96% Fe3O4 NPs are extremely stable (~ 
-120mV). The magnetic studies demonstrated that the presence of the oleic acid bilayer reduces 
the magnetic saturation of the NPs. Additionally this surfactant does not change the superpara-
magnetic nature of the Fe3O4 NPs, as shown by the absence of coercivity and remanence magnet-
ization at 320 K. 




In this chapter nanometric iron oxide colloids that are stable in aqueous medium and have super-
paramagnetic properties were studied. These iron oxide colloids were fully characterized, provid-
ing the basis to evaluate their potential in biomedical applications such as magnetic hyperthermia, 
drug delivery and MR imaging contrast agents. Moreover, cytotoxicity evaluation and biomedical 
applications are further studied in Chapter 6 and Chapter 7. 
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 Chitosan-based coating 
This chapter introduces chitosan and its derivatives as the coating for the theranostic system de-
veloped in this thesis. Their biological activity and toxicity are reviewed, as well as some of their 
applications. The methodology chitosan and O-HTCC coating are described, and the most im-
portant results are presented and discussed. 
4.1. Introduction 
Chitosan (CS) was first discovered in the 19th century when Rouget found that boiling chitin in 
potassium hydroxide rendered a material soluble in organic acids. However, only five decades 
later it was first named chitosan. Moreover, only in 1950 the structure of chitosan was finally 
stablished [1, 2]. Chitosan is a biopolymer obtained from naturally occurring sources, for exam-
ple, exoskeleton of crustacean, arthropod and fungi [1, 3, 4]. It is a linear copolymer composed 
of β-(1-4) linked 2-acetamino-2-deoxy--D-glycopyranose and 2-amino-2-deoxy--D- glycopy-
ranose subunits (Figure 4.1).  
 
Figure 4.1. Chemical structure of chitin or chitosan, depending on the deacetylation degree (DD). Chitin is 
present when DD < 50%, while chitosan has a DD > 60%. Besides the deacetylation degree, the structure 
of both biopolymers is similar. 




Chitosan is non-toxic, hydrophilic, biocompatible, biodegradable and anti-bacterial, and has been 
widely used as a biomaterial and a pharmaceutical excipient in drug formulations [1, 3]. 
 Chitosan and chitin  
 Source, structure and physicochemical properties 
Chitosan is obtained from the thermochemical deacetylation of chitin in the presence of alkali. 
Several other alkali methods are available, most of them involving the hydrolysis of the acetate 
position using sodium or potassium hydroxide solution as well as a mixture of anhydrous hydra-
zine and hydrazine sulfate. Chitin is the second most abundant polysaccharide in nature, cellulose 
being the most abundant. The main commercial sources of chitin are shell waste of shrimps, lob-
sters, krill, and crabs, being a cheap and readily available source. Chitin is highly hydrophobic 
and is insoluble in water and most organic solvents. On the other hand, chitosan is soluble in 
diluted acids such as acetic acid, among others [1]. 
Being obtain from chitin deacetylation, chitosan is a polycationic polymer with one amino group 
and two hydroxyl groups in the repeating glycosidic residue. The carbohydrate backbone contrib-
utes to the rigid crystalline structure obtained after chitosan refinement. This structure is depend-
ent on inter- and intra-molecular hydrogen bounding [1]. 
Both the source of chitin and the chosen method for chitin deacetylation influence the degree of 
deacetylation (DD) and polymer molecular weight [1]. The degree of acetylation (DA = 1 – DD) 
is the amount of nitrogen sites occupied by acetyl groups (each nitrogen atom can react with one 
acetyl group) [5]. Chitosan is often considered when the DD is above 60%, while its molecular 
weight typically ranges from 50 to 2000 kDa. On the other hand, chitin typically has a DD below 
50% (Figure 4.1) [2, 6]. 
Chitosan solubility in water medium depends not only upon the DD, but also with the ionic con-
centration, the pH, the nature of the acid used for protonation, and the distribution of acetyl groups 
along the chain, as well as the conditions of isolation and drying of the polysaccharide. Moreover, 
it is also important to consider the intra-chain hydrogen bonds involving the hydroxyl groups [7]. 
 Structure-propriety relationship  
The presence of amino groups in the chitosan structure differentiates chitosan from chitin. Chi-
tosan has a pKa in the range of 6 to 6.5. Below this range, the amino groups are protonated and 
become positively charged, i.e., chitosan becomes a water-soluble cationic polyelectrolyte. Above 




6.5 the amino groups get deprotonated and thus the polymer becomes insoluble in water medium. 
Since the amino groups are the ones that determine chitosan solubility, pKa value is highly de-
pendent on the degree of N-acetylation [1, 6].  
Moreover, the presence of the amino groups gives chitosan the capacity to complex various spe-
cies, such as metal ions. As such, chitosan is often used for the treatment of waste waters, purify-
ing them by recovering heavy metals [6]. In its protonated state, chitosan is able to form ionic 
complexes with a wide variety of natural or synthetic anionic species such as lipids, proteins, 
DNA and some negative charged synthetic polymers [6].  
Chitosan shows crystallinity and polymorphism, depending on the origin of the polymer and its 
treatment during extraction process. In acidic environment, chitosan behaves as a pseudoplastic 
material and decreases viscosity with increasing shear rates. Viscosity of chitosan solution in-
creases with an increase in concentration, decreases with temperature and with increasing DD [1]. 
The degradation rate of chitosan augments when DD decreases, it is inversely related to the degree 
of crystallinity and also affected by the polymer molecular weight [1].  
Other notable intrinsic properties of chitosan are: antibacterial activity [8-10]; antifungal [11-14]; 
mucoadhesive [15-17]; analgesic [18, 19] and hemostatic properties [20, 21]; is biodegradable 
into non-toxic residues [1]. 
 Biological activity  
As above-mentioned, chitosan has remarkable properties that make it an interesting material for 
developing biomedical applications. These properties are controllable and a consequence of the 
protonable amino groups in chitosan’ structure [6]. 
The mucoadhesion results from negatively charged residues (sialic acid) in the glycoprotein that 
composes the mucus, the mucin. The protonated amino groups of chitosan in acidic medium in-
teract with the mucin, since the number of protonable amino groups is directly related to the DD, 
higher DD leads to improved mucoadhesion properties [6, 22]. 
The hemostatic property of chitosan is also related with the presence of the protonated amino 
groups of chitosan. When in contact with blood, positively charged chitosan tends to attract cir-
culating plasma proteins, resulting in platelet adhesion and activation on the surface of the mate-
rial and then thrombus formation [2, 6, 23]. 
Some studies also have proven that chitosan is only able to open the cellular membrane tight 
junctions in its protonated form due to the negative part of cellular membrane [24, 25]. 




The antibacterial activity of chitosan is partially explained by the presence of the amino groups. 
Microorganisms’ surface has predominantly anionic components (such as Gram-negative lipo-
polysaccharide and cell surface proteins) for which the chitosan has a high affinity. This ionic 
interaction alters cell permeability and prevents essential materials to enter the cells and/or leak 
fundamental solutes out of the cell. The other possible mechanism occurs for low molecular 
weight water-soluble chitosan and ultrafine nanoparticles that could penetrate cell wall of bacteria 
and combine with DNA inhibiting the synthesis of mRNA and DNA transcription [2, 26]. 
Other biological attributes of chitosan have been proved, such as anti-ulcerogenic, anti-tumor, 
immune modification, renal protective and osteogenic actions, analgesic effect, and scaffold to 
allow skin or bone cell growth [27, 28]. 
 Biodegradability 
Chitin and chitosan are partially biodegradable in the presence of human enzymes and are non-
toxic and beneficial to the human body [29]. It is important to consider that chitosan is a polysac-
charide and consequently contains breakable glycosidic bonds [6]. Glucosamine is the major com-
ponent of chitosan and is a natural substance produced in the body from glucose. Glucosamine is 
involved in the manufacture of glycosaminoglycan, which forms cartilage tissue in the body; this 
molecule is also present in tendons and ligaments [2]. 
Chitosan can undergo chemical and enzymatic degradation. Chemical degradation, also men-
tioned as acid catalyzed degradation can occur in the stomach. Enzymatic degradation can occur 
by several proteases, and mainly lysozyme. Other degradation fates can also occur such as oxida-
tion-reduction reaction and free radical degradation. However, these are unlikely to play an im-
portant role in chitosan’ degradation in vivo [1, 6]. 
Chitosan degradation depends upon the DD of the polymer. If a fully deacetylation of chitosan 
(DD of 100%) is achieved its structure changes from semi-crystalline to a crystalline polymer 
enhancing the biodegradation rate. Furthermore, the reduction of molecular weight also increases 
its biodegradation rate, since smaller chains are more rapidly degraded into oligosaccharides [1, 
6]. 
 Chitosan derivatives 
Chitosan has three types of reactive functional groups, the amino group and the primary and sec-
ondary hydroxyl groups. The presence of these groups provide many possibilities for covalent 




and ionic modifications of chitosan [30]. Consequently, chitosan derivatives can be roughly di-
vided according the site of functionalization: 1) specific reactions involving the NH2 group; and 
2) nonspecific reactions of the –OH groups (mainly esterification and etherification). 
Chitosan typically undergoes amines reactions such as N-acylation and Schiff reaction. N-acyla-
tion with acid anhydrides or acyl halides introduces amide groups at the chitosan nitrogen [31], 
through the quaternization of the amino group or a reaction in which an aldehyde function reacts 
with –NH2 by reductive amination. The latter reaction can happen in aqueous solution under very 
mild conditions to obtain randomly distributed substituents in a controlled amount along the chi-
tosan chain [7]. Linear aliphatic N-acyl groups above propionyl allow rapid acetylation of hy-
droxyl groups [31]. Chitosan and simple aldehydes produce N-alkyl chitosan upon hydrogenation. 
The presence of bulky substituent weakens the hydrogen bonds of chitosan; therefore N-alkyl 
chitosan swell in water in spite of the hydrophobicity of the alkyl chains, but they retain the film 
forming property of chitosan [31]. 
Consequently, a large number of chitosan derivatives have been produced. In the next paragraphs 
some examples of chitosan derivatives are detailed.  
 O- and N-Carboxymethyl chitosan 
O- and N-carboxymethyl chitosan is a chitosan derivative having carboxymethyl substituents on 
some or both the amino and primary hydroxyl sites of chitosan backbone [32]. This is an ampho-
teric polymer with solubility dependent on the pH used [32-36]. Under controlled reaction condi-
tions with sodium monochloroacetate in the presence of NaOH, the substitution in both the N- 
and the O-site can be obtained [7].  
N-carboxymethyl chitosan is obtained from glyoxylic acid in the presence of a reducing agent 
[31]. This derivative is water soluble in a wide range of pH, with the condition of being prepared 
from fully acetylated chitin [7]. 
 N-methylene phosphoric chitosan 
This anionic derivative of chitosan shows some amphoteric character and can be synthetized from 
several precursors. It has proven to have good complexing efficiency with cations such as Ca2+ 
and those of transition metals (Cu (II), Cd (II), Zn (II), among others). This complexation provides 
corrosion protection for metal surfaces, among other applications [7, 37-40]. 




 Trimethylated chitosan 
N-trimethyl chitosan is a water-soluble chitosan derivative that can be prepared by reductive 
methylation of amine groups of chitosan. The degree of quaternization directly influences the 
water solubility and the mucoadhesive properties [4, 41]. 
This chitosan derivative increases the permeation of hydrophilic macromolecules (like peptides 
and proteins) in neutral and basic environments, being applicable in intestinal delivery of peptide 
drugs. Moreover, effects are caused by opening the tight junctions [4, 41]. 
 HTCC and O-HTCC 
Ammonium quaternary chitosan derivatives have a permanent positive charge, that enables its 
full solubility in a large range of pH, and allows its interaction with cellular membranes [25]. The 
first quaternized chitosan was synthetized by alkylation of the primary amine groups of chitosan 
with various aldehydes using sodium borohydrate as reducing agent [4].  
Other quaternary derivatives of chitosan have been synthetized by attaching a quaternary ammo-
nium moiety to the amine group of chitosan. Xu et al. synthetized a quaternary derivative of 
chitosan, N-(2-hydroxyl) propyl-3-trimethyl ammonium chitosan chloride (HTCC), by reaction 
of chitosan with glycidyl trimethyl ammonium chloride (GTMAC) [42]. This chitosan derivative 
has excellent water solubility over wide pH range, besides maintaining its antibacterial and anti-
fungal properties, anti-tumoral activity, among others. Kaminski et al. [43] studied the ability of 
HTCC to bind to high-molecular-weight (unfractionated) heparin in PBS (phosphate buffer solu-
tion) at pH equal to 7.4. They proved that HTCC is able to bind with efficiency comparable to 
that for the clinically used protein, protamine sulfate. As such, the authors considered that HTCC 
is a good candidate to be used as intravenously for reversal of high- and low-molecular-weight 
heparin in blood. 
Sun and his coworkers have prepared a new chitosan derivative, O-HTCC (O-(2-hydroxyl) pro-
pyl-3-trimethyl ammonium chitosan chloride), through the reaction of chitosan with GTMAC. 
This reaction protects the amino groups and the obtained compound is soluble at neutral and basic 
pH values [25]. 





Figure 4.2. Chemical structure of chitosan and some of its derivatives. 
 Chitosan-based micro/nanoparticles 
The solubility in aqueous acidic solutions gives chitosan an inherent advantage for the preparation 
of micro/nanoparticles since it avoids the use of hazardous organic solvents and allows ionic 
cross-linking with multivalent ions in the free amine groups. In the form of micro/nanoparticles, 
chitosan’ structure has the inherent ability to control the release of active agents. Moreover, chi-
tosan’ inherent mucoadhesive character is maintained once in micro/nanoparticles structure and 
is the reason to increase residual time at the site of adsorption. Finally, chitosan micro/nanoparti-
cles can be sterilized by different methods such as ionizing radiation, heat, steam, and chemical 
methods, which is an advantage for clinical applications [44]. Because of all of these advantages, 
chitosan micro/nanoparticles have been widely used as drug delivery systems [36, 45-48]. 




There are several reported methods for the production of chitosan micro/nanoparticles. Selection 
of one of the available methods depends upon factors such as the desired particle size and size 
distribution, thermal and chemical stability of the active agent when the application is a drug 
delivery system, stability of the final product, and residual toxicity associated with the final prod-
uct, among others [44]. 
 Emulsion cross-linking 
The emulsion cross-linking method is based on the cross-linking between the free amine group 
of chitosan with the aldehyde group from the cross-linking agent (for example, glutaraldehyde) 
[44].  
In this method, a water-in-oil (w/o) emulsion is prepared whereas chitosan is dissolved in the 
water phase. The emulsion is stabilized by an adequate surfactant. Further, hardening of the drop-
lets is performed by crosslinking with the crosslinking agent. The size of the particles obtained is 
generally in the micron range since it is dependent upon the size of the droplets. Moreover, the 
size of the obtained particles also depends upon the extent of crosslinking agent used and the 
speed of stirring during the emulsion preparation [3, 44]. 
Kumbar and his team [49] used this method to prepare chitosan microspheres to encapsulate di-
clofenac sodium using three crosslinking agents, glutaraldehyde, sulfuric acid and heat treatment. 
The produced particles were spherical with smooth surfaces and a size within the range of 40 to 
230 m. However, Ohya et al. [50] was able to produce chitosan-gel nanospheres using the emul-
sion crosslinking method. These nanospheres had an average diameter of 250 nm and were able 
to encapsulate 5-fluorouracil and its derivatives.  
An important drawback in this technique is the use of harsh crosslinking agents that have proven 
to have negative effects on cell viability [3]. 
 Coacervation/precipitation 
The coacervation/precipitation method uses the cationic profile of chitosan since it is insoluble at 
alkaline pH medium. As such, chitosan precipitates/coacervates when in contact with alkaline 
solution. Particles are produced by blowing chitosan solution into an alkaline solution like sodium 
hydroxide (NaOH), NaOH-methanol or ethanediamine, using a compressed air nozzle to form 
coacervate droplets [44].  
The diameter of the nanoparticles can be controlled by varying the compressed air pressure or 
spray-nozzle diameter. In addition, the use of a crosslinking agent to harden particles can control 




the drug release [44]. The advantage of this technique is the better stability of particles compared 
to other methods [44]. 
 Emulsion droplet coalescence 
The emulsion droplet coalescence technique combines both emulsion crosslinking and precipita-
tion described above. Here, the precipitation is induced by allowing coalescence of CS droplets 
with NaOH droplets [3, 44]. 
In a first instance, two stable w/o emulsion are prepared: the first one contains chitosan aqueous 
solution in an oil phase; the second one contains aqueous solution of NaOH. When both emulsions 
are mixed under high-speed stirring, the droplets of each emulsion collide at a random manner 
and coalesce, thereby precipitating chitosan droplets to give small size particles [3, 44]. 
 Ionic gelation 
Ionic gelation method is a very simple and mild process to prepare chitosan micro/nanoparticles, 
which is the main reason for being a widely used technique [45, 48, 51-54]. 
This method is based upon a reversible physical crosslinking by electrostatic interaction, avoiding 
possible toxic effects of the reagents used in chemical crosslinking. Tripolyphosphate (TPP) is a 
polyanion that is able to interact with chitosan by electrostatic forces and consequently is the most 
used crosslinking agent. In this technique, chitosan is dissolved in aqueous acidic solution to ob-
tain the cation of CS. This solution is added dropwise under constant stirring to polyanionic TPP 
solution. Due to the complexation between oppositely charged species, CS undergoes ionic gela-
tion and precipitates to form spherical particles. The disadvantage of this technique is the poor 
mechanical strength of the obtained particles, limiting their use in drug delivery applications [3, 
44, 55]. 
Bodmeier et al. [56] first prepared TPP-CS complex by dropping CS droplets into a TPP solution. 
The technique was first reported in 1997 by Calvo et al. [57] for the preparation of chitosan, 
chitosan–poly(ethylene oxide) and chitosan–poly(ethylene oxide)–poly(propylene oxide) nano-
particles. Chitosan particles of nanometric size were obtained for chitosan concentrations up to 
2.8 g.l−1 and TPP concentrations from 0.21 to 0.43 g.l−1. Jonassen et al. [51] evaluated the stability 
of CS-TPP nanoparticles and found that upon storage in saline solvents the NPs were stable over 
a period of one month with respect to changes in particle size and particle compactness. 




Other techniques to produce chitosan micro/nanoparticles have been reported: spray drying [58], 
reverse micellar method [59], microemulsion method [60], polyelectrolyte complex method [61, 
62]. 
 Toxicity 
As a biocompatible polymer, chitosan is considered to be non-toxic [63]. It is approved for dietary 
applications in Japan, Italy and Finland [64] and for use in wound dressings by the FDA [65]. 
However, chitosan modifications can make it more or less toxic and any residual reactants should 
be carefully removed [1, 66]. Moreover, it is important to consider that chitosan toxicity also 
depends upon the route of administration, which determines the uptake, concentration, contact 
time and cell types affected [66]. 
 In vitro toxicity 
In a series of publications, Schipper et al. studied chitosan with different molecular weights and 
degree of deacetylation on CaCo-2 cells, HT29-H and in situ rat jejunum. The obtained toxicity 
results depend upon both DD and molecular weight. At high DD the molecular weight and con-
centration are responsible for the toxicity, being less toxic and less related to the molecular weight 
at lower DD. Indeed most of the chitosan tested did not increase dehydrogenase activity signifi-
cantly in the concentration range tested (1–500 μg.ml-1) on Caco-2 cells. The in situ rat jejunum 
study showed no increase in lactate dehydrogenase (LDH) activity with any of the CS tested (50 
μg.ml-1) [67, 68]. 
To investigate the safety of materials the red cell hemolysis assay is widely used. Richardson et 
al. [69] performed this assay using chitosan with different molecular weights. Their results show 
no hemolysis (< 10%) over 1 h and 5 h with chitosan of molecular weight below 5 kDa, between 
5-10 kDa and above 10 kDa at concentrations up to 5 mg.ml-1. In another study, no red blood cells 
lysis was observed with paclitaxel chitosan micelles at 0.025 mg.ml-1 [70]. 
An oligomer of trimethyl chitosan, a chitosan derivative with low cytotoxicity (Mw 3-6 kDa) with 
degrees of quaternization below 55% have an IC50 > 10 mg.ml-1. However, the cytotoxicity of 
this derivative increases with the increase of degree of trimethylation and increase in molecular 
weight (100 kDa) [71]. 
The combination of two biocompatible polymers, chitosan and alginate, represents an interesting 
development for microencapsulation of cells. An interesting study combined these two polymers 
to provide long-term viability of encapsulated baby-hamster kidney cells. In this case, no toxic 




effect was observed using an optimal one-step coating method. Four chitosan were tested: chi-
tosan chloride of 103 and 288 kDa at 87% and 84% DD and chitosan glutamate of 218 and 415 
kDa and 85% and 86% DD, respectively. The results were observed over time (40–60 days) con-
cerning the viability. Data were compared to non-encapsulated cells at 12 h post seeding; this is 
a poor comparison, as cell proliferation would increase ‘viability’. All capsules were shown to be 
mechanically stable for 4 months [72]. 
Interestingly, chitosan and its derivatives seem to be toxic to several bacteria [73], fungi [74] and 
parasites [75]. This pathogen related toxicity is an effect that could be advantageous in infectious 
disease control. When emulsions containing chitosan were tested, bacterial inhibition took place 
in acidic solutions pH 5–5.3, and an 87 kDa 92% DD chitosan was more effective than a 532 kDa 
73% DD chitosan against both Pseudomonas aeruginosa and Staphylococcus aureus. A lipid 
emulsion of the same chitosan was found to have antimycotic effect against Candida albicans 
and Aspergillus niger [73]. However, none of these studies hypothesized a mechanism of action 
for the inhibitory effect observed. 
 In vivo toxicity 
In vivo toxicity after administration is of great importance for the design chitosan based structures 
for biomedical applications. Hirano et al. [76] performed a relatively long study (65 days) in 
which no detrimental effect on body weight was found when chitosan oligosaccharides were in-
jected (7.1 – 8.6 mg.kg-1 over 5 days). Only an increase in lysozyme activity was apparent on the 
first day post injections. However, the administration of chitosan intravenously with a higher 
concentration (50 mg.kg-1) caused death. Rao et al. [77] have found no significant toxic effects 
of chitosan in acute toxicity tests in mice, no eye or skin irritation in rabbits and guinea pigs 
respectively. Moreover, the authors concluded that chitosan was not pyrogenic. Zhang et al. [70] 
found that LD50 (lethal dose for 50% of individuals) of paclitaxel chitosan micelles in mice was 
72.2 mg.kg-1, no anaphylaxis was observed in guinea pigs and no intravenous irritation was ob-
served histopathologically in rabbits at 6 mg.kg-1. Furthermore, another research group reported 
no adverse effects at 3.3-4 mg.kg-1 [78]. 
In a study on fat chelation, 4.5 g.day-1 chitosan (molecular weight and DD not specified) in hu-
mans was reported not to be toxic, although no significant reduction in fat was found [79]. Arai 
et al. [80] found that chitosan has an LD50 comparable to sucrose of >16 g.kg-1 in oral administra-
tion to mice. No oral toxicity was found in mice treated with 100 mg.kg-1 chitosan nanoparticles 
(80 KDa, 80% DD) [81]. After oral administration of trimethyl chitosan/pDNA nanoparticles a 
slight toxicity at high dose was observed, causing light diarrhea, which was relieved by stopping 




administration [82]. Buccal discs did not cause inflammation of the buccal mucous membrane 
[83]. Mukhopadhyay et al. [84] investigated the chronic oral toxicity of chitosan derivatives in 
the mice model. No death or other signs of toxicity were observed with a dose of 30 mg.kg-1 for 
one month. Furthermore, the intestinal luminal microbes successfully degraded the administrated 
polymers (chitosan and its derivatives). 
Exposure of rat nasal mucosa to chitosan solutions at 0.5% (w/v) over 1 h caused no significant 
changes in mucosal cell morphology compared to control [85]. Although most studies reveal low 
toxicity of chitosan and is approved its adoption as a safe material in drug delivery, among other 
biomedical applications, it is necessary to consider that any modification of chitosan can change 
its toxicity profile and so further safety studies are required. 
 Applications 
Chitosan’ interesting properties conjugated with its versatility to form different derivatives and 
different structure (micro/nanoparticles, hydrogels, films, etc.) explains the huge interest in this 
biopolymer for several applications. Being a polymer obtained from natural sources, chitosan is 
biocompatible and non-toxic. Furthermore, biodegradation studies have shown that chitosan is 
degraded into non-toxic residues.  
The main areas of applications for chitosan were summarized by Rinaudo et al. [7] and include: 
agriculture, water and waste treatment, food and beverages, cosmetics and toiletries, and finally 
biopharmaceutics. The latter include a wide range of applications from immunologic to anti-
tumoral and wound healing, drug delivery and tissue engineering. In the following, some of the 
most relevant applications of chitosan in the biomedical field are described. 
 Wound healing 
Alemdaroğlu et al. [86] prepared a simple chitosan hydrogel system by dissolving chitosan in 
acid/water mixture. This hydrogel was loaded with epidermal growth factors (EGF) and were able 
to release EGF within 24 h in vitro. In vivo studies showed a fastest healing with chitosan gels 
containing EGF compared to the non-GF-loaded chitosan gel. Another research group has found 
that chitosan and chitosan-bFGF (basic fibroblast growth factor) scaffolds caused accelerated 
wound closure in pressure ulcer treatment compared to control. However, only the chitosan-bFGF 
loaded samples enhanced angiogenesis [87]. 




Takei et al developed a gluconic acid chitosan derivative that is soluble at neutral pH. [88]. A gel 
of this derivative was formable by cryogelation (freeze-thawing) being able to maintain pH neu-
trality, without additives. Moreover, the gel was found to be nontoxic. When applied to full-thick-
ness skin wounds the cryogels were found to promote the accumulation of inflammatory cells, 
especially polymorphonuclear leukocytes, accelerating wound healing. 
 Tissue engineering 
Tissue engineering is a highly interdisciplinary field that combines the principles and methods of 
life sciences and engineering, which utilizes structural and functional relationships in normal and 
pathological tissue to develop biological substitutes to restore, maintain, or improve biofunction-
ality. Chitosan’ properties such as biodegradability, nontoxicity and the possibility of being for-
mulated in a variety of forms including powders, gels and films, increases its potential of appli-
cations in tissue engineering [1]. 
Zhang and Zhang [89, 90] have developed chitosan-calcium phosphate composites with a three-
dimensional (3D) macroporous bioceramic embedded with porous chitosan sponges to minimize 
additional local inflammation and to allow osteoconduction. The chitosan sponge enhances the 
mechanical strength of the ceramic phase through matrix reinforcement and preserves the osteo-
blast phenotype. Hu et al. [10] prepared a chitosan– hydroxyapatite (HA) multilayer nanocompo-
site with high strength and bending modulus rendering the material suitable for possible applica-
tion for internal fixation of long bone fractures. 
Ang et al. [91] designed a robotic desktop rapid prototyping (RP) system to fabricate scaffolds 
for bone tissue engineering applications. The set-up consisted of a computer-guided desktop robot 
and a one-component pneumatic dispenser. The dispensing material, chitosan and chitosan–HA 
dissolved in acetic acid, were forced out through a small Teflon lined nozzle into a dispensing 
sodium hydroxide–ethanol medium. Layer-by-layer, the chitosan was fabricated with a pre-pro-
grammed lay-down pattern. The attachment between layers allowed the chitosan matrix to form 
interconnected channeled architectures. The in vitro osteoblast studies revealed the biocompati-
bility of the scaffolds with cells exhibiting healthy morphology and avid proliferation throughout 
the culture period. The rapid prototyping robotic dispensing system is capable of fabricating 3D 
scaffolds with regular and reproducible macropore architecture. 
Chitosan is also used for cartilage [92], liver [93, 94], and nerve tissue [95, 96] engineering. 




4.2. Materials and methods 
All the chemical reagents used in this research work were of analytical grade and used without 
further purification. 
 Chitosan depolymerization 
Chitosan (DD 75.5%, Cognis) was depolymerized by chemical reaction with sodium nitrite 
(NaNO2, Sigma-Aldrich) based on an adapted method of Huang and coworkers [97]. Briefly, 2.5 
g of chitosan was dissolved in 250 ml of acetic acid 1% (V/V) (Panreac), followed by addition 
of the desired amount of NaNO2, previously dissolved in 10 ml of ultrapure water. The mixture 
was let to react for 1 hour under mechanical agitation. Low molecular weight chitosan was pre-
cipitated with sodium hydroxide (NaOH, Eka) 1 M, followed by centrifugation and several 
washes with ultrapure water. The final obtained product was freeze-dried and stored in a dry 
place.  
  Dilute solution viscosity 
The molecular weight of depolymerized chitosan was measured by dilute solution viscosity using 
an Ubbelöhde capillary viscometer (No 0a) at 30 ºC. Chitosan solutions of different concentra-
tions in 0.2 M acetic acid and 0.1 M sodium acetate (Scharlau) were prepared. The flow times of 
chitosan solutions and solvent were recorded in quintuplet and the average value was calculated. 
The intrinsic viscosity [] was calculated graphically by extrapolating the curve of reduced vis-
cosity versus concentration to zero concentration. The Mark-Houwink-Sakurada (MHS) equation 
was used to calculate the molecular weight of depolymerized chitosan (K = 2.26x10-5 dl.g-1, = 
0.95) [98]. 
 O-HTCC synthesis 
O-HTCC was synthetized using an adapted method of Wang and his coworkers [99]. Chitosan 
with different molecular weights was used to produce the ammonium quaternary derivative. 
Briefly, 5 g of chitosan was dissolved in 250 ml of acetic acid 2% and 125 ml of methanol (Sigma-
Aldrich). After complete dissolution, 32 ml of benzaldehyde (Fluka) was added to the reaction 
vessel. The reaction occurred for 24 h with agitation, forming a white gel. The gel was neutralized 
with sodium hydroxide 1 M, filtered and washed in turns with acetone (Fisher chemical) and 
methanol. After freeze-drying, the product was mixed with 5 g of glycidil trimethyl ammonium 




chloride (GTMAC, Sigma-Aldrich) and 50 ml of isopropyl alcohol. The second reaction occurred 
at 70 ºC for 16 hours. The obtained product was filtered, and washed with acetone and methanol 
several times. Again, after freeze-drying, the obtained product was added to 100 ml of ethanolic 
HCl 0.25 M (Fluka) and let to react for 24 hours at room temperature. At the end of the reaction, 
25 ml of ultrapure water was added, followed by an excess of acetone to precipitate the final 
product. This product was filtered, and washed several times with acetone and methanol. In order 
to purify O-HTCC, it was re-dissolved in water and precipitated with excess acetone. After filter-
ing and washing, the obtained O-HTCC was freeze-dried and stored in a dry place. 
 Preparation of CS and O-HTCC NPs 
Chitosan and O-HTCC nanoparticles were produced through ionotropic gelation [100] using dif-
ferent concentrations and molecular weight of the polymers and several concentrations of tripol-
yphosphate (TPP, Sigma-Aldrich) (Table 4.1). TPP solution was rapidly added to the polymer 
solution with magnetic stirring. The nanoparticles suspension was kept on magnetic stirring for a 
determined incubation time before any characterization. 
To produce chitosan and O-HTCC coated iron oxide nanoparticles, an appropriate amount of iron 
oxide NPs suspension (4 mg.ml-1) was added to either chitosan or O-HTCC solution followed by 
the addition of TPP. The addition of the polyanion was performed under ultraturrax, and kept 
under stirring for 5 minutes. For purification, core-shell nanoparticles where separated using a 
magnet and washed several times with ultrapure water. The final product was freeze-dried and 
stored in a dry place for further characterization. 
 Characterization 
 Fourier Transform Infrared (FTIR) spectrometry 
To investigate changes in the chemical bounds of the samples Infrared spectrometry was used. 
FTIR spectra of the samples were obtained using a Nicolet 6700 – Thermo Electron Corporation 
Attenuated Total Reflectance-Fourier Transform Infrared spectrometer (ATR-FTIR). Measure-
ments were performed in freeze-dried samples in the range of 480 to 4500 cm-1. 
 




Table 4.1. Studied conditions by dynamic light scattering to optimize the production of chitosan and O-
HTCC nanoparticles. 
 CS O-HTCC TPP Incubation 























0.1 8.8 0 






























 1H NMR and 13C NMR 
1H NMR and 13C NMR spectra were recorded on a Bruker Avance III 400, at 400 and 100 MHz 
respectively, using D2O as solvent. The solvent signals were used as internal standards for both 
1H NMR and 13C NMR recordings. 
 Thermogravimetric analysis (TGA) 
Thermogravimetric analysis and differential thermal analysis (DTA) studies were carried out us-
ing a Thermal Analyzer NETZSCH STA 449 F3 Jupiter® at a rate of 10 ºC.min-1 in a N2 atmos-
phere.  




 Dynamic light scattering (DLS) 
Hydrodynamic diameter (DH) of the nanoparticles was measured by means of dynamic light scat-
tering equipment (Avid Nano) using the blade cell at 20 ºC.  
Dynamic light scattering and zeta potential measurements were performed using a SZ-100 nano-
partica series (Horiba, Lda) with a laser of 532 nm and controlling temperature with a Peltier 
system (25 ºC). DLS measurements were carried out for diluted NPs suspensions in triplicates 
using a disposable cell with a scattering angle equal to 90º. Data analysis was performed using 
cumulants statistics to measure hydrodynamic diameter and polydispersity unless stated other-
wise. Zeta potential measurements were performed with a scattering angle equal to 173º, in a 
graphite electrode cell. 
 X-ray diffraction (XRD) 
The crystalline phases of the samples were verified using powder X-ray diffraction. X’Pert PRO 
PANAlytical X-ray diffractometer was used to obtain X-ray diffraction patterns of the iron oxide 
nanoparticles previously freeze-dried. The 2θ values were taken from 15º to 80º using a Cu-Kα 
radiation (k = 1.54060 Å) with a step size of 0.033. The Scherrer’s equation was used to measure 
the average crystallite size. 
 Iron content determination 
The iron content of the samples was determined using the 1,10-phenantroline colorimetric method 
[101], similarly to the description in Chapter 3.  
To obtain the nanoparticles concentration the formula [Fe] = 0.7 x [NPs] was used. The ratio was 
obtained from control experiments. 
 Superconducting quantum interference device (SQUID) 
The DC magnetic properties were performed using a 7T SQUID magnetometer (S700X; Cryo-
genic Ltd.). The zero-field cooled (ZFC) and field-cooled (FC) measurements were performed by 
cooling the sample to 5 K at zero fields or in the presence of an external field of 100 Oe, respec-
tively. All the magnetic measurements were carried out in increasing temperature range 5–320 K. 
Isothermal magnetization curves were obtained for fields up to 5 T for temperatures of 10 and 
320 K. 




4.3. Results and discussion 
 Chitosan depolymerization 
Being a product of chitin deacetylation, chitosan is characterized mainly by two variables, 
namely, degree of deacetylation and the molecular weight. Degree of deacetylation determines 
the number of free amino groups present in chitosan chain, which determines it functionality, 
polarity, and water solubility. On the other hand, molecular weight determines the strength of its 
fibers/films and viscosity of its solution. Chitosan molecular weight can be manipulated using 
different depolymerization methods such as acid hydrolysis (HCl, HNO2, etc.), free radicals 
(H2O2, K2S2O8) enzymatic, radiations (UV, -rays), ultrasound, microwave, and thermal treat-
ments [102].  
Chitosan depolymerization was performed in order to evaluate the influence of the molecular 
weight in the nanoparticles physicochemical properties. The used technique is very common, 
simple, and rapid, and allows obtaining chitosan with different molecular weights only by chang-
ing the amount of NaNO2 added to the reaction vessel. In acidic solution sodium nitrite produces 
nitrous acid (HNO2), which lowers chitosan molecular weight by deamination reaction with sub-
sequent cleavage of -glycosidic linkages. 
FTIR spectrum of the initial chitosan with 469 kDa is shown in Figure 4.3 exhibiting the typical 
bands for this natural polymer. The band at 3357 cm-1 corresponds to the O-H stretching overlap-
ping the N-H stretching, while the band at 2874 cm-1 is attributed to the C-H stretching. The amide 
II bands can be found at 1649 cm-1 and 1587 cm-1, corresponding to the C-O stretching of the 
acetyl group, and to the N-H bending, respectively. The sharp bands at 1415 cm-1, 1374 cm-1 and 
1316 cm-1 are attributed to the –CH2 bending, the asymmetrical C-H bending of the CH2 group, 
and the amide III band, respectively. The bands related to the C-O-C bridge are located at 1150 
cm-1 (anti-symmetric stretching of C-O-C bridge), 1023 cm-1 (skeleton vibrations involving the 
C-O-C stretching bands), and 892 cm-1 (C-O-C stretching of the glycosidic linkage). Finally, the 
band at 1064 cm-1 is attributed to the C-N stretching vibration mode [103].  
Figure 4.4 shows the FTIR spectra of the four low molecular weight chitosan obtained after de-
polymerization. Comparison between chitosan and depolymerized chitosan shows almost similar 
spectra, which indicates that the process of depolymerization caused no chemical change in the 
structure of the polymer. 





Figure 4.3. FTIR spectrum of initial chitosan before depolymerisation with a molecular weight of 469 kDa. 
 
Figure 4.4. FTIR spectra of four low molecular weight chitosan samples obtained from chitosan with 469 
kDa using NaNO2 as the depolymerisation agent. 
The molecular weight of depolymerized chitosan was measured by dilute solution viscosity. This 
is a simple and rapid technique to determine a polymer molecular weight. Typically, a polymeric 
sample is dissolved in an appropriate solvent at a specified concentration in the range of g.dl-1. 




Polymer solution viscosity is measured relative to the pure solvent viscosity. Relative viscosity 






Where  is the polymer solution viscosity and is the viscosity of the pure solvent. The specific 





 Equation 4.2 
The reduced viscosity (red) is the fluid viscosity increase per unit of polymer solute concentration 
(C). The intrinsic viscosity ([]) can be determined as the limit of the reduced viscosity as the 
polymer solute concentration approaches zero, or the limit of the inherent viscosity (inh), 














Note that the intrinsic viscosity is not viscosity. Intrinsic viscosity is the volume per unit mass 
that the polymer occupies in a solution, which is the inverse of molecular density. Extrapolation 
to zero polymer concentration is intended to eliminate polymer intermolecular interactions. The 
plots used to find the intrinsic viscosity are called the Huggins plot (red vs. C) and the Kraemer 
plot (ln(/0) vs. C) as represented in Figure 4.5. The common intercept between both plots is the 
intrinsic viscosity.  
The intrinsic viscosity measured in a specific solvent is related to the average molecular weight 
(Mv) of the polymer by the Mark-Houwink-Sakurada (MHS) equation: 
[𝜂] = 𝐾. 𝑀𝑣
𝛼
 Equation 4.4 
Where K and  are Mark-Houwink constants that depend upon the type of polymer, solvent, and 
the temperature of the viscosity determinations. These constants can be determined experimen-
tally by measuring the intrinsic viscosities of several polymer samples with known molecular 
weight, measured by an independent method. By plotting the log [] vs. log Mv the  constant 
can be determined from the slope of the obtained straight line, while K is obtained from the log 




of the intercept. Kasaai [104] proposed two equations as a model to determine  and K for chi-
tosan in any solvent-temperature system, using viscosimetric constants data reported by several 
research groups. These equations were used in the present work to determine the viscosimetric 
constants,  (Equation 4.5) and K (Equation 4.6). 
𝛼 = 0.6202 +
0.699𝑥
0.4806 + 𝑥
 Equation 4.5 
log 𝐾. 10−5 = −5.7676. 𝛼 + 5.9232 Equation 4.6 




 Equation 4.7 
With DA being the degree of acetylation, pH of chitosan solution in any solvent with ionic 
strength of , within a range of temperature of 20 ºC to 30 ºC. 
 
Figure 4.5. Schematic representation of typical Huggins and Kraemer plots showing the common intercept 
for both curves, which corresponds to the intrinsic viscosity [] of the polymer. 
Five different samples of low molecular weight chitosan were obtained (Table 4.2) using NaNO2 
as a depolymerization agent. The depolymerization process used in the present work was not only 
fast and simple, but also very successful since the Mv of chitosan was lowered by twelvefold, 
from 469 kDa to 38 kDa. Moreover, the process is reproducible. The obtained low molecular 




weight samples were used subsequently for O-HTCC synthesis and for chitosan nanoparticles 
preparation. 
Table 4.2. Results from dilute solution viscosity, comparing the amount of NaNO2 used, the intrinsic vis-
cosity ([]) and the obtained average viscosimetric molecular weight (Mv). 
NaNO2 (mg) [] (dL.g-1) Mv (kDa) 
0 7.34 469 
12.5 3.31 ± 0.05 215 ± 4 
25 2.34 ± 0.14 152 ± 9 
50 1.34 ± 0.11 87 ± 7 
75 0.78 ± 0.03 50 ± 2 
100 0.59 ± 0.04 38 ± 3 
 
 O-HTCC synthesis 
O-HTCC synthesis was performed not only to obtain water-soluble chitosan derivative, but also 
to study the differences between CS and O-HTCC NPs.  
 
Figure 4.6. Schematic representation of the O-HTCC reaction mechanism. 




The reaction mechanism is relatively simple and can be divided in three steps as shown in Figure 
4.6: the first step is the addition of benzaldehyde to protect the NH2 groups. This step is crucial 
to obtain O-HTCC, otherwise the GTMAC that couples to chitosan in the second step would have 
couple to NH2 group instead of OH. In this scenario, chitosan would lose its positive charge once 
in acidic solution. The final and third step is the removal of benzaldehyde, reestablishing the NH2 
group. 
 FTIR analysis 
FTIR studies were performed to confirm the synthesis of chitosan derivative. Figure 4.7 shows 
the FTIR spectra of O-HTCC and the two intermediate reactions. The first intermediate reaction 
(CTB) in addition to CS characteristic bands should have the bands correspondent to the aromatic 
ring of benzaldehyde. The band at 3153 cm-1 is attributed to the =CH stretching vibration, while 
the bands at 2869 cm-1 and 1693 cm-1 are attributed to the H-C=O and C=O stretching vibrations 
in the aldehyde group, respectively. The band at 1640 cm-1 is caused by the stretching vibration 
for C=N, obtained from the reaction between –NH2 group of chitosan and benzaldehyde. Further 
the bands at 1602 cm-1, 1553 cm-1 and 1399 cm-1 are related to the C-C stretch in the aromatic 
ring of benzaldehyde [24, 25, 105]. 
 
Figure 4.7. FTIR spectra of O-HTCC and the two reaction intermediates. 
The second intermediate reaction has an extra trimethylammonium group in comparison to CTB 
that comes from GTMAC. Despite the presence of the remaining bands already described, the 




FTIR spectrum of this reaction shows the bands at 1638 cm-1 and 1582 cm-1 attributed to the C=N 
stretching vibration and the C-C stretching vibration in the aromatic ring, respectively, showing 
the presence of benzaldehyde protecting the NH2 groups. In addition, a band at 1478 cm-1 appears 
which can be attributed to the asymmetric angular bending of methyl groups of quaternary hy-
drogen [106]. 
Finally, in O-HTCC FTIR spectrum the typical bands of chitosan are present. The band of the 
primary amino group of O-HTCC shifted to 1647 cm-1. The band at 1484 cm-1 confirms the pres-
ence of the methyl groups of the quaternary hydrogen, which indicates that the substitution reac-
tion occurred successfully The bands at 1522 cm-1 and 1309 cm-1 are attributed to the stretching 
vibration of amide II and amide III, respectively, which confirms the successful removal of ben-
zaldehyde [24, 25, 106].  
 1H NMR and 13C NMR of O-HTCC 
Figure 4.6 represents 1H NMR and 13C NMR spectra of O-HTCC. The peak at 3.36 ppm related 
with the 1H NMR spectra of CH2 (O-CH2) is due to characteristic methylene protons of the reacted 
chitosan hydroxyl group with quaternary ammonium salts. The peak at 3.13 ppm belongs to three 
methyl protons of the quaternary ammonium salt. 13C NMR spectra confirm the successful sub-
stitution; the peak at 54 ppm is due to the carbon of methyl groups in the ammonium quaternary 
salt [24, 25]. 
  
Figure 4.8. A) 1H-RMN of O-HTCC; B) 13C-RMN of O-HTCC. 
 Thermal analysis of chitosan and O-HTCC 
Chitosan and O-HTCC were both characterize by thermogravimetric analysis for better under-
standing of the physical and chemical changes that may have occur in the polymer during synthe-
sis. Thermogravimetric curves (sample weight % as a function of temperature) and its derivative 




(DTA) are displayed in Figure 4.9. The chitosan degradation took place in two stages. The first 
stage occurred between 30 ºC to 130 ºC, which corresponds to a mass loss of 8.5% and is associ-
ated to water removal. The second stage started at 260 ºC and reached a maximum at 304 ºC, 
resulting in a mass loss of 50%. This stage is associated to a complex process including dehydra-
tion of saccharide rings, depolymerization, and decomposition of the acetylated units of polymer 
[105]. The remaining amount of product at 900 ºC was 29.1%. 
  
Figure 4.9. TGA and DTA of chitosan (CS 469 kDa) and O-HTCC 469 kDa. 
Similarly, to chitosan, O-HTCC thermal degradation occurred in two steps. The first step that 
corresponds to the removal of water occurred from 30 ºC to 190 ºC with a weight loss of 14%. 
The second stage observed among the temperature as 190-300 ºC with a weight loss of 42.3%, 
corresponds to O-HTCC degradation. At 900 ºC the remained amount of product was 26%. 
 Preparation of CS and O-HTCC nanoparticles  
There are several available methods to prepare chitosan NPs. In the present work a simple and 
rapid method was used, the ionotropic gelation technique. In this technique sodium tripolyphos-
phate (TPP) complexes with chitosan to form ionically cross-linked nanoparticles (Figure 4.10) 
[47, 57].  
 FTIR analysis 
To confirm the ionic bonding between chitosan and TPP, FTIR measurements were performed. 
Figure 4.11 shows the FTIR spectra of chitosan, tripolyphosphate and chitosan nanoparticles pro-
duced by ionotropic gelation. Comparison of the FTIR spectra of chitosan NPs with the one of 
chitosan shows only small differences. The band at 3357 cm-1 becomes wider, indication that 
hydrogen bounding is enhanced. The band at 1587 cm-1 that corresponds to N-H bending vibration 




disappears and a new band at 1536 cm-1 appears which may be attributed to N-O asymmetric 
stretching vibration mode [107]. These differences are consistent with the bonding between TPP 
and CS through the amino groups of chitosan. 
 
Figure 4.10. Schematic representation of the ionic interaction between chitosan and TPP.  
 
Figure 4.11. FTIR spectra of chitosan (CS), tripolyphosphate (TPP) and chitosan nanoparticles (NP CS). 




 Thermal analysis 
Chitosan and O-HTCC nanoparticles were both characterized by thermogravimetric analysis for 
better understanding the physical and chemical changes that may have occurred in the polymer 
structure upon formation of the nanoparticles. Thermogravimetric curves (sample weight % as a 
function of temperature) and its derivative (DTA) are displayed in Figure 4.23. Similar to chi-
tosan, chitosan nanoparticles degradation took place in two stages. The first stage occurred be-
tween 30 ºC to 160 ºC, corresponds to a mass loss of 20% that is associated with the removal of 
water. The second stage started at 230 ºC and continued up to 360 ºC, resulting in a mass loss of 
32%. This stage is associated to polymer degradation. The remaining amount of product at 900 
ºC was 31%. In the case of CS nanoparticles polymer degradation is softer, and starts earlier, 




Figure 4.12. TGA (A, C) and DTA (B, D) of chitosan and chitosan nanoparticles, O-HTCC and O-HTCC 
nanoparticles, respectively. 
Thermal degradation of O-HTCC nanoparticles (Figure 4.12 C and D) occurred also in two steps. 
The first step that corresponds to the removal of water occurred from 30 ºC to 120 ºC with a 




weight loss of 9%. The second stage observed among the temperature as 200-330 ºC with a weight 
loss of 28%, corresponds to O-HTCC degradation. At 900 ºC the remained amount of product 
was 46%. 
 Dynamic light scattering studies 
Ionic gelation is a rapid and simple technique to produce chitosan nanoparticles that is highly 
dependent upon experimental conditions. As a way to optimize the NPs production, an extensive 
dynamic light scattering study was performed. 
Preliminary studies were performed to identify the range of concentrations that produced nano-
particles. Figure 4.13 shows the aspect of chitosan nanoparticles suspension with different TPP 
and chitosan concentrations. Chitosan solutions with 0.2 wt.%  and 0.4 wt.% were prepared by 
dissolving the desired amount of chitosan in acetic acid 1% (v/v). Further, an equal volume of 
TPP solutions with different concentrations ranging from 0.05 wt.% to 0.4 wt.% was added to 
chitosan solution. Different aspects were found from the taken photographs. For smaller concen-
trations of TPP, a clear solution or an opalescent suspension is visible. Moreover, larger aggre-
gates are formed when the initial concentration of TPP is higher. 
 
Figure 4.13. Photograph of chitosan nanoparticles prepared by ionotropic gelation using different concen-
trations of TPP and chitosan. 
Based on these preliminary results the initial concentration of TPP selected was within the range 
of 0.05 wt.% to 0.15 wt.%, since for higher concentrations of TPP larger aggregates are produced. 
Therefore, in a first step of the dynamic light scattering study CS NPs were produced using chi-
tosan with higher molecular weight, 469 kDa. The variable parameters were chitosan concentra-
tion and TPP concentration. At the same time, O-HTCC nanoparticles were produced and ana-
lyzed using the same conditions as the ones for chitosan. 




Figure 4.14 shows the obtained results for the first step of the DLS study for CS and O-HTCC 
NPs. At a first glance, a huge difference in the hydrodynamic diameter can be observed between 
chitosan and O-HTCC NPs. Further, the increase in TPP concentration leads to nanoparticles with 
higher hydrodynamic diameters for almost all cases. The initial CS concentration of 0.2 wt.% 
seams to produce nanoparticles with smaller hydrodynamic diameters but for O-HTCC the oppo-
site occurs: an initial O-HTCC concentration of 0.4 wt.% corresponds to smaller hydrodynamic 
diameters. 
  
Figure 4.14. Results from the first step of the dynamic light scattering study for CS and O-HTCC NPs: 
hydrodynamic diameter as a function of TPP concentration (wt.%) for two different chitosan and O-HTCC 
concentrations. 
Further steps were performed for a TPP concentration of 0.1% for both chitosan and O-HTCC 
nanoparticles production. Next, the ideal concentration of CS and O-HTCC for the formation of 
NPs was confirmed. For that, nanoparticles of either chitosan or O-HTCC were produced by 
changing the polymer concentration and molecular weight (Figure 4.15). Chitosan results show 
that within the tested range of chitosan molecular weight the obtained hydrodynamic diameter is 
smaller for nanoparticles produced with CS 0.2 wt.%. Similarly, O-HTCC of higher molecular 
weight produced smaller nanoparticles for an initial concentration of 0.2 wt.%. For the remaining 
molecular weights, no significant difference can be observed. That said, the remaining DLS study 
was performed using an initial polymer concentration of 0.2 wt.% for the production of both CS 
and O-HTCC NPs. 
The effect of incubation time on the NPs hydrodynamic diameter was evaluated, by producing 
polymeric nanoparticles using an initial polymer concentration of 0.2 wt.% and TPP 0.1 wt.% 
(Figure 4.16). DLS measurements were performed immediately after NPs production, 24 h, and 
48 h after NPs production. For almost all cases, no significant differences were found between 




measurements. Only for nanoparticles produced with chitosan 469 kDa some differences were 
observed, as the NPs diameter increases with the increase of incubation time. 
 
Figure 4.15. Hydrodynamic diameter of chitosan and O-HTCC nanoparticles produced with different pol-
ymer concentrations (0.2 and 0.4 wt.%) and molecular weight (469 – 50 kDa). 
  
Figure 4.16. Hydrodynamic diameter of polymeric NPs produced using an initial CS (A) or O-HTCC (B) 
concentration of 0.2 wt.% and TPP 0.1 wt.% measured immediately, 24 h and 48 hours after NPs produc-
tion. 
Furthermore, the effect of two variables was accessed: the effect of stirring and the pH of TPP 
initial solution, by producing polymeric nanoparticles using polymers (CS and O-HTCC) with 
different molecular weights. To a known volume of polymeric solution, the same volume of TPP 
solution was added, with and without magnetic stirring. TPP solutions were prepared with a con-
centration of 0.1 wt.% and final pH was adjusted to 5, 9, and 13. Figure 4.17 shows the obtained 
results. Regarding the influence of the pH of TPP solution, in almost all cases no significant dif-
ference is observed between pH 5 and 9, except for the highest molecular weight. Moreover, in 
some cases pH 13 originates larger nanoparticles. Since no reasoned conclusion was found, TPP 
0.1 wt.% was prepared without further adjustments, giving a final pH of about 8.8.  






Figure 4.17. Influence of the pH of the initial solution of TPP and of stirring. Hydrodynamic diameter of 
CS and O-HTCC NPs produced (A, C) without and (B, D) with stirring as a function of polymer molecular 
weight. 
Regarding the influence of magnetic stirring (Figure 4.17 B and D) again no significant difference 
was found. To analyze this issue, O-HTCC nanoparticles were subject to sonication for a few 
seconds and then again measured in DLS. Comparing the O-HTCC nanoparticles produced with-
out stirring, with magnetic stirring and with sonication (Figure 4.18) it is clear that within the 
tested range of molecular weight sonication provides the means to obtain smaller O-HTCC nano-
particles. As such, for the next steps polymeric nanoparticles were prepared using sonication for 
a few seconds, to avoid the degradation of the polymeric chain. 
To summarize, optimal conditions to produce both chitosan and O-HTCC conditions, under the 
tested ranges, are: 
 Chitosan solution of 0.2 wt.% in acetic acid 1%; 
 TPP solution of 0.1 wt.% in water; 
 Incubation time has no influence in the hydrodynamic diameter, for almost all cases; 
 TPP solution pH as prepared (around 8.8); 
 Sonication for a few seconds. 





Figure 4.18. Hydrodynamic diameter of O-HTCC nanoparticles prepared without stirring, with magnetic 
stirring and with sonication.  
Finally, the hydrodynamic diameter of chitosan and O-HTCC within the range of molecular 
weight tested was measured, and is presented in Figure 4.19. The produced polymeric nanoparti-
cles have an average hydrodynamic diameter below 200 nm, even for the higher molecular weight 
tested (469 kDa). Comparison between chitosan and O-HTCC nanoparticles with similar molec-
ular weight shows no significant differences in almost all cases. 
 Zeta potential measurement 
Zeta potential measurements (Figure 4.20) were performed in diluted samples in a volume factor 
of 1:100, without further adjustment of pH. The final pH of the nanoparticles suspensions is 
slightly acidic, around 5-6. In both cases, polymeric nanoparticles show a positive zeta potential. 
Chitosan nanoparticles have a zeta potential above +30 mV that does not significantly change 
with the molecular weight. This means that the produced chitosan may be considered stable in 
aqueous suspensions [108]. 





Figure 4.19. Hydrodynamic diameter of CS and O-HTCC NPs produced under optimal conditions as a 
function of the polymer molecular weight. The results are expressed as the average ± standard deviation 
for 3 independent experiments. *p<0.05 compared with chitosan nanoparticles with similar molecular 
weight. 
 
Figure 4.20. Zeta potential of chitosan and O-HTCC nanoparticles prepared under optimal conditions as a 
function of the polymer molecular weight. The results are expressed as the average ± standard deviation 
for 3 independent experiments. 




 Preparation of chitosan coated Fe3O4 nanoparticles 
Chitosan is often used as a coating for Fe3O4 NPs for biomedical applications. Since the final 
purpose of this PhD thesis is to produce multifunctional NPs suitable for cancer theranostics, in 
this section the optimal conditions for CS-Fe3O4 NPs productions are studied. 
Preparation of CS-Fe3O4 NPs was performed using the optimal conditions obtained for the prep-
aration of Fe3O4 NPs and of chitosan NPs. Coating of chitosan was performed for two types of 
Fe3O4 NPs prepared in Chapter 3: pristine Fe3O4 and Fe3O4 TD. Unless state otherwise, the fol-
lowing studies were performed using chitosan with the highest molecular weight, 469 kDa. 
 Structure and physical characterization 
FTIR measurements were performed to confirm the bonding between chitosan and iron oxide 
nanoparticles. Figure 4.21 shows the FTIR spectrum of chitosan coated Fe3O4 NPs in comparison 
to chitosan spectrum (NP CS) and the respective Fe3O4 sample. 
FTIR spectrum of chitosan coated Fe3O4 NPs produced by chemical precipitation (Figure 4.21 A) 
is very similar to the one of chitosan coated Fe3O4 NPs produced by thermal decomposition (Fig-
ure 4.21 B). In both cases, typical bands of chitosan are present in the spectra, with the addition 
to the band at 560 cm-1 attributed to Fe-O stretching vibration mode. 
  
Figure 4.21. FTIR spectra of chitosan coated Fe3O4 NPs: A) chitosan conjugated with pristine Fe3O4 pro-
duced by chemical precipitation (NPs CS Fe3O4); B) chitosan conjugated with pristine Fe3O4 produced by 
thermal decomposition (NPs CS Fe3O4 TD). 
XRD measurements were performed to analyze the structure and crystallinity of the samples. 
Figure 4.22 shows the XRD patterns obtained for pristine Fe3O4 NPs, chitosan and chitosan coated 
Fe3O4 NPs. The six characteristic peaks occurred at 30.1, 35.5, 43.2, 53.5, 57.0, and 62.8 and have 
been previously identified in Chapter 3 as the diffraction peaks of crystalline cubic magnetite 




structure. The same diffraction peaks are present in the spectra of chitosan coated Fe3O4 NPs, 
indicating that the presence of chitosan does not change the crystalline phase of Fe3O4. 
 
Figure 4.22. X-ray patterns of pristine Fe3O4 NPs, chitosan (CS), and chitosan coated Fe3O4 NPs (NP CS 
Fe3O4). 
 Thermal analysis 
Chitosan-coated pristine Fe3O4 nanoparticles were characterized by thermogravimetric analysis 
for better understanding the physical and chemical changes that may have occurred in the polymer 
during coating. Thermogravimetric curves (sample weight % as a function of temperature) and 
its derivative (DTA) are displayed in Figure 4.23. 
The degradation took place in two stages. The first stage occurred between 30 ºC to 160 ºC, cor-
responds to a mass loss of 21% that is associated with the removal of water. The second stage 
resulted in a mass loss of 24% correspondent to chitosan degradation between 210 ºC and 380 ºC. 
The remaining amount of product at 900 ºC was 27%. The remaining product of CS Fe3O4 NPs 
is inferior in percentage compared to chitosan nanoparticles. This seams contradictory to what 
was expected since Fe3O4 is not degraded within the tested range of temperature. However, it is 
important to consider that the total percentage of nanoparticles is not only composed of chitosan. 
As such, if the remaining amount is normalized taking into consideration the partial amount of 
chitosan, the remaining amount is composed of 3% of Fe3O4 nanoparticles. This means that chi-
tosan was able to encapsulate 3% of Fe3O4 nanoparticles. 





Figure 4.23. TGA and DTA of chitosan nanoparticles (NP CS), chitosan coated Fe3O4 NPs (CS Fe3O4) and 
pristine Fe3O4 nanoparticles produced by chemical precipitation. 
 Dynamic light scattering studies 
Dynamic light scattering studies were performed to compare the differences in the hydrodynamic 
diameter between chitosan nanoparticles and chitosan coated Fe3O4 nanoparticles. Figure 4.24 
displays the comparison between the hydrodynamic diameters of chitosan nanoparticles vs. chi-
tosan coated Fe3O4 nanoparticles for the tested range of chitosan molecular weight.  
 
Figure 4.24. Hydrodynamic diameter of chitosan nanoparticles and chitosan coated pristine Fe3O4 and 
Fe3O4 TD nanoparticles as a function of chitosan molecular weight. 
The results show that in general the hydrodynamic diameter of chitosan coated Fe3O4 NPs in-
creases with the increase of chitosan molecular weight. However, for the highest molecular 




weight, 469 kDa, the hydrodynamic diameter is significantly smaller in both cases. The difference 
between single chitosan NPs and chitosan Fe3O4 NPs is remarkable: chitosan coated Fe3O4 NPs 
have a much higher hydrodynamic diameter than chitosan nanoparticles but it is significantly 
reduced for CS Fe3O4 TD NPs of higher molecular weights. For the higher molecular weight, the 
hydrodynamic diameter is similar between chitosan and chitosan Fe3O4 TD NPs. 
The observed differences between the obtained hydrodynamic diameter were analyzed by auto-
correlation functions (ACF) of the two types of chitosan coated Fe3O4 NPs (Figure 4.25). Auto-
correlation functions of chitosan coated pristine Fe3O4 NPs (Figure 4.25 A) show two different 
behaviors dependent on the molecular weight. For the three lowest molecular weights, the ACF 
curves show only one relaxation mode as a typical single-exponential relaxation. For higher mo-
lecular weight a slow relaxation mode is present, here attributed to very large aggregates of NPs, 
and contributes largely to the overall measurement. Moreover, the contribution of the slow relax-
ation mode increases with the increase of the molecular weight. 
Autocorrelation functions of chitosan coated Fe3O4 TD NPs (Figure 4.25 B) show only one re-
laxation mode for all cases except for the highest molecular weight. A slow relaxation mode is 
present, here attributed to very large aggregates of NPs, and contributes largely to the overall 
measurement. Although the measured hydrodynamic diameter of the NPs is smaller, larger ag-
gregates are present in this sample, which influences the obtained results. 
  
Figure 4.25. Comparison of measured (dots) and adjusted (lines) autocorrelation curves of dynamic light 
scattering measurements between (A) chitosan coated pristine Fe3O4 NPs and (B) chitosan coated Fe3O4 
TD NPs. 
The presence of larger aggregates in some samples may be attributed to chitosan chains that are 
not cross-linked to form nanoparticles. Consequently, the presence of such polymeric chains in 




the solution causes scattering in DLS measurements represented as the slow relaxation modes in 
ACF curves. 
 SQUID measurements  
DC magnetic measurements were performed to access the influence of chitosan in pristine iron 
oxide NPs magnetic properties. Magnetic saturation values are presented in emu per gram of the 
whole particle (magnetic and non-magnetic material). Pristine iron oxide NPs exhibit a saturation 
magnetization (MS) of around 59 emu.g-1 at 320 K (see Chapter 3). When pristine Fe3O4 NPs are 
coated with either high or low molecular weight chitosan, MS of the nanoparticles is greatly re-
duced to 18 and 29 emu.g-1, respectively. Based on this difference, the reduction caused by chi-
tosan seems to be dependent upon the polymer molecular weight. Figure 4.26 displays the zero-
field cooled (ZFC) and field cooled (FC) and the magnetization versus applied magnetic field at 
320 K results for chitosan of high (469 kDa) and low (38 kDa) molecular weights. Inset corre-
sponds to the magnification of the same hysteresis loops.  
  
  
Figure 4.26. Magnetic characterization of chitosan coated pristine Fe3O4 nanoparticles (A) Zero-field 
cooled and field cooled results for chitosan of high molecular weight (469 kDa), (B) Magnetization vs. 
applied magnetic field at 320 K for chitosan of high molecular weight (469 kDa); (C) ZFC and FC results 




for chitosan of low molecular weight (38 kDa); (D) Magnetization vs. applied magnetic field at 320 K for 
chitosan of low molecular weight (38 kDa). 
For all cases it is evident the absence of coercivity and remanence at 320 K, which confirms the 
superparamagnetic behavior of all samples above the blocking temperature. Accordingly, it is 
possible to conclude that chitosan coating does not change the superparamagnetic behavior of the 
NP. However, with the chitosan molecular weight increase, the magnetic saturation of the NPs 
decreases, which may be attributed to surface effects, caused by the coating. 
4.4. Summary 
Chitosan is a derivative of chitin, the second most abundant biopolymer in nature, therefore is 
obtained from natural sources. Moreover, chitosan has profitable properties for biomedical appli-
cations, such as biodegradability, nontoxicity, antibacterial, and antifungal activity, and mucoad-
hesive properties. Due to the great range of beneficial properties, chitosan is used in a widely 
range of applications, from water treatments to agriculture, not forgetting the biomedical ones. 
This vast number of applications comes from one of the most interesting characteristic of chitosan 
that is a huge number of possible conjugations in the amine and hydroxyl free groups.  
In this chapter, a detailed study of chitosan and its application in iron oxide NPs was performed. 
The chitosan was depolymerized starting from the available chitosan in the laboratory, which had 
a molecular weight of 469 kDa. Five new molecular weights were successfully obtained and ap-
plied in the synthesis of a chitosan derivative (O-HTCC), an ammonium quaternary derivative of 
chitosan that is soluble in a wide range of pH, contrary to what happens with chitosan that is 
soluble only in acidic pH (below pH 6). This derivative was synthetized starting from the high 
molecular weight chitosan and some of the depolymerized samples. Chitosan and O-HTCC were 
used to produce polymeric nanoparticles by ionic gelation method. The production of these na-
noparticles was optimized to achieve an average diameter within the range of 100-200 nm for the 
overall molecular weights studied. After optimization of the reaction parameter, chitosan-coated 
Fe3O4 nanoparticles were produced by the same method and fully characterized. 
Solubility (acidic pH) may limit chitosan’s applications in the biomedical field. As such, several 
modifications performed in chitosan have the purpose to add moieties that provide the polymer 
solubility in a wide range of pH. Coupling of chitosan with GTMAC provides the desired polymer 
solubility in a wide range of pH. However, addition of GTMAC to chitosan without previous 
protection of the free amino groups leads to coupling in both -NH2 and -OH groups. Since several 




properties of chitosan depend upon the free amino groups, the -NH2 groups were protected with 
previous treatment with benzaldehyde. Consequently, the final chitosan derivative maintains chi-
tosan free amino groups and adds an ammonium quaternary moiety. 
Polymeric nanoparticles were produced by using either chitosan or O-HTCC with different mo-
lecular weights. The chosen method for the polymeric NPs production was ionic gelation, a sim-
ple, rapid, and low cost method. Preliminary hydrodynamic measurements did not show the pres-
ence of nanoparticles, but microparticles instead. As such, to optimize the average hydrodynamic 
diameter and obtain a monodisperse sample, an extensive study was performed using dynamic 
light scattering. Dynamic light scattering was used as a comparison between samples and exper-
imental conditions were optimizing in such a way to eliminate all possible artefacts. At the end 
of this extensive study, both chitosan and O-HTCC polymers produced nanoparticles with aver-
age diameters within the range of 100 to 200 nm and the molecular weight of the polymer has no 
remarkable influence to it. However, the higher molecular weight used (469 kDa) produced larger 
particles.  
Zeta potential of the polymeric nanoparticles suspensions was measured and found to be positive 
in all cases. Furthermore, chitosan nanoparticles have a zeta potential above +30 mV that does 
not significantly change with the molecular weight. Consequently, the produced chitosan may be 
considered stable in aqueous suspensions. 
Chitosan was used to coat Fe3O4 NPs produced by either chemical precipitation or thermal de-
composition technique (Chapter 3). The samples were fully characterized to confirm the influence 
of the coating. DLS measurements show an increase of the hydrodynamic diameter when the iron 
oxide nanoparticles are coated with chitosan. To understand the observed difference in the hydro-
dynamic diameters, the autocorrelation functions were analyzed. Autocorrelation functions of 
chitosan coated pristine Fe3O4 NPs showed two different behaviors dependent on the molecular 
weight. For the three lowest molecular weights, the ACF curves show only one relaxation mode 
as a typical single-exponential relaxation. For higher molecular weight a slow relaxation mode is 
present, here attributed to very large aggregates of NPs, and contributes largely to the overall 
measurement. The contribution of the slow relaxation mode increases with the increase of the 
molecular weight and the presence of larger aggregates in some samples may be attributed to 
chitosan chains that are not cross-linked to form nanoparticles. Consequently, the presence of 
such polymeric chains in the solution causes scattering in DLS measurements represented as the 
slow relaxation modes in ACF curves. 




In this chapter was demonstrated the possibility to produce chitosan, O-HTCC and polymer-Fe3O4 
nanoparticles that are stable in aqueous medium. Polymeric nanoparticles are available in differ-
ent molecular weights and have an average diameter suitable for drug delivery systems. Polymer-
Fe3O4 NPs were able to maintain the superparamagnetic properties of the iron oxide core. The 
obtained NPs were fully characterized providing the basis to evaluate their potential in biomedical 
applications such as magnetic hyperthermia, drug delivery, and MR imaging contrast agents. 
Moreover, cytotoxicity evaluation and biomedical applications were further studied in Chapter 6 
and Chapter 7. 
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 Monoclonal antibody 
production 
This chapter is related to the production of the targeted part of the theranostic system developed 
in this PhD thesis. The chapter starts with a review of some basic concepts related to monoclonal 
antibodies and their production. A special attention is given to carbonic anhydrase IX, the specific 
antigen of cancer cells. Following, the methods used for the production of the monoclonal anti-
body, and the main results obtained are presented and discussed. 
5.1. Introduction 
According to the National Cancer Institute, biological therapy is “a type of treatment that uses 
substances made from living organisms to treat disease” [1]. Biological therapy is also called 
biotherapy, immunotherapy, or biological response modifier therapy. Biological therapies are 
mechanistically dependent upon tumor–host interaction and use the body's immune system, either 
directly or indirectly, supressing or stimulating the immune system to fight cancer, infection, and 
other diseases. The increasing use of molecular biological techniques continues to improve the 
understanding of the pathophysiology of cancer, with the associated definition of potential thera-
peutic targets [2].  
Biological therapies include immunotherapy, which uses immune-related agents, such as cyto-
kines, cellular or humoral products, some antibodies, and vaccines. Gene therapy and some tar-
geted therapies are also considered biological therapies [3]. 




 Monoclonal antibodies 
Paul Ehrlich, the German physician and scientist winner of the Nobel Prize in Physiology or 
Medicine in 1908 for its contributions in immunology, popularized the concept of a “magic bul-
let”. This concept emerged from the idea of having a compound that selectively target and kill a 
specific disease-causing organism. Antibodies fit in perfectly into this concept, as they are spe-
cific target agents [4]. 
 Antibody composition 
Antibodies, or immunoglobulins, are proteins produced by the immune system in response to 
foreign molecules. Each antibody binds to a particular target molecule, an antigen, with remark-
able specificity. All antibody molecules share the same basic structural characteristics but display 
remarkable variability in the regions that bind antigens. An antibody is composed of four poly-
peptide chains: two identical light chains (220 amino acids) and two identical heavy chains (300-
400 amino acids). These chains are bounded through disulfide bonds and non-covalent bonds to 
compose a Y-shape molecule. Both heavy chains and light chains consist of amino-terminal var-
iable (V) regions that participate in antigen recognition and carboxy-terminal constant (C) re-
gions; the C regions of heavy chains mediate effector functions. In the heavy chains, V region is 
composed of one Ig domain, and C region is composed of three or four Ig domains. Each light 
chain is composed of one V region Ig domain and one C region Ig domain. The peptide sequence 
of the NH2 extremity of these chains determines the specificity of the antibody to a certain antigen 
and specific of the antibody (variable domain). This region determines the antibody idiotype, i.e., 
the site of specific bounding. The remaining domains (constant domains) exist in a specific num-
ber of forms: two types for the light chains ( and ) and five types for the heavy chains 
(and). The latter determines the classification of the immunoglobulin into one of the 
five existent classes (or isotypes) in Mammalian: IgM, IgD, IgG, IgE, and IgA [5-7].  
The most commonly used immunoglobulin form is IgG. IgG (Figure 5.1) have two binding 
‘arms’, the variable domains of the light chain (VL) and of the heavy chains (VH). Antibodies are 
composed of three functional units: two Fab (fragment antigen binding) units and one Fc (frag-
ment crystallizable) unit. The Fab unit is located in the NH2 terminal and is composed of by 
variable region of the light chain and the heavy chain. Antibody-binding specificity is encoded 
by three complementary determining regions (CDRs), while Fc-region is responsible for binding 
to some proteins (complement) or cells [8, 9]. 
An antibody itself does not kill target cells; instead, two possibilities can occur. The antibody can 
mark the target cell for other components or effector cells of the body. This mechanism in named 




antibody dependent complement mediated cytotoxicity (CMC). The alternative occurs when the 
antibody initiates signaling mechanisms in the targeted cell that leads to self-destruction. The 
latter mechanism is named antibody dependent cellular toxicity (ADCC). CMC mechanism oc-
curs when IgGs are in close proximity to each other, activating a cascade of complement proteins. 
The outcome is either cell lysis or attraction of other immune cells to this location for effector 
cell function. On the other hand, ADCC mechanism requires the recognition of the antibody by 
immune cells that engage the antibody-marked cells. In this case, cell death is caused by either 
direct action or through the recruitment of other cell types [9]. 
 
Figure 5.1. Schematic representation of a typical antibody molecule, i.e., an IgG molecule. The molecule 
is composed of four polypeptide chains, two identical heavy chains and two identical light chains, bounded 
by disulfide bonds. Each chain is composed of several different domains. The antigen-binding site is formed 
where a heavy-chain variable domain (VH) and a light-chain variable domain (VL) come close together 
(Adapted from [5, 9]). 
Natural occurring antibodies are polyclonal in nature. In other words, an invading organism elicits 
a response from numerous B-cells, and IgGs of different epitope specificity are produced. On the 
other hand, monoclonal antibodies (mAb) are monospecific antibodies, i.e., are only specific for 
binding to one antigen.  
Monoclonal antibodies have been considered an important class of pharmaceutical products for 
cancer treatment, infectious disease, allergy, autoimmune disease and inflammation. Moreover, 
mAbs belong to a well-established drug class, that has a high success rate from first human studies 




to regulatory approval [10]. The high specificity of mAbs is not the only reason for its popularity. 
mAbs can also be conjugated to another therapeutic entity such as a toxin or radioisotope. The 
delivery of this entity to a target site can reduce potential side effects [10]. 
 Monoclonal antibodies production 
Köhler and Milstein [11] produced the first hybridomas (antibody production cells) by fusion of 
a mouse myeloma and mouse spleen cells from an immunized donor. These researchers won the 
Nobel Prize in Physiology or Medicine in 1984 for their discovery. 
Recombinant mAbs can be produced in transgenic mice that carry human antibody gene loci in-
serted in their germ line, through bacteriophage display-based technologies yielding high quanti-
ties of high-affinity antibodies, and ribosome mRNA display allowing for construction of high-
member, high-affinity human immune repertoire antibody libraries. Synthetic antibodies (di-
abodies, triabodies, tetrabodies) are generated using chemical or molecular biological crosslink-
ing to produce di-, tri-, and tetrameric multivalent conjugates exhibiting enhanced specificity and 
functional activity [12]. 
Hybridoma technology has the issue of mouse immunization, i.e., patients treated with mouse 
antibodies may produce antibodies against the mouse Ig, called human anti-mouse antibodies 
(HAMA). These anti-Ig antibodies block the function or enhance clearance of the injected mAb 
and can also cause a disorder called serum sickness [7, 13]. However, hybridoma technology is 
still the most used technique to produce mAbs for both research and diagnostic applications [12]. 
5.1.1.2.1. Hybridoma technology 
The basis of hybridoma technology is the immortalization of lymphocytes with antibody-produc-
ing capacities but limited in vitro growth characteristics. The lymphocytes are fused with mye-
loma cells, a non-antibody-producing and continuously growing tumor cell line. The resultant 
hybrids, hybridoma cells, continue to secrete antibodies while gaining the immortality of the par-
ent tumor cell. During the fusion process, the number and variety of hybridomas obtained is so 
large that an intelligent design of assay systems is necessary to select with minimal effort the 
hybridoma clones which produce the predefined quality of the antibody [14]. 
The first step to produce mAbs through the hybridoma technology is immunization. This is one 
of the most significant factors in generating successful hybridomas. The main purpose is to obtain 
high number and highly proliferating antigen-secreting B-cells. The immunization protocol de-




pends on the investigator’s experimental objectives, model, and personal style. However, a spe-
cific schedule is followed to avoid neutralization of the injected antigen by circulating antibodies. 
The harvest of splenocytes and cell fusion occurs generally after 59 days of the first immuniza-
tion. After successful fusion under optimal conditions, it is expected that approximately 50% of 
the wells exhibit clonal growth of hybridoma cells. Screening protocols are conducted to identify 
functional hybridomas. Every primary hybridoma clone requires at least three consecutive rounds 
of recloning. The purpose of cloning is to have one or less cells per well in order to obtain isolated 
highly selected hybridoma cell lines [12]. 
The major problem associated with mAbs obtained from hybridoma technology is the immuno-
genicity caused by a murine mAb, as above mentioned. These mAb generally have short half-life 
and decreased effector function. Most of these problems were overcome by replacing all or most 
of the constant regions of the murine mAb with human ones [15]. Genetic engineering techniques 
have been used to expand the usefulness of mAbs. The complementary DNA (cDNA) that en-
codes the polypeptide chains of a mAb can be isolated from a hybridoma, and these genes can be 
manipulated in vitro. Moreover, DNA segments encoding antigen-binding sites from a mouse 
mAb are inserted into a cDNA encoding a human myeloma protein, creating a hybrid gene. The 
resultant hybrid protein retains the antigen specificity of the original mouse monoclonal but has 
the core structure of a human Ig. This hybrid is called a humanized antibody [7]. These humanized 
mAbs are preferred for chronic administration, since the risk of generation of human anti-mouse 
antibodies is reduced [10]. Consequently, mAbs are produced in the following main forms: mu-
rine (100% mouse protein), chimeric (approximately 65% human and 35% mouse protein), hu-
manized (95% human and 5% mouse protein), fully human (100% human protein) [10]. Fully 
human mAbs are derived using phage display methods or in mice with B cells expressing human 
Ig transgenes [7].  
 Commercial mAbs 
There are numerous reasons why mAbs have become increasingly popular for commercial devel-
opment. Monoclonal antibodies are highly specific and bind to a single antigen, causing fewer 
side effects than conventional drugs. mAbs can also be conjugated with another therapeutic mol-
ecule. Advances in molecular biology and protein engineering have enabled the rapid develop-
ment of highly specific mAbs with high binding affinities for their targets. mAb fragments and 
mAbs with different isotopes can also be produced to provide control over the pharmacokinetics 
and effector function of the drug product [10]. 




In 1986 the US Food and Drug Administration (FDA) approved Muromab, a murine IgG1 specific 
for CD3, for the therapy of transplanted patients undergoing rejection [16]. Since then, dozens of 
mAbs (murine, chimeric and humanized) have been approved by international regulatory agen-
cies including FDA and EMA (European Medicines Agency) for use in humans against multiple 
diseases. Of these, at least 14 mAbs are nowadays approved for use in cancer patients (Table 5.1) 
[8].  
mAbs that may have antineoplastic effects can be divided into at least six classes, depending on 
their function: a) mAbs that target cancer cell-intrinsic pro-survival signal transduction cascades; 
b) mAbs that interrupt the trophic interaction between malignant cells and their stroma, thus in-
directly inhibiting tumor growth; c) mAbs that recognize antigens expressed on the surface of 
tumor cells and exert antineoplastic effects by initiating immune effector mechanism such as 
ADCC and CMC; d) trifunctional (bispecific) mAbs that can bind two distinct antigenic targets 
while retaining the ability of activation immune effector functions; d) immunoconjugates; and e) 
immunostimulatory mAbs that facilitate the development of an antitumor immune response by 
influencing the balance between immunogenicity of malignant cells and the immunosuppressive 
mechanisms that they normally establish [8]. 
mAbs have also been used to achieve a tumor-specific targeting. For this purpose, an ideal antigen 
should be expressed in all tumor cells but not on critical host cells. Moreover, the chosen antigen 
must not suffer any mutation or variation and it should be required for cell survival or for a critical 
cellular function. Although the mAbs described in Table 5.1 possess a therapeutic effect in their 
own right, they can also be used as carriers of drug delivery systems for even more effective and 
less intrusive cancer therapy [17]. This conjugation results in the so-called active targeting. Active 
targeting is based upon recognition of the ligand by its target substrate. Active targeting can be 
used to improve cellular internalization of its payload. For example, anti-HER2 targeting moieties 
on the surface of liposomes strongly increase the uptake of the nanoparticles (NPs) in HER2-
expressing cancer cells [18]. Moreover, mAbs can increase the circulation time of its payload. In 
mice, immunoliposomes (PEGylated liposomes with an active targeting component) with surface-
conjugated antibody fragments (Fab’) of the mAb 21B2 showed approximately double the circu-
lation time of immunoliposomes with surface-conjugated 21B2 whole mAbs (IgG) over a 24 h 
period. Immunoliposomes have lower circulation times and consequently are less able to accu-
mulate in the tumor due to the enhanced permeation retention (EPR) effect [19]. In another study 
immunoliposomes were conjugated with three targeting moieties (whole mAb, Fab’, and single 
chain variable fragment (scFv) targeting CD19, a B-cell antigen. The Fab’ immunoliposomes 
exhibited the most prolonged circulation times [20].  










Type Indications Company 
Alemtuzumab 
(Campath) 
CD52 2001 Hz IgG1 CLL Genzyme 
Bevacizumab 
(Avastin) 
VEGF 2004 Hz IgG1 
Glioblastoma multiform, 







CD30 2011 Ch IgG1 
Hodgkin and anaplastic 
large cell lymphoma 









Malignant ascites in pa-
















RANKL 2011 H IgG2 





CD33 2000 Hz IgG4 


































CD20 2013 Hz IgG1 CLL Roche 
Ofatumumab 
(Arzerra) 





CD20 1997 Ch IgG1 CLL and NHL Roche 
Tositumomab 
(Bexxar) 
CD20 2003 H IgG1 






HER2 1998 Hz IgG1 
Breast carcinoma and 
gastric or gastroesopha-
geal junction cancer 
Genentech 
Ch, chimeric; CLL, Chronic lymphocytic leukemia, CTLA-4, cytotoxic T lymphocyte antigen 4; EGFR, 
epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; H, human; Hz, humanized; 
MMAE, monomethyl auristatin E; NHL, Non-Hodgkin lymphoma; RANKL, receptor activator of NFκB 
ligand; VEGF, vascular endothelial growth factor. 




Some other key factors in the development of antibody-conjugated NPs are the configuration of 
the antibodies, its origin, and the mode in which these are attached to the nanoparticles. These 
factors influence the in vivo tolerability and efficacy of the system. Antibody fragment containing 
only the variable region of the antibody are currently more used for targeting-specific therapies. 
The antibody fragments retain the specificity while lacking the constant Fc effector region which 
could cause immunogenicity [21]. 
There are some innate problems associated with the use of antibodies and antibody fragments as 
targeting agents. The decrease of receptor affinity due to conjugation methods, circulating free 
antigen, insufficient tumor penetration, binding of antibodies to non-specific Fc receptors and 
possible changes in the antigen over time, are some of the associated problems [21]. 
 Carbonic Anhydrase 
Carbonic anhydrases (CA) are metalloenzymes (zinc) and essential molecules/ions in many im-
portant physiologic processes in all life kingdoms (Bacteria, Archaea, and Eukarya). In humans 
14 different CA isozymes or Ca-related proteins (CARP) were described so far (Table 5.2), dif-
fering in its subcellular localization and tissue distribution. CARPs appear to lack activity because 
of substitutions in one or more of the histidine residues required to bind to the zinc ion, which is 
essential for CO2 hydration activity. Several CA isozymes are located in the cytosol (CA I-III, 
VII), four are bound to the phospholipidic membrane (IV, IX, XII and XIV), one in located within 
the mitochondria (CA V) and one is secreted (CA VI) [22-24]. 
These enzymes play an important role in the red blood cell by catalyzing the hydration of carbon 
dioxide (Equation 5.1): 
𝐶𝑂2 + 𝐻2𝑂 ↔ 𝐻𝐶𝑂3
− + 𝐻+ Equation 5.1 
Consequently, CA enzymes are involved in crucial physiological processes such as: 
 Respiration and transport of CO2/bicarbonate between metabolizing tissues and lungs; 
 pH and CO2 hemostasis; 
 Electrolyte secretion in a variety of tissues/organs; 
 Biosynthetic reactions (e.g. gluconeogenesis, lipogenesis, ureagenesis); 
 Bone resorption; 
 Calcification; 
 Tumorogenicity [22, 24].  




Drugs interfering with the activity of CAs have been clinically used for almost 60 years, and most 
of them belong to the sulphonamide class. Inhibition of CAs has pharmacological applications in 
many fields, such as anti-hypertensive, anti-glaucoma, anticonvulsant, some anti-thyroid drugs, 
anti-obesity, and anticancer/diagnostic tools [22, 23]. 
Table 5.2. Human CA isozymes known so far, their CO2 hydrase activity, sub-cellular localization and 





Tissue distribution  
(examples) 
CA I Low (10%1) Cytosol Red blood, cell, intestine 
CA II High Cytosol Ubiquitous 
CA III Very low (0.3%1) Cytosol Red muscle, adipose tissue 
CA IV High 
Membrane-bound (extra-
cellular) 
Kidney, lung, gut, brain, eye 
CA V Moderate-high2 Mitochondria Liver 
CA VI Moderate Secreted into saliva Saliva 
CA VII High Cytosol Brain, salivary gland, lung 
CARP VIII - NA 
Brain, especially Purkinje 
cells of the cerebellum 
CA IX High 
Transmembrane (extra-
cellular domain) 
Various tumors, gastric mu-
cosa 
CARP X - Unknown Brain, pineal gland, placenta 
CARP XI - Secreted Brain 
CA XII Active3 
Transmembrane (extra-
cellular domain) 
Colon, kidney, prostate 
CA XIII NA4 Unknown NA 




1Compared to CA II catalytic activity; 2Depending upon pH: moderate at 7.4; high at pH 8.2 or higher; 3No 
quantitative data available; 4NA – data not available. 




 CA IX 
As mentioned above, some CA isozymes are predominantly found in cancer cells and are lacking 
from their counterparts. It is the case of CA IX, a membrane bound CA isozyme that is controlled 
via the hypoxia-inducible factor (HIF). CA IX has been identified in human HeLa call line derived 
from carcinoma of the cervix [25], in the tumorigenic phenotype of somatic cell hybrids between 
HeLa and normal human fibroblasts in vitro [26], among others. 
Although this CA isoform expression is related to several physiological processes including lipo- 
and ureagenesis, gluconeogenesis and bone resorption, its most relevant function is the intracel-
lular pH (pHi) regulation in cancer cells exposed to acidic environment caused by metabolic prod-
ucts of glycolysis [27].  
During solid tumor growth, subpopulations of cancer and stromal cells are exposed to variable 
conditions depending upon local and temporal supply of oxygen, nutrients, growth factors and 
signaling molecules. Highly proliferative cancer cells generate excessive amounts of lactate, car-
bon dioxide, and protons. These metabolites are extruded to the extracellular environment where 
they accumulate due to poor vasculature. The combination of these factors leads to a continuously 
decrease of the extracellular pH (pHe). To neutralize their pHi, bicarbonate anions generated by 
CA IX-catalyzed hydration of CO2 are transported into the cells by anion transporters to interact 
with protons liberated by the glycolytic metabolism. This process leads to an extracellular acidi-
fication, generating acidosis partially caused by tumor hypoxia [27].  
Hypoxia is a biologically and clinically important phenomenon with pronounced effects on tumor 
phenotype and cancer progression. The connection between hypoxia and poor prognosis and re-
sistance to conventional treatments modalities is clearly proved and has led to implementation of 
modified treatment regimens [28].  
Reduced oxygen availability leads to the activation of a core cellular response to hypoxia initiated 
by its master regulators, the transcription factor HIF. HIF is composed of two subunits,  and , 
being  sensitive to oxygen [29, 30]. In normoxia HIF- is dependent upon von Hippel-Lindau 
tumor suppressor protein (pVHL)-mediated poly-ubiquitylation and subsequent proteasome deg-
radation. In hypoxia, HIF- is stabilized and following entry to the nucleus and dimerization with 
the constitutive HIF- subunit, it can either turn on or elevate the transcription of numerous genes 
containing HIF-responsive elements in regulatory regions. The proteins encoded by these genes 
execute the adaptive responses to hypoxia and are therefore active players in tumor progression 
[29]. 




Being a hypoxia-induced enzyme, CA IX plays important roles in tumor progression such as 
increased adaptation of tumor cells to microenvironmental stress, resistance to therapy, increased 
tumor cell migration and invasiveness, increases focal adhesion during cell spreading, destabili-
zation of intracellular contacts, maintenance of stem cell phenotype, tumor-stroma crosstalk, sig-
nal transduction, among others [30]. The consequence of pharmacological inhibition of CA IX, 
either by mAb or small molecule CA IX inhibitors, is explained in Figure 5.2. Hypoxia induces a 
HIF-1-mediated signaling cascade that results nuclear translocation of HIF-1 and activation of 
hypoxia-regulated genes, including GLUT1, MCT1/4 and CA IX. Cells undergo the glycolytic 
pathway, which results in increased production and export of lactate, leading to a decline in pHe. 
One consequence of extracellular acidification is the disruption of the intracellular pH, which 
affects basic cellular functions. The overexpression of CA IX in hypoxia catalyzes the hydrolysis 
of CO2 to HCO3- and H+ in the extracellular microenvironment. The HCO3- is actively transported 
into the cancer cell, thereby regulating pHi and maintaining cell survival. The H+ contributes to 
the increasingly acidic extracellular space, promoting tumor cell invasiveness. Inhibition of CA 
IX catalytic activity prevents the production of these enzymatic metabolites, leading to decreased 
survival and reduced invasive capacity [31]. 
 
Figure 5.2. Inhibition of cancer cell survival and invasion by pharmacologic inhibition of CA IX (adapted 
from [31]).  




Consequently, CA IX appears to have an important role as a predictive outcome of cancer treat-
ments. Theoretically, the association with hypoxia and acidosis, factors that are linked with poor 
prognosis, predisposes CA IX to indicate bad outcome and serve as the stratification marker. 
Furthermore, the correlation between decrease CA IX levels and progression of kidney cancer 
indicates that reduced CA IX expression in this tumor type may be linked with better treatment 
outcome [30]. Several evidences confirmed these theories. CA IX was shown to be predictive of 
outcome of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A 
amplification [32]. In addition, it may also predict chemosensitivity to neoadjuvant taxane and 
anthracycline therapy in breast cancer patients [33]. CA IX is also helpful to indicate preoperative 
chemotherapy response in renal adenocarcinoma [34] and to predict survival benefit from lower 
dose of bevacizumab in metastatic colorectal cancer [35]. 
 CA IX as a therapy target 
CA IX is an attractive target for anticancer therapy since it is selectively expressed by tumor cells 
being absent in its counterparts. Moreover, it provides functions critical for tumor growth and 
metastasis, including pH regulation, survival, and adhesion/migration. It is located on the extra-
cellular surface of cell membranes, which allows efficient targeting by antibodies or small mole-
cule inhibitors. Direct binding of CA IX-specific mAbs to CA IX can trigger an anti-tumor re-
sponse by activating the ADCC mechanism, delivering of therapeutic payloads (e.g. cytotoxins 
and radionuclides) or selective blocking of CA IX function [31].  
Rencarex® is an anti-CA IX antibody currently under phase III clinical trials as an adjuvant ther-
apy aimed to reduce recurrence in surgically treated renal cell carcinoma patients. This chimeric 
mAb could elicit ADCC mechanism [36]. So far, it has demonstrated to be safe, well tolerated, 
and able to positively influence disease burden, alone and together with interferon (IFN)- treat-
ment [37, 38]. 
Other antibodies have been developed with the aim of targeting CA IX catalytic domain by phage 
display. These ones are expected to selective blocking of CA IX function. Some studies have 
shown that these antibodies are able to selectively bind to tumors in vivo. However, evaluation of 
anti-tumor efficacy was not performed [39]. Furthermore, a similar mAb was developed and 
tested in vivo using hybridoma technology. The results showed efficient binding, internalization 
and persistence in cultured cells [40].  




5.2. Materials and methods 
 Cell culture 
SaOs-2 osteosarcoma cell line was grown in McCoy 5A medium (Sigma-Aldrich), supplemented 
with 10% fetal bovine serum (Sigma-Aldrich) and 1% Penicillin-Streptomycin (10,000 U/mL; 
Gibco/Invitrogen), while MDA-MB-231 cells were grown in Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with 10% fetal bovine serum, Penicillin-Streptomycin (100 U/ml 
penicillin and 100 g/ml Streptomycin, Gibco/Invitrogen), and 2 mM L-glutamine (Gibco/Invi-
trogen). Cells were maintained in CO2 incubator (37°C; 5% CO2). 
 Mice immunization 
Female Balb/c mice (4-5 weeks) were immunized with intraperitoneal injection of the CA IX 
antigens: total protein (R&D Systems 2188-CA), N-terminal and central peptide (Eurogentec 
EP112430 and EP112431) emulsified in complete Freund’s adjuvant (Sigma). In addition, SaOs-
2 extract was intraperitoneal injected, emulsified in incomplete Freund’s adjuvant under similar 
conditions to the proteins. Antigens were inoculated separated by 1-2 weeks intervals, 6-times for 
total protein and N-terminal peptide, and 9-times for central peptide. After each inoculation, the 
presence of mAbs was verified by collecting serum and evaluating it by flow cytometry. Three 
days after the last injection mice were sacrificed and the spleen was removed and used for cell 
fusion. Collected sera were stored at -20 ºC until used. 
 Cell fusion 
Splenocytes (7.7×107) and Sp2/0 Ag14 myeloma cells (5.3×107) previously grown Dulbeco’s 
Minimal Essential Medium (DMEM) (Sigma) containing 20% (v/v) fetal calf serum (FCS) and 
gentamicin were pooled and fused in the presence of 50% PEG 4000/DMSO. 0.8 ml of 
PEG/DMSO was added slowly over a one min period with gently stirring and kept without any 
stirring for one further minute. The fusion suspension was then diluted adding 1 ml of DMEM 
medium over a period of 1 min, followed by 20 ml at a rate of 4 ml per min. Total fusion time 
was therefore 8 min. After centrifugation (290xg, 5 minutes) the fusion product, resuspended in 
DMEM containing 20% (v/v) fetal calf serum and HAT medium (1×10−4 M Hypoxanthine, 
4×10−7 M Aminopterin,1.6×10−5 M Thymidine) (Sigma), was placed on 96-well plates and incu-
bated overnight at 37ºC, 5% CO2, 95% humidity, for hybrid selection. The supernatants of each 




well were replaced with fresh HAT medium when necessary judged by pH medium color and 
microscopy visualization. 
Circa the day 15, the wells were screened for the desired antibody by flow cytometry. Positive 
wells were transferred to 24-well plates (Costar) previously filled with 1 ml of HAT. Afterwards, 
the supernatants were screened by Flow Cytometry and the positive antibody-producing cells 
were expanded for analysis and frozen in FCS containing 4% DMSO. Tubes were first frizzed at 
-20 ºC and after transferred to liquid nitrogen container (-180 ºC) for long storage. 
 Flow cytometry 
The presence of anti-CA IX mAbs in both the serum and the hybridomas supernatant was tested 
by flow cytometry. Flow cytometry acquisition was performed, using the Attune® Acoustic Fo-
cusing Cytometer (Applied Biosystems). File data was analyzed using the Attune Cytometric Soft-
ware v1.2.5 and FLOWING (Turku, Finland) software to discriminate specific populations, and 
to determine the mean fluorescence intensity (MFI) of the cells. 
The used protocol was as follows: The presence of anti-CA IX mAbs was tested using SaOs-2 
and MDA-MB-231 cell lines. Cells were washed with PBS 1x, centrifuged at 1500xg for 2 
minutes and resuspended in PBS 1x. Cell suspensions were previously treated with BD Cy-
tofix/Cytoperm™ fixation/permeabilization kit. Then, cell suspensions (0.4x106 cell/microtube) 
were incubated with 1 ml of the respective supernatant, and with the positive control using anti-
CA IX mAb (clone H-11, Santa Cruz Biotechnology, Inc.). After 30 minutes of incubation at 4ºC, 
cell suspensions were washed with PermWash buffer®, centrifuged at 1500 xg, 2min and resus-
pended in PermWash buffer. Next, cell suspensions were incubated with the secondary antibody, 
anti-mouse polyvalent immunoglobulins (G, A, M)-FITC (Dako), for 15 minutes, 25 ºC. As a 
negative staining control, cells were incubated with only the secondary antibody. Finally, cells 
were washed, resuspended in PermWash buffer, and analyzed by flow cytometry. 
 Western blot 
Protein samples were prepared by resuspend SaOs-2 and MDA-MD-231 cell lines pellets with 
lysis buffer [150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 20 µg.ml-1 PMSF, 2% NP-40 and protease 
inhibitor cocktail (Roche)] and vortexed at 4ºC, overnight. The protein amount was determined 
by Pierce™ BCA Protein Assay Kit. Cell pellets were resuspended in 1x loading buffer (nzytech) 
and heated for 5 min at 100 ºC. A 8% polyacrylamide gel was used as the resolving gel and 4% 
as the stacking gel. Both gels were placed in the Multiple Gel Caster (Amersham Biosciences). 




After gel solidification, both were placed in the SDS-Page electrophoretic system (Amersham 
Biosciences) with the running buffer. Protein samples and molecular weight standards were 
placed into the wells and separated at 150 V. Samples were blotted onto PVDF membrane (Bio-
RAD) previously activated with methanol (VWR) for 5 min, for 90 min at 0.4 A. The membranes 
were blocked for 1h with 10% dry milk in TBS-T (Tris-buffered saline with 0,1% Tween-20) and 
probed either with anti-CA IX mAb (1:100) or the hybridoma supernatant overnight at 4 ºC, fol-
lowed by incubation with anti-mouse Ig secondary antibody (1:1000; BD biosciences) for 1 h. 
Finally, the membranes were covered with Lumi-Light Western Blotting substrate (Roche) and 
revealed in Amersham hyperfilm ECL (GE Healthcare). 
 Dot blot 
Dot blot was performed to confirm the specific bounding between CA IX and the mAbs produced 
by the selected hybridomas. 1 ng of CA IX protein was placed in each spot. Membranes were 
blocked with 10% milk in PBS-T for 1h, and probed either with anti-CA IX mAb (1:100) or the 
hybridoma supernatant for 1 h at 4º C, followed by incubation with anti-mouse Ig secondary 
antibody (1:1000; BD biosciences) again for 1 h. Finally, the membranes were covered with 
Lumi-Light Western Blotting substrate (Roche), and reveled in Amersham hyperfilm ECL (GE 
Healthcare). 
 Confocal laser scanning microscopy 
Cells were cultured in cover glasses overnight to adhere. Then cells were treated with BD Cy-
tofix/Cytoperm™ fixation/permeabilization kit. After blocking with 1% bovine serum albumin 
(BSA), cells were stained using anti-CA IX mAb (clone H-11) or hybridoma supernatants, fol-
lowed by fluorescent polyclonal anti-mouse Ig antibody. The cell nuclei were stained with 1 mM 
TO-PRO-3 dye (Molecular Probes, Leiden, Netherlands). Images were acquired with a Leica 
TCS SP2 AOBS confocal microscope (Leica Microsystem, Mannheim, GmbH). 
5.3. Results and discussion 
Carbonic anhydrase IX are one of the most induced proteins in response to hypoxia. Several stud-
ies showed an abnormal expression of CA IX in a broad range of human tumor, including carci-
nomas of the uterine cervix, kidney, brain, head and neck, esophagus, lung, colon, ovaries, endo-
metrium, vulva and breast [41]. 




The main purpose of the present work was to produce monoclonal antibodies anti-CA IX through 
hybridoma technology. To achieve this goal, three antigens were used: the whole CA IX protein, 
a central peptide and an N-terminal peptide of CA IX. Further, the produced mAbs were tested 
for effectiveness in two tumor cell lines: a breast cancer (MDA-MB-231) and an osteosarcoma 
(SaOs-2) cell line. The purpose of using these two cell lines is to test the versatility of the final 
multifunctional nanoparticle. Nevertheless, before mice immunization, both cell lines were tested 
for the presence of CA IX expression using a commercial mAb anti-CA IX. 
 Identification of Ca IX presence in cell lines 
Flow cytometry was used to identify the presence of CA IX in both breast cancer and osteosar-
coma cell lines. Figure 5.3 displays the flow cytometry results for MDA-MB-231 cells stained 
for CA IX using the anti-human CA IX. Two protocols were tested: cells without permeabilization 
(Figure 5.3 A), and cells treated with the fixation/permeabilization kit (Figure 5.3 B). 
 
Figure 5.3. Flow cytometry analysis of MDA-MB-231 cell line expression of CA IX extra- (A) and intra-
cellular (B). Gray histogram corresponds to the negative staining control, i.e., cells stained with only the 
secondary antibody. 
The results show that cells without previous permeabilization treatment do not show the presence 
of CA IX. However, when cells are previously treated with the fixation/permeabilization kit, the 
presence of CA IX is positive, meaning that CA IX is present intracellularly but not in the mem-
brane of these cells. In the case of SaOs-2, the results are similar (data not shown). 




Both breast cancer and osteosarcoma cell lines were maintained in normoxia. Being CA IX over-
expressed in response to hypoxia, its expression should be lower and maintained in a stationary 
state in these cell conditions. Moreover, we hypothesize that CA IX location must not be restricted 
to the membrane, but may also be located intracellularly, e.g., in high-density (ER/Golgi) frac-
tions [42].  
To confirm the flow cytometry results, confocal microscopy was performed. Figure 5.4 shows 
the confocal microscopy results for MDA-MB-231 and SaOs-2 cell lines. Both cell lines were 
stained with anti-CA IX mAb followed by fluorescent polyclonal anti-mouse Ig antibody. The 
cell nuclei were stained with 1 mM TO-PRO-3 dye. Negative control was obtained by staining 
with only the secondary antibody. In both cell lines, the expression of CA IX is confirmed. How-
ever, the obtained images do not allow confirming the location of CA IX within the cell, which 
may be or not in the membrane. 
 
Figure 5.4. Confocal microscopy of MDA-MB-231 and SaOs-2 cell lines stained with commercial anti-CA 
IX mAb (Green) and TO-PRO3 (Red) for the nucleus. 
Ultimately, western blot analysis provides crucial information about a protein, including molec-
ular weight, abundance, and post-translational modifications. Figure 5.5 shows the western blot 




results of CA IX expression in SaOs-2 and MDA-MB-231. CA IX protein was detected in both 
breast cancer and osteosarcoma cell lines. Typically, CA IX migrates as a doublet of 54 KDa and 
58 KDa [42], which corresponds to the obtained data. 
 
Figure 5.5. Western blot analysis of total lysates from SaOs-2 and MDA-MB-231 cell lines treated with 
commercial mAb anti-CA IX 
 Murine immunization 
Different murine were immunized with CA IX N-terminal peptide and CA IX central peptide. To 
evaluate the immunization effectiveness, murine serum was removed at fixed times and checked 
for the presence of antibodies anti-CA IX. Further, the same evaluation was performed before 
fusion of the splenocytes from the murine with the myeloma cells. Figure 5.6 shows the flow 
cytometry analysis on murine serum immunized with CA IX N-terminal peptide using SaOs-2 
cell line. The results show the presence of antibodies anti-CA IX in the murine serum. 
After confirmation that the immunized mice was producing antibodies anti-CA IX, the mice was 
sacrificed, the spleen removed and used for cell fusion. Cell fusion was carried out between sple-
nocytes from both mice immunized with CA IX N-terminal peptide and CA IX central peptide, 
and Sp2/0 myeloma cells to produce hybridomas. 





Figure 5.6. Flow cytometry analysis of murine serum immunized with CA IX N-terminal peptide using 
SaOs-2 cell line stained intracellularly. Gray histogram corresponds to the negative staining control, i.e., 
cells stained with only the secondary antibody. 
 Hybridomas selection 
Hybridomas selection was performed using the following techniques: flow cytometry, fluores-
cence microscopy, and dot blot. 
 mAb anti-CA IX N-terminal 
After fusion, cells were seeded in 96-well plates. The supernatants were screened after a fixed 
time to identify the positives one. A good technique to perform this screening is flow cytometry. 
Figure 5.7 corresponds to two positive hybridoma supernatants resultant from fusion of spleno-
cytes from mice immunized with CA IX N-terminal peptide with myeloma cells. Moreover, the 
same technique was also used to evaluate the stability of the hybridoma. As such, the analysis 
was performed 7 weeks and 4 months after fusion (Figure 5.7 A and B, respectively). 3G9 hy-
bridoma cells appear to maintain its antibody producing ability over time. However, 3B5 hybrid-
oma cells decrease their antibody production ability over time. These results suggest that 3G9 
cells are more likely to be selected for future developments. 
Furthermore, flow cytometry analysis was performed 8 months after fusion using two cell lines: 
MDA-MB-231 and SaOs-2 (Figure 5.8). In SaOs-2, it is possible to verify that supernatant 3G9 
remains stable after 8 months, while supernatant 3B5 continues to decrease its intensity. In MDA-
MB-231 cell line, the expression of CA IX is lower and consequently, the signal intensity is lower.  





Figure 5.7. Flow cytometry analysis of hybridoma supernatant producing N-terminal antigen using SaOs-
2 cell line 7 weeks (A) and 4 months (B) after fusion. Gray histogram corresponds to the negative control, 
i.e., cells stained treated with only the secondary antibody. Red histogram corresponds to the supernatant 
from 3B5 hybridoma cells and the blue one to 3G9. 
 
Figure 5.8. Flow cytometry analysis of hybridoma supernatant producing N-terminal antigen using Samos 
cell line (A) and MDA-MB-231 cell line (B) 8 months after fusion. Gray histogram corresponds to the 
negative control, i.e., cells stained with only the secondary antibody. Red histogram corresponds to the 
supernatant from 3B5 hybridoma cells and the blue one to 3G9. 
Fluorescence microcopy was performed using both SaOs-2 and MDA-MB-231 cell lines (Figure 
5.9). Cells were incubated with supernatant from 3G9 hybridoma cells (green), the apparently 
most stable one, followed by fluorescent polyclonal anti-Ig antibody. The cell nuclei were stained 




with TO-PRO-3 dye (red). Negative control was obtained by staining with only the secondary 
antibody. In both cell lines, the presence of CA IX is barely noted. This may be a consequence of 
two factors: since the used cell lines are grown in normoxia, CA IX expression is low; the amount 
of anti-CA IX antibody produced by the hybridoma is low, and consequently, the amount of an-
tibody available to bind to CA IX in the cells is not enough to produce a fluorescence good signal. 
 
Figure 5.9. Fluorescence microscopy of MDA-MB-231 and SaOs-2 cell lines treated with hybridoma su-
pernatant 3G9 producing N-terminal anti-CA IX mAb (Green) and TO-PRO3 (Red) for the nucleus. 
To confirm whether the supernatant from 3B5 hybridoma cells, which was losing signal capacity 
by flow cytometry as time was passing, contained anti-CA IX antibodies, dot blot analysis was 
performed using CA IX protein as target. In this technique, a known amount of CA IX protein is 
placed in a spot in a membrane and the membrane is incubated with the respective antibody. In 
this case, the positive control was incubated with commercial mAb anti-CA IX (H-11), while the 
sample was incubated with the 3B5 hybridoma supernatant. As can be seen in Figure 5.10, there 
are anti-CA IX antibodies IX in the 3B5 hybridoma supernatant, although its titer appears to be 
low judging by the low intensity of the signal. 





Figure 5.10. Dot blot analysis of 3B5 hybridoma supernatant producing N-terminal anti-CA IX mAb using 
CA IX protein as target. 
 Anti-CA IX central peptide mAb 
Figure 5.11 corresponds to the staining of SaOs-2 and MDA-MB-231 cells with three positive 
hybridoma supernatants resultant from fusion of splenocytes from mice immunized with CA IX 
central peptide with myeloma cells. Supernatant 3D2 (red histogram) corresponds to the hybrid-
oma with higher specificity and/or titer. 
 
Figure 5.11. Flow cytometry analysis of hybridoma supernatant containing central peptide antibodies using 
SaOs-2 (A) and MDA-MB-231 (B) cell lines, 3 months after fusion. Gray histogram corresponds to the 
negative control, i.e., cells stained with only the secondary antibody. Red histogram corresponds to the 
supernatant from 3D2 hybridoma cells, green histogram corresponds to supernatant 4C5 and the blue his-
togram corresponds to supernatant 1D3. 
Fluorescence microscopy images of SaOs-2 and MDA-MB-231 cells incubated with the super-
natants of each of the selected hybridomas are showed in Figure 5.12. In the three cases the pres-
ence of antibodies against CA IX are confirmed in both cell lines. However, similarly to what 
occurred in the previous cases, it is not possible to distinguish the location of the CA IX within 
the cell. Furthermore, expression of CA IX in MDA-MB-231 cells appears to be smaller than the 
one observed in SaOs-2 cells. 





Figure 5.12. Fluorescence microscopy of MDA-MB-231 and SaOs-2 cell lines treated with hybridoma su-
pernatant containing central peptide anti-CA IX mAb (Green) and TO-PRO3 (Red) for the nucleus staining. 
Dot blot analysis was performed to confirm the specificity of the antibodies produced by the 
selected hybridomas to CA IX. This analysis was performed for the two supernatants with best 
performance in both flow cytometry and fluorescent microscopy. Figure 5.13 shows the obtained 
results where it is visible that 3D2 hybridoma supernatant has antibodies against CA IX although 
in a small amount. Furthermore, 4C5 supernatant has a very low signal, which may indicate that 
the hybridoma is producing antibodies that are not only specific for CA IX protein, since it shows 
a significant staining of both cell lines by flow cytometry and fluorescence microscopy. 
 
Figure 5.13. Dot blot analysis of hybridoma supernatant containing central peptide anti-CA IX mAb using 
CA IX protein as target. 
Since 3D2 supernatant is the one with best performance in flow cytometry, fluorescence micros-
copy and dot blot, western blot analysis was performed to confirm the specificity of the produced 
antibody. Both SaOs-2 and MDA-MB-231 cell lysates were used. Figure 5.14 displays the ob-
tained results for both cell lines, compared to positive staining control for CA IX. In the case of 
SaOs-2 cells, the antibodies produced by the selected hybridoma clearly bound to CA IX, pro-
ducing a similar pattern as the positive control. This is not the case of MDA-MB-231 in which 
the obtained pattern has more bands comparing to control. However, CA IX specific bands are 
present in the obtained pattern. This means that the selected hybridoma is producing antibodies 
against CA IX but not exclusively. 





Figure 5.14. Western blot analysis of total lysates from SaOs-2 and MDA-MB-231 cell lines stained with 
3D2 hybridoma supernatant containing antibodies against the central peptide of CA-IX. 
5.4. Summary 
Monoclonal antibodies, the “magic bullet” imagined by Ehrlich, are nowadays and important 
class of pharmaceutical products for treatment of cancer, infectious disease, allergy, autoimmune 
disease and inflammation. Typically, monoclonal antibodies are produced using the hybridoma 
technology. However, for clinical application, humanization of these mAbs is required to decrease 
their immunogenicity. 
In the present work, the main purpose was the production of monoclonal antibodies anti-CA IX, 
a carbonic anhydrase protein present mostly in tumor tissues and recognized as a predictive out-
come of cancer treatments. The desired antibody was produced using the hybridoma technology 
and tested against to tumor cell lines: a breast cancer cell line (MDA-MB-231) and an osteosar-
coma cell line (SaOs-2). 
In a first stage of this work, the used cell lines were tested for the presence of CA IX. It is im-
portant to consider that both cell lines were maintained in normoxia conditions. As such, CA IX 
should not be overexpressed. However, the presence of CA IX was still identified by flow cytom-
etry, confocal microscopy, and western blot analysis. For a more complete analysis, both cell 
lines should be cultured in hypoxia conditions and CA IX catalytic activity measured. Moreover, 
subcellular location of CA IX should be determined, to confirm if whether the protein was kept 
in the membrane. 




Murine were immunized with three different antigens: the whole CA IX protein, an N-terminal 
peptide, and a central peptide. Only the N-terminal and central peptide were selected for further 
cell fusion. After fusion, viable hybridomas were selected using flow cytometry, fluorescence 
microscopy and dot blot analysis. The hybridomas’ supernatants were tested against both MDA-
MB-231 and SaOs-2 cell lines. The obtained results showed that at least one hybridoma from 
each immunization were viable for production of antibodies anti-CA IX.  
Some lack of specificity was observed when the supernatant of the hybridoma producing a central 
peptide anti-CA IX was observed. This may be resolved by the following step, which was not 
performed during this work. Further recloning would provide the means to obtain isolated highly 
selected hybridoma cell lines. Although this step was not performed, the obtained results provide 
the basis to predict a successful outcome. Moreover, the produced antibodies using hybridoma 
technology demonstrated to bind to both osteosarcoma and breast cancer cell lines. This versatil-
ity is crucial when developing a mAb to be used for active targeting therapies. Nevertheless, a 
large amount of work still need to be done in order to obtained a mAb suitable for use as an active 
targeting agent. 
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 Theranostic part I: Mag-
netic hyperthermia, MRI 
and cytotoxicity 
In the previous chapters, the individual parts of the theranostic system were developed and fully 
characterized. In this chapter, their suitability as theranostic agents is accessed, starting with a 
brief introduction to two possible applications: magnetic hyperthermia agents and contrast agents 
for magnetic resonance imaging. The obtained results are presented and discussed. At the end of 
this chapter, results of in vitro cytotoxicity assays of the produced components of the theranostic 
system are presented and discussed. 
6.1. Introduction 
In the last decade several nanoparticle-based products for diagnostic and therapeutic have been 
approved for clinical applications, and even more are currently under clinical trials [1-5]. An 
important aspect of nano-medicine research is the development of multifunctional nanoparticles, 
i.e., nanoparticles (NPs) with the ability to accomplish multiple purposes such as imaging and 
therapy [1]. Among the different type of nanoparticles, magnetic NPs have been extensively in-
vestigated for biomedical applications such as magnetic resonance image (MRI) contrast agents 
for diagnosis [6-9] and magnetic hyperthermia agents for cancer treatment [10-14]. 
 Magnetic Hyperthermia 
Hyperthermia is an old technique recognized as a possible treatment option for cancer. Hippoc-
rates, the father of medicine, treated surface tumors by cauterizing them with a hot iron. More 
recently further advanced hyperthermia methods have been employed in cancer treatment such as 




hot bath water, pyrogen (for example, a mixture of bacterial toxins), perfusion heating, high fre-
quency radiation and magnetic fluid hyperthermia [15]. The theory behind hyperthermia is to kill 
cancer cells without the use of drugs (chemotherapy) or radiation (radiotherapy) just by increasing 
temperature in the tumor site. This idea is based on the higher sensitivity of cancer cells to tem-
perature oscillations when compared to normal cells, therefore decreasing the side effects [16, 
17]. Tumor cells usually survive in a microenvironment with reduced blow flow, thus favoring 
hypoxia, acidosis and energy deprivation. Many researchers have demonstrated that hyperthermia 
reduces blow flow, and as a consequence there is a reduction of oxygen and nutrients supply, 
leading to intracellular acidosis [18-20]. 
 Hyperthermic perfusion 
Hyperthermic perfusion was one of the first used techniques, probably because it tends to mimic 
the natural occurrence phenomena in a mammalian body, i.e., fever. Fever is a mechanism by 
which the body fights disease because it has more adverse effect on the pathogen or diseased 
tissue than on the rest of the body, thus allowing the body to overcome the disease condition [21]. 
As so, hyperthermic perfusion may be used for cancer treatment locally or systemically, as well 
as for other diseases such as viral infections like hepatitis C [22] or herpes viruses [23]. The 
whole-body hyperthermic perfusion has the inherent difficulty of body temperature control, thus 
causing side effects such as elevation of serum transaminases and bilirubin, neurological damage 
associated with serum hypophosphatemia or even death presumably from massive liver tumor 
necrosis. Another technique for hyperthermic perfusion is by heating only a cavity of the body 
like peritoneal or chest cavity with treated fluids. This method is simpler, since it can be accom-
plished using a hemodialysis equipment, but it may be more aggressive for the patient than the 
disease itself [24]. Despite of these difficulties, intraperitoneal and intrapleural hyperthermia per-
fusion is still being performed. Li et al. [25] used a swine model of experimental distal gastros-
tomy with Billroth II reconstruction to investigate the safety of intraoperative and early postop-
erative continuous hyperthermia intraperitoneal perfusion. The results showed that at perfusate 
temperature above 43.5 ºC promotes harmful, hampering anastomotic healing and abdominal ad-
hesion. However, at a perfusate temperature of 42.5 ºC, the pigs were not significantly harmed in 
terms of their vital signs, liver function, renal function, and anastomotic healing. Ba et al. [26] 
went further on the studies of hyperthermic perfusion and studied the efficacy of B-ultrasound 
guided and laparoscopic-assisted continuous hyperthermic intraperitoneal perfusion chemother-
apy to treat malignant ascites. The results showed similar clinical efficacy between both methods 
being the main difference the duration of surgery and hospitalization costs, but B-ultrasound 
guided continuous hyperthermic intraperitoneal perfusion chemotherapy was more advantageous. 




These authors used the same method for malignant pleural effusion [27]. They were able to heat 
uniformly the entire pleural cavity with distilled water at 46ºC, while the temperature in the tho-
racic esophagus did not exceed 40 ºC during one hour of treatment. In addition, chemotherapy 
was avoided during this procedure. Other authors studied the effect of intrapleural hyperthermic 
perfusion chemotherapy for metastatic pleural malignancies [28], or for thymoma or thymic car-
cinoma with pleural dissemination [29], both with improved results. Further, hyperthermic per-
fusion may be useful for some patients, for example, as adjuvant of chemotherapy, thus sensitiz-
ing the tumor cells for the drug. However, it still misses on the specificity and on the ability to 
maintain a severe temperature control to avoid damaging the surrounding tissues. 
 Hyperthermia by an external electromagnetic field 
The application of an external electromagnetic field for hyperthermic treatment is common to 
several techniques. However, the use of plain wave electromagnetic radiation, such as microwave 
heating and radiofrequency waves and ultrasound have some disadvantages, for example: low 
tissue penetration, rapid decrease of energy with depth increase; perturbations induced by tissue 
interfaces with air or bone; variation in heat effect or focusing on heating deeper organs; all cells 
are heated [30]. Researchers have employed ways to circumvent these problems and to improve 
the effectiveness of the treatment, for example using frequency enhancers, catheters, or magnetic 
particles. The use of small magnetic particles that generate heat by application of an alternate 
magnetic field of high frequency is currently one of the most interesting and more researched 
techniques. These particles may be delivered to the target by many ways such as direct injection, 
antibody targeting or intravascular infusion [30]. 
 Magnetic hyperthermia 
Magnetic hyperthermia is based on locating magnetic nanoparticles into the desired site and to 
apply an external alternating magnetic field in such a way to cause heat generation by the mag-
netic nanoparticles. The magnetic field has the advantage of not being absorbed by the living 
tissues and enabling deep penetration into those tissues. The important properties of magnetic 
particles for inducing hyperthermia are non-toxicity, biocompatibility, injectability, high-level 
accumulation in the target tumor and effective absorption of the energy of the alternating mag-
netic field [16, 31]. The best candidates for effective treatment are magnetic materials with Curie 
temperatures between 42 ºC and 60 ºC, since they act as in vivo temperature control switches 
avoiding overheating [16]. An important requirement for hyperthermia treatment is the thermal 




dose applied which is related to the volume of the tumor and with the procedure used. For exam-
ple, for a tumor with a diameter of 3 mm and a concentration of magnetic NPs of 0.01 g.cm-3 it is 
required a power of more than 1 kW.g-1. The correlation between the thermal dose applied and 
the clinical outcome parameters can be estimated by the “cumulative equivalent minutes at 43 
ºC”. This parameter is related with the heat exposure time at the given temperature and in clinical 
trials it is attained at 90% of tumor related measure points [17, 31, 32]. 
Gilchrist and his coworkers [33] were the first to study the use of magnetic iron oxide nanoparti-
cles to induce heat in lymph nodes missed at operation. Later in 1979, Gordon et al. [34] first 
proposed the concept of inducing intracellular hyperthermia using dextran magnetic NPs. Mag-
netite nanoparticles were administered intravenously to Sprague-Dawley rats bearing mammary 
carcinomas and showed that AMF-induced heating occurred in their in vivo experiments. Jordan 
et al. [35] have proposed magnetic fluid hyperthermia (MFH) in several other comprehensive in 
vitro studies. They have demonstrated that magnetic fluid hyperthermia is able to inactivate tumor 
cells in vitro and that there is a sensitizer effect of ferrofluids at 43 ºC, probably caused by the 
oxidative stress induced by free ferric ions. With these findings, Jordan and his team proposed 
MFH as a new method of cancer treatment. Chan et al. [36] reported on modified dextran mag-
netite and its hyperthermic effect by using several human carcinoma cell lines in vitro. The spe-
cific absorption rate (SAR) of conventional dextran magnetite, which indicates the heat evolution 
rate in hyperthermia, is low. Magnetite NPs behave as superparamagnetic rather than ferromag-
netic due to its small size; hence, its hysteresis loss is very low. These authors controlled the 
oxygen concentration in the preparation of dextran magnetite and selected particles of approxi-
mately 15 nm. Other authors reported that particle size is a critical factor in obtaining a high SAR 
value [15]. In addition, some theoretical considerations have been made to study the size depend-
ence of the SAR and to predict the optimum parameters of the nanoparticles employed in the 
magnetic hyperthermia [37-39].  
 Clinical application of hyperthermia 
Clinical application of hyperthermia is not established as a single treatment modality but as a way 
to improve chemotherapy and radiotherapy results, when applied in repetitively short intervals. 
Local and regional radiofrequency hyperthermia can be regarded as a well-established, non-toxic 
treatment, which is used according standardized protocols worldwide. In fact, according to the 
US National Institutes of Health, there are currently 158 clinical studies related with hyperthermia 
and cancer, from which only three studies evaluate hyperthermia as a single treatment option. The 




majority of the clinical trials correlate hyperthermia with chemotherapy or radiation therapy. Alt-
hough, these studies are distributed among the world (Figure 6.1), there are more studies ongoing 
in the developed countries [40].  
 
Figure 6.1. World map representing the distribution per region of clinical trials related with hyperthermia 
and cancer (Source: www.clinicaltrials.gov. Search terms: ‘hyperthermia’ and ‘cancer’. Date of search: 
August 2015). 
NanoThermTM is a ferrofluid composed of iron oxide nanoparticles with an average diameter of 
15 nm, coated with an aminosilane. NanoThermTM is still in clinical trials for three types of tu-
mors: glioblastoma multiform, prostate carcinoma [41-43] and pancreatic carcinoma. The re-
search group that formed the company MagForce Nanotechnologies AG has tested their iron ox-
ide formulations for glioblastoma multiform in a feasibility study and found that all the patients 
tolerated the administration of the nanoparticles without further complications. Thermotherapy 
was applied at magnetic field strengths of 3.8 to 13.5 kA.m-1, leading to a T90 median (tempera-
ture exceeded by 90% of the tumor) of 40.5 ºC [44]. The autopsy findings of two glioblastoma 
patients treated with MFH demonstrated that most of the nanoparticles were aggregated and pref-
erentially located in geographic necrosis within the tumor, restricted to the sites of instillation. In 




addition, at the borders of the aggregates the nanoparticles were phagocytosed mainly by macro-
phages [45]. Phase II clinical trials showed an extension of the median OS-2 (overall survival 
following the first diagnosis of tumor recurrence or progression) to 13.4 months, comparing to 
6.2 months of a reference study. In this study, thermotherapy was applied in combination with a 
lower radiotherapy dosage of 30 Gy [46]. Preclinical studies are also being developed in different 
types of tumors, such as lung cancer [47], bladder cancer [48], pancreatic cancer [49], or for 
general cancer treatment [50, 51]. 
Currently, hyperthermia is approved to treat advanced cancer, such as recurrent rectal cancer, 
prostate cancer, uterine cancer, head and neck cancer, lung cancer, and breast cancer, in conjuga-
tion with chemotherapy and radiotherapy [32, 52]. 
 Magnetic Resonance Imaging 
Another application of magnetic NPs is MRI, which is a powerful imaging tool due to its non-
invasive nature, high spatial resolution, and tomographic capabilities [16]. MRI is based on the 
principles of nuclear magnetic resonance (NMR), a spectroscopy technique used to obtain micro-
scopic and physical information about molecules [53].  
 Brief history of MRI 
In 1946, Bloch and Purcell first discovered the magnetic resonance phenomenon, both of whom 
were awarded the Nobel Prize in 1952. In the following two decades, NMR was developed for 
chemical and physical molecular analysis. Only later, in 1971, Damadian demonstrated that nu-
clear magnetic relaxation times of healthy tissues and tumoral tissues differed [54].  
Meanwhile, Lauterbur developed the first NMR imaging technique, obtaining a “zeugmatogram”, 
a cross-sectional image of NMR test tubes containing pure water [55]. A few years later, Ernst 
proposed MRI using phase and frequency encoding, and the Fourier Transform, which are the 
basis of current MRI techniques [56].  
Later on, in 1980, Edelstein demonstrated imaging of the body using Ernst’s technique, taking 5 
minutes to obtain a single image [57]. Six years later, this time was reduced to 5 seconds, without 
highly compromise image resolution [53]. 
 MRI fundamentals 
MRI fundamentals relay on computer-assisted imaging of relaxation signals of proton spins 
within a body excited by radiofrequency waves in a strong magnetic field. Most commonly, water 




protons (1H) are imaged due to its abundance in living organisms. Water protons that exist in the 
same magnetic environment resonate at the same frequency. Consequently, NMR signal is pro-
portional to the volume of water. Moreover, MRI may impose special variations on the magnetic 
field to distinguish spins by their locations. As such, the magnetic gradient causes oscillations at 
different frequencies in water protons at different locations, originating a map of the spatial dis-
tribution of nuclear spins [6, 58, 59]. 
The relaxation of proton spins to their equilibrium state occurs by two independent processes: 
longitudinal relaxation, characterized by relaxation time T1, and transverse relaxation, character-
ized by relaxation time T2. In soft tissues, T1 is around one second while T2 is much faster, within 
the milliseconds range. However, these values depend upon the tissue type in addition to their 
dependence on external magnetic fields, providing MRI a large soft tissue contrast [6, 58, 59]. 
 MRI contrast agents 
Various types of contrast agents have been developed to enhance MRI contrast between healthy 
and diseased tissues. The main purpose of these agents is to reduce the T1 or T2 relaxation times 
of protons located nearby. Reduction of T1 relaxation time originates a positive contrast by hyper-
signaling. On the other hand, reduction of T2 relaxation time originates negative contrast by re-
ducing both T2 and T2* (describing the decay of transverse magnetization taking into account 
the inhomogeneity of local static magnetic fields). Agents with unpaired electron spins such as 
gadolinium, manganese, and iron, can effectively reduce the T1 relaxation time. Consequently, 
these metals have been incorporated into several types of small molecular weight metal-organic 
complexes to be used as positive contrast agents. One of the most used positive contrast agents is 
gadolinium (Ga)-based small molecular complexes, such as Ga-DTPA (DTPA, diethylenetri-
aminepentaacetic acid) [58, 60]. 
Iron oxide nanoparticles provide contrast enhancement by producing predominantly spin-spin re-
laxation effects due to the induced local field inhomogeneities, resulting in shorter T1 and T2 
relaxation times. However, T1 shortening process requires a close interaction between protons 
and T1-agents that can be hindered by the thickness of the coating on the NP. On the other hand, 
T2 shortening is caused by the large susceptibility difference between the particles and surround-
ing medium, originating microscopic magnetic field gradients. Diffusion of protons through these 
field gradients leads to dephasing of the proton magnetic moments, thus decreasing T2 relaxation 
times. As a result, iron oxide NPs are typically used as negative contrast agents. 




 Iron oxide NPs as MRI contrast agents 
The use of superparamagnetic iron oxide nanoparticles provides a better differentiation between 
healthy and pathological tissues and specifically allows for cancer cell targeting [61]. For exam-
ple, some authors have used magnetic NPs to detect apoptosis, an active process of cellular self-
destruction present in many disorders, such as neurodegenerative diseases (e.g. Alzheimer, Par-
kinson), by MRI [62-64]. The specific targeting may be achieved using numerous biomarkers, 
specifically overexpressed by the target cells [16]. Monoclonal antibodies were the first targeting 
agents to exploit molecular recognition to deliver magnetic NPs [65]. Huh et al. [66] used mag-
netic nanocrystals conjugated with Herceptin, a cancer-targeting monoclonal antibody used for 
breast cancer treatment, and successfully monitored in vivo selective targeting events of human 
cancer cells implanted in live mice. In addition, radioconjugated nanoparticles have been devel-
oped using recombinant antibody fragments. DeNardo and his team [67] conjugated a bioprobe 
(111In- DOTA-ChL6) to polyethylene glycol-iron oxide-impregnated dextran 20 nm particles 
(111In-probes) and tested its effectiveness in human breast cancer xenografts in mice. The results 
showed tumor response with heat dose dependence without toxicity. In fact, a member of the 
same work group invented the magnetic nanoparticles coated with dextran and embedded with a 
specific ligand to its use in targeted thermotherapy [68]. Other authors tested the recombinant 
antibody fragments di-scFv-c (111In-DOTA-di-scFv-NP) for imaging and therapy of anti-MUC-1 
10 expressing cancers [69]. Further conjugation with fluorescent dye-labeled antibodies enables 
both in vitro and ex vivo optical detection of cancer, as well as in vivo MRI, which are potentially 
applicable for an advanced multimodal detection system. 
6.2. Materials and methods 
All the chemical reagents used in this research work were of analytical grade and used without 
further purification. 
 Samples preparation 
Iron oxide nanoparticles were prepared according to the protocol described in Chapter 3. For this 
study were used the following NPs: iron oxide NPs produced by chemical precipitation technique 
without further treatment (Pristine Fe3O4 NPs); stabilized with either tri-sodium citrate (Fe3O4 
TC), or oleic acid (Fe3O4 OA 64 mM); and finally, iron oxide NPs prepared by thermal decom-
position technique (Fe3O4 TD). 




Polymeric coating of both chitosan (CS) and O-HTCC (the chitosan derivative) was produced 
according to the procedure described in Chapter 4. 
 Magnetic hyperthermia 
Magnetic hyperthermia measurements were obtained using a DM100 series from Nb Nanoscale 
Biomagnetics apparatus. This apparatus allows measurements at different magnetic field intensi-
ties up to 24 kA.m-1 with a fixed frequency of 418.5 kHz. The heating ability of 1 ml sample of 
freshly prepared NPs solution was measured in different sets.  
To evaluate the concentration effect on thermal behavior of pristine Fe3O4 colloids, measurements 
were performed during 40 minutes by keeping magnetic field intensity and frequency constant, 
and varying iron concentration. 
To study the influence of both oleic acid and tri-sodium citrate in the heating ability of the NPs 
samples with different NPs concentrations were subjected to magnetic field intensities from 8 to 
24 kA.m-1, varying the surfactant concentration. 
Samples for in vitro heat generation were prepared as following: NPs colloids were dispersed in 
a hot agar solution (1 wt.% of agar) in a glass vial. Samples were sonicated for 1 min. to disperse 
the NPs, and then solidified at room temperature. Iron content of all samples was kept constant at 
94 mM. Agar phantoms were subjected to an alternating current (AC) magnetic field of 24 kA.m-
1, with a frequency of 418.5 kHz for 10 minutes. The overall study is summarized in Table 6.1.  
Further studies were performed using the following fixed conditions, unless stated otherwise: AC 
magnetic field of 24 kA.m-1, with a frequency of 418.5 kHz for 10 minutes, using 1 ml of sample. 
 Nuclear magnetic resonance  
Measurement of the NPs efficiency as contrast agents for MRI was performed using samples 
prepared with iron concentrations ranging from 0.2 to 2.6 mM in aqueous agar solution of 0.5 
wt.%. The longitudinal and transverse relaxation times of these samples were measured in a 
Bruker Avance III NMR spectrometer in a 7 T magnetic field at 25 ºC using an inversion-recovery 
and a Carr Purcell Meiboom Gill impulse sequences, respectively.  




Table 6.1. Tested conditions to evaluate the influence of the stabilizers (oleic acid and sodium tri-citrate) 















40 [0.4 – 376] 
-- 
10 [5.4 – 107] 
8, 12, 18, 24 10 [32.6 – 376] 




24 10 [5.4 – 107] 64 
8, 12, 18, 24 10 [32.6 – 376] [0 – 64] 




24 10 [5.4 – 107] 10 
8, 12, 18, 24 10 [32.6 – 376] [0 – 30] 
Agar 24 10 94 10 
 Cytotoxicity assays 
Cell viability studies were performed on Vero (fibroblast-like kidney cell) and SaOs-2 (primary 
osteogenic sarcoma) cell lines using the resazurin assay. The cells were seeded at density of 5x104 
cells.ml-1 in 96-well plates. SaOs-2 cell line was grown in McCoy 5A medium, supplemented 
with 10% fetal bovine serum and 1% Penicillin-Streptomycin (10,000 U.ml-1), while Vero cell 
line was grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum, 1% Penicillin-Streptomycin (10,000 U.ml-1), sodium pyruvate (100 mM), and Glu-
taMAX™ Supplement followed by incubation at 37 ºC in 5% CO2 overnight. Next day, cells were 
treated with fresh medium containing a known concentration of nanoparticles ranging from 12.5 
mM to 0.78 mM Fe in each well in triplicates and the plates were incubated for 24 h. After this 
time, the medium was removed and rezasurin was added to each well. After 2 h incubation, time 
the absorbance was measured at 570 and 600 nm. Control cells were treated similarly, and were 
incubated with the respective medium at the same dilution as the one used for incubation with 
nanoparticles. Cell viability was expressed as a percentage of the control, given by [% cell via-
bility = NP treated cells/control cells x 100]. 




 Magnetic hyperthermia in vitro 
Cell viability studies were performed by resazurin assay on Vero and SaOs-2 cell lines. The cells 
were seeded at density of 40x104 cells.ml-1 in hyperthermia tubes. SaOs-2 cell line was grown in 
McCoy 5A medium, supplemented with 10% fetal bovine serum and 1% Penicillin-Streptomycin 
(10,000 U.ml-1), while Vero cell line was grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum, 1% Penicillin-Streptomycin (10,000 U.ml-
1), Sodium Pyruvate (100 mM), and GlutaMAX™ Supplement followed by incubation at 37 ºC 
in 5% CO2 overnight. Next day, cells were treated with fresh medium containing a known con-
centration of either 1 mg.ml-1 or 5 mg.ml-1 in each tube, in triplicates. Hyperthermia control cells 
and tested tubes were subjected to an AC magnetic field of 24 kA.m-1 and frequency of 418.5 kHz 
for 10 minutes, unless stated otherwise. Then plates were incubated for 24 h. After this time, the 
medium was removed and rezasurin was added to each well. After 2 h incubation, time the ab-
sorbance was measured at 570 and 600 nm. Control cells were treated similarly, and were incu-
bated with the respective medium at the same dilution as the one used for incubation with nano-
particles. Cell viability was expressed as a percentage of the control, given by [% cell viability = 
NP treated cells/control cells x 100]. 
 Iron content determination 
The iron content of the samples was determined using the 1,10-phenantroline colorimetric method 
[70], similarly to the description in Chapter 3.  
To obtain the nanoparticles concentration the formula [Fe] = 0.7 x [NPs] was used. The ratio was 
obtained from control experiments. 
6.3. Results and discussion 
 Magnetic hyperthermia 
Magnetic hyperthermia assays were performed to evaluate the heating ability of the iron oxide 
nanoparticles produced in Chapter 3. Further, the influence of both surfactants and polymeric 
coating on the heating ability of the same colloids was also accessed. For a better understanding, 
the obtained results are divided into bare iron oxide nanoparticles, and polymer-coated iron oxide 
nanoparticles. It should be noted that bare iron oxide includes Fe3O4 NPs stabilized with surfac-
tants. 




 Bare iron oxide NPs 
Bare iron oxide NPs includes four types: Fe3O4 produced by chemical precipitation method with-
out further treatment (Pristine Fe3O4), Fe3O4 produced by chemical precipitation method stabi-
lized with either tri-sodium citrate (Fe3O4 TC) or with oleic acid (Fe3O4 OA), and Fe3O4 NPs 
produced by thermal decomposition method (Fe3O4 TD). 
In a first step the hyperthermia capability of several concentrations of pristine Fe3O4 NPs were 
tested for a frequency of 418.5 kHz, AC magnetic field intensity of 24 kA.m-1, 1 ml of the colloid 
and 40 minutes of field application. All the heating curves where adjusted to a mathematical 
model (Equation 6.1) of the ZAR v1.0 software from Nb nanoscale Biomagnetics. 
𝑇(𝑡) = (𝑇0 − 𝑇𝑒𝑞)𝑒
−
1
𝜏𝑡 + 𝑇𝑒𝑞 Equation 6.1 
In the equation T0 is the initial temperature of the colloid, Teq is the equilibrium temperature of 
the colloid; T the maximum temperature reached by the colloid and  is characteristic time of 
heating. 
Figure 6.2 represents the temperature variation of pristine Fe3O4 NPs as a function of iron con-
centration obtained using the above stated experimental conditions. The red line is an exponential 
adjustment to the obtained data. This exponential adjustment demonstrates that the heating ability 
of the NPs tends to decrease for high NPs concentration according to the empirical equation: 
∆𝑇(º𝐶) = −33.2𝑒−
[𝐹𝑒](𝑚𝑀)
11.1 + 60.0 Equation 6.2 
with a correlation factor (R2) of 0.995. Exponential adjustment to experimental data suggests an 
increase of generated heat as the NPs concentration increases with a tendency to saturate at a very 
high iron concentration. This is correlated to the appearance of agglomerates. Superparamagnetic 
nanoparticles show weak dipole-dipole interaction, whereas the exchange interactions dominate. 
On the other hand, agglomerates behave like a particle, with an effective volume larger than a 
single core, behaving like a ferromagnetic particle. 
Figure 6.3 represents the temperature variation as a function of iron concentration for the optimal 
surfactant concentrations. These experiments were performed for 10 minutes, with an AC mag-
netic field intensity of 24 kA.m-1 and a frequency of 418.5 kHz. 





Figure 6.2. Temperature variation generated by pristine Fe3O4 during 40 minutes of an AC magnetic field 
application with intensity of 24 kA.m-1 and 418.5 kHz as a function of iron concentration. 
 
Figure 6.3. Generated temperature by pristine Fe3O4 (black dots), tri-sodium citrate 10 mM (red dots) and 
oleic acid 64 mM (green dots) stabilized NPs during 10 minutes of an AC magnetic field application with 
intensity of 24 kA.m-1 and 418.5 kHz of frequency as a function of iron concentration. 
Similarly to the observed in Figure 6.2, it is possible to verify that the pristine Fe3O4 heating 
ability tends to stabilize for high iron concentrations as expressed by the empirical equation: ∆𝑇 =






66.2 + 47.1. However, when the surfactant is present this effect is no longer observed 
and the best fitting equation is ∆𝑇 = 0.27[𝐹𝑒] + 0.53 and for OA ∆𝑇 = 0.43[𝐹𝑒] + 1.93 for TC. 
The surfactant reduces the aggregation and so the heating ability is still efficient even for higher 
concentration of iron NPs. However, if normal body temperature is considered, a temperature 
variation of five degrees is enough to achieve the hyperthermia range of temperature (around 
42ºC). Within the tested conditions, an iron concentration above 10 mM for pristine and tri-so-
dium citrate Fe3O4 and 20 mM for oleic acid Fe3O4 is enough to generate the required temperature. 
The influence of the surfactants in the heating ability of the NPs was tested with four iron con-
centrations: 32.6, 60.2, 125 and 376 mM, and four different applied AC magnetic field intensities: 
8, 12, 18, and 24 kA.m-1. Both frequency and time of experiment were fixed to 418.5 kHz and 10 
minutes, respectively.  
SAR is use to characterize the heating efficiency of a magnetic material through energy absorp-
tion during its exposure to an AC magnetic field. The value is defined as the quantity of power 
absorbed by the sample per mass unit (W.g-1) and was calculated using the following equation: 
𝑆𝐴𝑅 (𝑊 𝑔⁄ ) =







 Equation 6.3 
where (dT/dt)max is the maximum gradient of the temperature curve of the colloid submitted to an 
hyperthermia test, CNP is the specific heat of the nanoparticles, Cl is the specific heat of the liquid, 
ml is the fluid mass, and mFe is the iron mass in the colloid.  
An accurate estimation of SAR values of magnetic colloids must be taken under adiabatic condi-
tions. As such, to calculate SAR values we used the maximum of the derivative dT/dt. Since 
maximum increase always occurs in the initial few seconds of the experiments the adiabatic con-
ditions are secured [71]. 
SAR values as a function of the surfactant concentration are shown in Figure 6.4 for the four 
different magnetic field intensities and different iron concentrations. The results clearly show that 
the addition of surfactants, even in concentrations as low as 5 mM for tri-sodium citrate or 8 mM 
for oleic acid, strongly reduces the SAR values to values below 60 W.g-1 and 20 W.g-1 respec-
tively. Moreover, this behavior is observed independently of the iron concentration or magnetic 
field applied. However, a small increase in SAR value is obtained for concentrations bellow 2 
mM of tri-sodium citrate. This increase depends on the iron concentration and on the magnetic 
field applied. 





Figure 6.4. SAR values as a function of surfactant concentration for different iron concentrations at 8, 12, 
18 and 24 kA.m-1of the AC magnetic field strength, with a fixed frequency of 418.5 kHz. 
Figure 6.5 represents the temperature variation obtained from magnetic hyperthermia test as a 
function of iron concentration for pristine NPs and 4 different concentrations of oleic acid. These 




experiments were performed for 10 minutes with an AC magnetic field intensity of 24 kA.m-1 and 
a frequency of 418.5 kHz. The heating ability of oleic acid coated NPs seem to have the same 
relation with the iron concentration, as observed for pristine Fe3O4 NPs. Moreover, with an 
amount of 8% of oleic acid the heating ability of Fe3O4 NPs is not greatly reduced, probably due 
to the small amount of surfactant. As the oleic acid concentration increases to values above the 
critical concentration of the formation of a bilayer, the heating ability of Fe3O4 greatly reduces. 
However, if the concentration increases and the bilayer stabilizes, the heating ability of the NPs 
is recovered, although not to values as high as for pristine Fe3O4. 
 
Figure 6.5. Temperature variation as a function of iron concentration generated by pristine Fe3O4 NPs 
(black dots) and Fe3O4 OA NPs with different surfactant concentrations: 8% (red dots) 64 mM (green dots) 
and 96% (pink dots) generated by the application of an AC magnetic field, for 10 minutes, with intensity 
of 24 kA.m-1 and with 418.5 kHz of frequency. 
In 2002, Rosensweig [37] developed relationships based on rotational relaxation of single domain 
magnetic particles dispersed in a liquid matrix. The magnetic material when submitted to an AC 
magnetic field exhibits both Brownian and Néel relaxations. Nevertheless, Néel relaxation must 
not be allowed to dominate. The expressions of Brownian (Equation 6.4) and Néel (Equation 6.5) 




 Equation 6.4 




𝜏𝑁 = 𝜏0. 𝑒
𝐾𝑒𝑓𝑓.𝑉𝑚
𝑘.𝑇  Equation 6.5 
Where η is the viscosity of the carrier liquid, Vh is the effective hydrodynamic volume and Vm is 
the particle volume, k is the Boltzmann constant, TB is temperature, Keff is the magnetic anisotropy 
and τ0 is the characteristic flipping time [72]. These relaxation times are related to the vanishing 
of the remnant magnetization once the applied AC magnetic field is removed.  
When the nanoparticles are in suspension both relaxation paths are present. Furthermore, Brown-
ian relaxation occurs due to the ability of the particles to freely rotate. This relaxation mechanism 
is mainly due to the NPs hydrodynamic volume and the viscosity of the carrier fluid as seen in 
Equation 6.4. However, when the NPs are injected into the body or directly into the tissue the 
NPs are taken up by tumor cells and stay fixed. In this situation, no Brownian relaxation may 
occur when an AC magnetic field is applied [73, 74]. 
Considering this magnetic hyperthermia tests in agar phantoms containing a known concentration 
of NPs have been performed. Figure 6.6 shows that SAR values decrease for lower iron concen-
tration of pristine iron oxide NPs, which is related to the aggregation of pristine iron oxide NPs, 
affecting their heating generation ability as previously discussed. 
 
Figure 6.6. Comparison of SAR values of pristine and coated NPs in agar phantoms and water. The results 
are expressed as the average ± standard deviation for 3 independent experiments. * p<0.05 compared with 
the respective agar sample. 




For pristine and tri-sodium citrate-stabilized Fe3O4 NPs, SAR values decrease about 50% when 
comparing to the ones obtained for water. Agar phantoms cause the entrapment of the NPs, elim-
inating their Brownian movements. Therefore, heat generation can only be attributed to Néel re-
laxation. However, for oleic acid stabilized NPs the SAR value is almost the same as the one of 
water dispersed NPs. This is related to the bilayer formed around the iron oxide cores where oleic 
acid has a similar effect than agar phantoms, entrapping the NPs and eliminating their Brownian 
movements, which can also explain the low MS observed in these samples (Chapter 3). 
Goya et al. [75] have proposed a versatile diagram to identify the dominant heating mechanism 
of magnetic single domains in magnetic fluid hyperthermia. This diagram considers the magnetic 
mechanism of relaxation (Néel relaxation) and the viscous mechanism of relaxation (Brownian 
relaxation). The probabilities of viscous and magnetic relaxation are proportional to 1/B and 1/N, 
respectively. In this diagram, they have identified three regions: 1) B < 0.1N where the viscous 
mechanism is dominant (viscous region), 2) N < 0.1B where magnetic mechanism is dominant 
and 3) N ~ B where both mechanisms contribute for heat generation. Analyzing the results in 
Table 6.2 is clear that when the NPs are dispersed in water the Brownian mechanism is dominant. 
In this case, the NPs are able to rotate freely and so the viscous mechanism is dominant over the 
magnetic mechanism. However, when the NPs are dispersed in the agar gel, they are entrapped 
into the gel and so their rotation is limited. In this case, the Néel mechanism is clearly dominant.  
Table 6.2. Estimated Brownian (B) or viscous and Néel (N) or magnetic relaxation times for pristine and 
tri-sodium citrate (TC) 10mM and oleic acid (OA) 64 mM iron oxide nanoparticles both in water and agar 
1% wt. 

















For pristine and tri-sodium citrate iron oxide NPs the reduction in the SAR value is probably due 
to this change in the dominant relaxation mechanism. However, for oleic acid this difference is 




not observed. In this case, although the viscosity of the fluid is not clearly affected, the coating 
acts as an entrapment for the iron oxide cores, eliminating their mobility, and consequently de-
creasing the Brownian relaxation mechanism influence for the effective relaxation time of the 
nanoparticles. 
6.3.1.1.1. Iron oxide NPs produced by thermal decomposition 
As previously described in Chapter 3, thermal decomposition technique was used to produce 
highly monodispersed NPs. This technique is based on the thermal decomposition of an iron pre-
cursor, Fe(acac)3, in triethyleneglycol (TREG) at high temperature, without the use of further 
stabilizers. This method is composed of two heating stages: the first related with solution dehy-
dration, and the second one causing decomposition of the iron precursor at the solvent boiling 
point. With the purpose of optimizing the synthesis protocol, different times on the first and sec-
ond stages were tested. Table 6.3 displays the permanence times in each stage from each tested 
condition to optimize synthesis of iron oxide NPs by thermal decomposition technique. 
Table 6.3. Tested conditions to optimize the synthesis of iron oxide NPs by thermal decomposition tech-
nique. 
Sample First stage (120 ºC) Second stage (300 ºC) 
Fe3O4 TD 1 - 30 min 
Fe3O4 TD 2 30 min 30 min 
Fe3O4 TD 3 1h 30 min 
Fe3O4 TD 4 1h 1h 
Fe3O4 TD 5 1h 2h 
 
Ideally, each of these conditions would be characterized by different techniques in order to cor-
rectly access the obtained differences. However, only magnetic hyperthermia was used to perform 
this evaluation. Figure 6.7 shows SAR values obtained by subjecting each Fe3O4 TD sample to 
an AC magnetic field intensity of 24 kA.m-1 and a frequency of 418.5 kHz for 10 minutes, at an 
iron concentration of 71.6 mM. The obtained results clearly show that sample 3 is able to generate 
more heat than the others are. These results correlate with visual analysis of each sample, i.e., 
except for sample 3, the other ones suffer a high degree of sedimentation after a few hours, while 
Fe3O4 TD 3 remained stable, without any sedimentation, for a large period of time (at least three 
months). 




Further analysis of Fe3O4 TD 3 sample was performed to access if the synthesis method influenced 
the heating ability of the iron oxide NPs. For that, the heating ability of Fe3O4 TD 3 NPs was 
evaluated at different iron concentrations, keeping the remaining parameters constant: AC mag-
netic field intensity of 24 kA.m-1, frequency of 418.5 kHz, 1 ml of sample and 10 minutes of 
application (Figure 6.8). The obtained results show that although the relation between the ob-
tained temperature variation and iron concentration is linear, the temperature variation is much 
smaller than the one obtained for either pristine Fe3O4 NPs, or stabilized Fe3O4 NPs, for the same 
iron concentration. Consequently, although the obtained iron oxide nanoparticles by thermal de-
composition technique are expected to be highly stable and are monodisperse in size, its applica-
tion in magnetic hyperthermia is compromised by the low heating ability of the obtained NPs. 
Nevertheless, further characterization of Fe3O4 TD NPs is required, and possibly a more detailed 
optimization of the synthesis protocol. 
 Polymer-coated iron oxide NPs 
After complete evaluation of the heating ability of bare iron oxide nanoparticles, the influence of 
polymeric coating has accessed. Primarily, low molecular weight chitosan (38 kDa) was used as 
a polymeric coating for three types of iron oxide nanoparticles: pristine Fe3O4, Fe3O4 TC 10 mM, 
and Fe3O4 OA 64 mM. In the three cases, the amount of CS and tripolyphosphate was kept con-
stant, while the amount of iron oxide NPs was varied. Moreover, magnetic hyperthermia meas-
urements were performed for not freeze-dried and freeze-dried samples. This later variation in-
tended to verify is freeze-drying process, which is used as a way to prevent polymer degradation 
upon storage, influences the heating ability of the NPs. Figure 6.9 show the variation of the gen-
erated temperature by each sample as a function of iron concentration. As a reference, bare iron 
oxide NPs results in the same tested conditions were added to each case.  
In the case of pristine Fe3O4 NPs (Figure 6.9 A) the presence of chitosan coating does not influ-
ence the generated temperature by the iron oxide cores. However, when chitosan-coated NPs are 
freeze-dried, the generated temperature by the iron oxide cores is lower. On the other hand, chi-
tosan-coated Fe3O4 TC 10 mM NPs (Figure 6.9 B) present a reduction in the generated tempera-
ture compared to the reference. As such, in this case chitosan has a negative influence for the 
application of Fe3O4 TC 10 mM NPs in magnetic hyperthermia. Similar to pristine Fe3O4 NPs, 
freeze-drying process also reduces the generated temperature by the iron oxide cores. The same 
was observed for chitosan-coated Fe3O4 OA 64 mM NPs (Figure 6.9 C). In this case, no differ-
ences are found between freeze-dried and not freeze-dried NPs, probably due to the very small 




T values obtained. The reduction of the generated temperature after freeze-drying process may 
be related to the formation of some aggregates of Fe3O4 NPs during the process. 
 
Figure 6.7. Comparison of SAR values of Fe3O4 TD NPs samples in water solution at an iron concentration 
of 71.6 mM. The results are expressed as the average ± standard deviation for 3 independent experiments. 
 
Figure 6.8. Generated temperature by Fe3O4 TD 3 NPs during 10 minutes of an AC magnetic field applica-
tion with intensity of 24 kA.m-1 and 418.5 kHz of frequency as a function of iron concentration. 




The influence of polymeric coating, CS or O-HTCC (the chitosan derivative synthesized in Chap-
ter 4), was accessed for the Fe3O4 NPs studied. Each of the polymers was used with two molecular 
weights. Figure 6.10 shows the obtained SAR values at a constant iron concentration of 6.3 mM 
and the samples were freeze-dried prior to magnetic hyperthermia measurements. Figure 6.10 
shows that SAR values decrease with the increase of polymer molecular weight and that SAR 
values are higher for O-HTCC Fe3O4 NPs than CS Fe3O4 NPs. This behavior is even more evident 
for Fe3O4 TD NPs, were the difference is around 7-fold. However, in the case of Fe3O4 OA 64 
mM NPs, the result is contradictory and may be related to the presence of an extra positive charge 
in O-HTCC, compared to chitosan, causing the later superficial charges of NPs unbalanced. 
 
  
Figure 6.9. Generated temperature by pristine Fe3O4 (A), Fe3O4 TC 10 mM, (B) and Fe3O4 OA 64 mM (C) 
during 10 minutes of an AC magnetic field application with intensity of 24 kA.m-1 and 418.5 kHz of fre-
quency as a function of iron concentration. Comparison between bare Fe3O4 NPs, not freeze-dried and 
freeze-dried (FD) chitosan-coated Fe3O4 NPs is displayed for each case. 





Figure 6.10. Comparison of SAR values of freeze-dried polymer-coated Fe3O4 NPs. Fe3O4 NPs were coated 
with either CS or O-HTCC of low and high molecular weight. The results are expressed as the average ± 
standard deviation for 3 independent experiments. 
 NMR relaxometry 
NMR relaxometry experiments were performed for a restrict number of samples due to equipment 
limitations. T1 and T2 relaxation times were measured for Fe3O4 OA 96% NPs, as a continuation 
of the study of oleic acid bilayer, since this was the most stable sample (see Chapter 3). 
Figure 6.11 show the transverse relaxation rate for Fe3O4 OA 96% NPs in different pH environ-
ment. The aim was to evaluate the existence of a difference in these parameters between OA NPs 
with and without the formation of a bilayer that make them efficient as contrast agents for MRI. 
As such, this was investigated at pH 5, 7, and 9. 






+ r2[Fe] Equation 6.6 
Where r2 stands for the NPs transverse relaxivity, a measurement of the efficiency of the nanosys-
tem as a contrast agent for MRI, [Fe] is the iron concentration, and 1/T20 is the transverse relax-
ation rate of the medium without Fe3O4 NPs. The same equation can be fitted for the longitudinal 
relaxation rate experimental data and the longitudinal relaxivity obtained at pH 5, 7 and 9 was 
0.05, 0.05, 0.07 (mMs)-1, respectively. 





Figure 6.11. Transverse relaxation rate (1/T2) for Fe3O4 OA 96% NPs at different pH: 5, 7, and 9, as a 
function of iron concentration. 
It is clear that the medium longitudinal relaxation time is slightly altered. However, for the trans-
verse relaxivity the obtained values for the three pH 5, 7 and 9 were 68.6, 88.4 and 128.1 (mMs)-
1, respectively. Thus, the transverse relaxation time remarkably increases with pH as expected by 
the enhancement of the proton exchange rate.  
 Cytotoxicity assays 
When developing a biomaterial one of the most important characteristics, if not the most im-
portant one, is its toxicity. In the present research work, two cell lines were used to evaluate NPs 
cytotoxicity in vitro: Vero, a fibroblast-like kidney cell, and SaOs-2, an osteosarcoma cell line. 
The purpose was to evaluate differences between a “normal” cell line and a tumoral cell line. 
Cytotoxicity of the iron oxide cores was evaluated for pristine Fe3O4, Fe3O4 TC 10 mM, Fe3O4 
OA 64 mM, and Fe3O4 TD. The results are expressed as % of cell viability calculated by [% cell 
viability = NP treated cells/control cells x 100]. Control cells were maintained with the same 
condition as the tested ones, without the addition of nanoparticles. Figure 6.12 and Figure 6.13 
show the obtained results of Vero and SaOs-2, respectively, cell line viability after 24 hours of 
exposition to the four types of iron oxide nanoparticles. 




The results show that both Vero and SaOs-2 cell lines do not show significant toxicity to pristine 
and tri-sodium citrate Fe3O4 NPs in the range of 62.5 – 1000 g.ml-1. However, oleic acid Fe3O4 
the cytotoxicity profile is different. For Vero cell line an iron concentration above 500 g.ml-1 
reduces cell viability up to 20%, thus causing severe cytotoxic effects. For SaOs-2 cell line, cell 
viability is reduced for the tested range of NP concentration, although the cytotoxic effect is mild 
for a NP concentration up to 250 g.ml-1. Finally, Fe3O4 TD NPs do not cause significant cyto-
toxic effects on Vero cell lines at a concentration below 500 g.ml-1. However, SaOs-2 cell lines 
are more sensitive to this type of iron oxide nanoparticles, thus showing severe cytotoxic effects 
with a NP concentration above 500 g.ml-1. 
Chitosan is known to be a non-toxic and biocompatible biopolymer. However, the presence of 
cross-linking agents may cause some toxic effects. Chemical modifications such as the ones to 
produce chitosan’ derivatives can also cause some toxic effects. Considering these facts, cytotox-
icity assays were also performed for both chitosan and O-HTCC NPs, at the highest and lowest 
molecular weight. 
 
Figure 6.12. Vero cell line viability after 24 h exposition to four types of iron oxide nanoparticles: pristine 
Fe3O4, Fe3O4 TC 10 mM, Fe3O4 OA 64 mM, and Fe3O4 TD. Data is expressed as average ± standard devi-
ation for at least three independent experiments. *p<0.05, **p<0.005, ***p<0.001 compared to untreated 
control cells. 




Figure 6.14 and Figure 6.15 show the obtained results of Vero and SaOs-2, respectively, cell line 
viability after 24 h ours of exposition to either chitosan or O-HTCC NPs. Analyzing the obtained 
results for Vero cell line, neither chitosan nor O-HTCC show severe toxic effects in the range of 
concentration tested. Low molecular weight chitosan (38 kDa) causes a small reduction in cell 
viability, which is more evident at the higher concentration tested (500 g.ml-1). Since low mo-
lecular weight CS was obtained by depolymerisation of high molecular weight CS, it is possible 
that some of the used reagents have remained in the sample, thus causing cytotoxic effects.  
SaOs-2 cell lines show a different cytotoxic profile when exposed to polymeric NPs. Chitosan 
nanoparticles of 469 kDa cause some severe cytotoxic effects for the intermediate concentrations. 
Since it is not a concentration-dependent effect, the best explanation for these results is the pres-
ence of reagents from the preparation of the NPs in this sample, which may be cytotoxic for SaOs-
2 cell lines. As for O-HTCC NPs, NP concentrations above 125 g.ml-1 cause cell viability re-
duction. Moreover, O-HTCC NPs of 469 kDa at a concentration of 500 g.ml-1 cause severe 
cytotoxic effects, reducing cell viability to 5%. 
 
Figure 6.13. SaOs-2 cell line viability after 24 h exposition to four types of iron oxide nanoparticles: pristine 
Fe3O4, Fe3O4 TC 10 mM, Fe3O4 OA 64 mM, and Fe3O4 TD. Data is expressed as average ± standard devi-
ation for at least three independent experiments. *p<0.05, **p<0.005, ***p<0.001 compared to untreated 
control cells. 





Figure 6.14. Vero cell line viability after 24 h exposition to chitosan NPs at 38 and 469 kDa, and to O-
HTCC NPs at 48 and 469 kDa. Data is expressed as average ± standard deviation for at least three inde-
pendent experiments. *p<0.05, **p<0.005, ***p<0.001 compared to untreated control cells. 
 
Figure 6.15. SaOs-2 cell line viability after 24 h exposition to chitosan NPs at 38 and 469 kDa, and to O-
HTCC NPs at 48 and 469 kDa. Data is expressed as average ± standard deviation for at least three inde-
pendent experiments. *p<0.05, **p<0.005, ***p<0.001 compared to untreated control cells. 




 Magnetic hyperthermia in vitro 
A preliminary study of the cytotoxic effects caused by magnetic hyperthermia in the presence of 
pristine Fe3O4 NPs was performed. Four samples were used to perform this study: Vero and SaOs-
2 cell control (cells without any further treatment); hyperthermia control (control cells exposed 
to an AC magnetic field with intensity of 24 kA.m-1 and 418.5 kHz of frequency for 10 minutes); 
NPs control (cells exposed to NPs at either 1 mg.ml-1 or 5 mg.ml-1 during 24h, without the appli-
cation of the AC magnetic field); and NPs + hyperthermia (cells exposed to NPs and an AC mag-
netic field with intensity of 24 kA.m-1 and 418.5 kHz of frequency for 10 minutes in the case of 
1 mg.ml-1 NPs, or 200 seconds in the case of 5 mg.ml-1). The later application of the AC magnetic 
field was performed for a shorter period of time since after 200 seconds the sample reaches a 
temperature of 43ºC, which was considered the limit temperature before massive cell death.  
Figure 6.16 shows the obtained results of both Vero and SaOs-2 cell line viability before and after 
application of magnetic hyperthermia at 1 mg.ml-1 pristine Fe3O4 NPs. In both cases, no cytotoxic 
effect was observed neither by the presence of NPs, nor by the application of the AC magnetic 
field. The main reason is that the NP concentration used was not enough to cause a reduction is 
cell viability. Moreover, although the application of the AC magnetic field was performed during 
10 minutes, it was not enough to achieve a hyperthermic temperature (all samples achieve a max-
imum of 37 ºC, considering that the starting temperature was room temperature).  
However, an important conclusion can be retained by the obtained results: the application of an 
AC magnetic field does not have any harm effect of both Vero and SaOs-2 cell lines. 
  
Figure 6.16. Vero and SaOs-2 cell line viability before and after 24 h exposition to hyperthermia with and 
without the presence of pristine Fe3O4 NPs at 1 mg.ml
-1. Data is expressed as average ± standard deviation 
for at least three independent experiments. *p<0.05, **p<0.005, ***p<0.001 compared to control cells. 




Figure 6.17 shows the obtained results of both Vero and SaOs-2 cell line viability before and after 
application of magnetic hyperthermia at 5 mg.ml-1 pristine Fe3O4 NPs. In this case, samples with 
NPs were subjected to the AC magnetic field during 200 seconds, since at this time a temperature 
around 43 ºC was achieved. If the test were maintained for 10 minutes, the temperature would 
most probably continue to rise up to temperatures where massive cell death would have occurred.  
The conclusion obtained in the later results can be obtained in this case: the application of an AC 
magnetic field do not cause harm to both cell lines tested. However, now hyperthermic tempera-
tures were achieved. Consequently, cytotoxic effects were observed in both cases. In Vero cell 
lines a significant difference was observed between cytotoxicity caused by the presence of pristine 
Fe3O4 NPs alone, and by the application of an AC magnetic field in the presence of pristine Fe3O4 
NPs. As such, the application of the magnetic field increases cell death, increasing the effective-
ness of pristine Fe3O4 NPs. However, in SaOs-2 cell lines, both the presence of pristine Fe3O4 
NPs as the application of the AC magnetic field in the presence of pristine Fe3O4 NPs, cause 
severe cell death. As such, no significant differences were found between both cases. As previ-
ously observed, SaOs-2 cell lines are more sensitive to pristine Fe3O4 NPs-induced cell death, 
which may justify the obtained results. 
  
Figure 6.17. Vero and SaOs-2 cell line viability before and after 24 h exposition to magnetic hyperthermia 
with and without the presence of pristine Fe3O4 NPs at 5 mg.ml
-1. Data is expressed as average ± standard 
deviation for at least three independent experiments. *p<0.05, **p<0.005, ***p<0.001 compared to control 
cells. 
Comparison of the later results with in vitro cytotoxicity assays seems contradictory. However, it 
is important to consider that in vitro cytotoxicity assays were performed using 5x104 cells per 
well, while magnetic hyperthermia was performed using 40x104 cells per vial. This is the main 




reason why a concentration of 1mg.ml-1 of pristine Fe3O4 NPs was not enough to reduce cell 
viability. The ratio between the number of cells and the NPs concentration is 5 cells per g of 
NPs in the cytotoxicity assays. In magnetic hyperthermia tests, the ratio is higher: 40 cells per g 
of NPs for 1 mg.ml-1, and 8 cells per g of NPs for 5 mg.ml-1. 
These preliminary data were preliminary results and some factors were not controlled such as 
cells were seeded in glass vials designed for hyperthermia tests, instead of containers designed 
for cell culture, and cell culture laboratory and the magnetic hyperthermia device are located in 
different buildings, requiring transport of cell cultures. This is also the reason why hyperthermia 
tests started at room temperature instead of 37 ºC. Further studies such as NPs uptake by cells 
should be performed to corroborate the obtained results. Moreover, NPs concentration should be 
optimized to allow the application of the AC magnetic field for a period of 10 minutes, similar to 
control cells. Also, different cell lines should be used to verify if tumoral cells are indeed more 
sensitive to both Fe3O4 NPs-induced cell death in the presence of an AC magnetic field or not.  
6.4. Summary 
Current interest in nanotechnology has expanded the range of applications, especially in the bio-
medical field. In the last decade, several nanoparticle-based products for diagnostics and thera-
peutics have been approved for clinical applications. Among the different type of NPs, magnetic 
NPs are of great interest due to their unique physical properties and ability to function at cellular 
and molecular level. These types of NPs have several biomedical applications such as contrast 
agents for magnetic resonance imaging and magnetic hyperthermia. 
In the present chapter, the iron oxide nanoparticles synthesized and characterized in Chapter 3 
were tested for its applicability in both MRI and magnetic hyperthermia. The influence of poly-
meric coating developed in Chapter 4 was also accessed in magnetic hyperthermia tests and cy-
totoxicity assays were performed for both iron oxide nanoparticles and polymeric nanoparticles. 
Magnetic hyperthermia measurements were performed in different set of samples to fully char-
acterize the synthesized iron oxide NPs. The main conclusion was the generated temperature dur-
ing the application of an AC magnetic field is proportional to the iron concentration. This con-
clusion is true for pristine Fe3O4 NPs, surfactant-stabilized Fe3O4 NPs, and polymeric-coated 
Fe3O4 NPs. The surfactants (tri-sodium citrate and oleic acid) reduce SAR values of Fe3O4 NPs, 
which is more evident for higher surfactant concentrations. For concentrations of oleic acid below 
the formation of the bilayer, SAR value is reduced in a directly proportional manner to surfactant 




concentration. However, when the bilayer stabilizes, the heating ability of the NPs is partially 
recovered. 
Magnetic hyperthermia assays were performed in agar phantoms to simulate the in vivo situation, 
where NPs are taken up by tumor cells and stay fixed. In this situation, no Brownian relaxation 
occurs when an AC magnetic field is applied. Therefore, heat generation can only be attributed 
to Néel relaxation. The elimination of Brownian movements highly affect pristine and TC 10 mM 
Fe3O4 NPs, but in in Fe3O4 NPs stabilized with an oleic acid bilayer no significant differences 
were observed between Fe3O4 NPs dispersed in water or agar phantoms. The conclusion is that 
oleic acid has a similar effect than agar phantoms, entrapping the NPs and eliminating their 
Brownian movements, which can also explain the low MS observed in these samples. 
The heating ability of coated Fe3O4 NPs shows that chitosan coating does not influence the tem-
perature generated by the iron oxide cores. However, freeze-drying process reduces the generated 
temperature, probably due to some aggregation that occurs during the process. In the case of 
surfactant-stabilized Fe3O4 NPs, the presence of chitosan reduced the heating ability of the iron 
oxide cores. Furthermore, SAR value decreases with the increase of polymer molecular weight; 
and O-HTCC Fe3O4 NPs have a higher SAR value than CS Fe3O4 NPs. The later difference is 
even more evident for Fe3O4 TD NPs, were the difference is around 7-fold.  
NMR relaxometry experiments were performed for a restrict number of samples, T1 and T2 re-
laxation times were measured for Fe3O4 OA 96% NPs for three pH: 5, 7, and 9. The medium 
longitudinal relaxation time is slightly altered while the transverse relaxation time remarkably 
increases with pH, which was expected due to the enhancement of the proton exchange rate. 
Cytotoxicity assays were performed in two cell lines: Vero, a fibroblast-like kidney cell, and 
SaOs-2, an osteosarcoma cell line. The results show that both Vero and SaOs-2 cell lines viability 
is not significantly affected by pristine and tri-sodium citrate Fe3O4 NPs in the range of tested 
concentrations. However, oleic acid Fe3O4 causes a significant reduction in cell viability in both 
Vero and SaOs-2 cell lines. Finally, Fe3O4 TD NPs do not cause significant cytotoxic effects on 
both Vero and SaOs-2 cell lines at a NP concentration below 500 g.ml-1.  
Cytotoxicity assays in polymeric NPs (chitosan and O-HTCC) do not show a significant reduction 
in cell viability in both SaOs-2 and Vero cell lines. In some cases, a reduction of cell viability 
was attributed to the presence of remnant reagents from NPs synthesis or chitosan depolymerisa-
tion. 
Magnetic hyperthermia assays were performed in both Vero and SaOs-2 cell lines and it was 
observed that the magnetic field does not harm both cell lines tested. Consequently, the presence 




of pristine Fe3O4 NPs is the major contribution for cell viability reduction. Furthermore, if hyper-
thermic temperature is achieved during the application of the AC magnetic field, pristine Fe3O4 
NPs-induced cytotoxicity is enhanced, at least in Vero cell lines. 
The present work demonstrated the potential of the developed iron oxide NPs as magnetic hyper-
thermia agents. Several details were studied such as NPs concentration, Brownian and Néel re-
laxations, the influence of surfactants and polymeric coating, among others. Moreover, cytotoxi-
city assays were performed. However, further studies should be performed before the developed 
iron oxide NPs are perfectly suitable for in vivo magnetic hyperthermia tests. 
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 Theranostic part II: 
Drug release studies 
This chapter is a continuation of the later one. In this chapter, the application as a drug delivery 
system is evaluated. In the first part of this chapter a brief introduction is given, related to the 
used drug, doxorubicin, and the need to encapsulate this drug is explored. Following, the mecha-
nisms of drug release from chitosan are explored and some mathematical models are presented as 
an aid to better understand these mechanisms. Drug release results are presented and discussed, 
as well as the results from the mathematical models fitting. 
7.1. Introduction 
Drug delivery systems consists in a controlled release system, where the active substance is 
loaded into a carrier or device and then released at a predictable rate in vivo when administered 
by an injected or non-injected route. This is an important field of research, which has caught the 
attention of pharmaceutical researchers, medical doctors, and industry. The main reason for this 
interest is that a safe and targeted drug delivery could improve the performance of some classic 
drugs already in the market.  
To develop appropriate drug carriers, it is important to have knowledge on drug incorporation 
and release, formulation stability and shell life, biocompatibility, biodistribution and targeting, 
and functionality. In addition, it is important to consider the fate of the carrier after the drug is 
completely released; in this respect, biodegradable nanoparticles (NPs) with a limited half-life in 
blood would be optimal [1-3]. 
Doxorubicin (DOX) is a member of the anthracyclines family, a chemotherapeutic agent’s family. 
It is a chemotherapeutic drug widely used clinically in the treatment of various solid tumors such 
as lung and breast cancer, as well as leukemia, and lymphomas. However, its use is limited by the 




severe side effects, which include specific cytotoxicity and dose-dependent congestive heart fail-
ure [4]. Consequently, DOX is a perfect candidate drug for a drug delivery system. 
 Anthracyclines family 
Anthracyclines belong to the group of the most effective anticancer drugs ever developed [5]. The 
first members of this family were originally isolated from the pigment-producing Streptomyces 
peucetius in the 1960s and were named doxorubicin (DOX) and daunorubicin (DNR) [6].  
DOX (Figure 7.1) is active against breast cancer, childhood solid tumors (like osteosarcoma), soft 
tissue sarcomas, and aggressive lymphomas while DNR is more active against acute lympho-
blastic or myeloblastic leukemia [5]. 
 
Figure 7.1. Chemical structure of doxorubicin. 
The major drawbacks of these compounds are their cardiotoxicity leading to congestive heart 
failure and the development of spontaneous and acquired resistance. Intensive researches to find 
analogues that circumvent these problems lead to the development of more than 300 new com-
pounds, whereas more than 2000 analogues were issued from structural modifications of natural 
compounds or from synthesis [7]. However, from those only few members of the anthracyclines 
family have reached the stage of clinical development and approval, including: DOX, DNR, epi-
rubicin (EPI, 4’-epi-doxorubicin or Farmorubicin®), idarubicin (IDA, 4-demethoxy-daunorubicin 
or Zavedos®), pirarubicin (4’-tetrahydropyranyl-doxorubicin), aclacinomycin A (aclarubicin) and 
mitoxantrone [5, 8]. 
 Mechanism of action 
The mechanism by which anthracyclines inhibit cancer growth is still not completely clear and 
multiple pathways are thought to be involved in the cytotoxicity of this class of anticancer drugs. 




According to Gewirtz [9] anthracyclines act by eight different mechanisms: 1) intercalation into 
DNA, leading to inhibited synthesis of macromolecules; 2) generation of free radicals, leading to 
DNA damage or lipid peroxidation; 3) DNA binding and alkylation; 4) DNA cross-linking; 5) 
interface with DNA unwinding or DNA strand separation and helicase activity; 6) direct mem-
brane effects; 7) initiation of DNA damage via inhibition of topoisomerase II; and 8) induction 
of apoptosis in response to topoisomerase II inhibition. However, these mechanisms did not occur 
all at the same dosage; more so, some of them were observed at concentrations considered too 
high to be administrated to patients. 
 Cardiotoxicity 
One of the major problems of anthracyclines usage is related to cumulative dose-dependent car-
diotoxicity, responsible for developing late-onset heart failure. Anthracycline-induced secondary 
cardiotoxicity is seen in 5-23% of patients [10, 11]. 
The mechanism behind the anthracyclines cardiac toxicity and their specificity to myocyte cells 
remains controversial and not completely understood. Sawyer et al. [10] propose several mecha-
nisms to explain the cardiotoxicity of anthracyclines, including (Figure 7.2): 1) generation of ox-
idative stress through formation of hydroxyl radical, leading to myocyte cell dead; 2) inducing 
apoptosis via a mitochondrial pathway involving Bax, cytochrome c and caspase-3 activation; 3) 
inducing apoptosis through intercalation between base pairs in DNA, originating DNA damage; 
4) DNA damage by suppression of expression and/or activity of transcription factors that modu-
late sarcomere synthesis, as well as cell survival; 5) suppression of sarcomere protein synthesis. 
These mechanisms may not occur all at once, they are probably induced by different doses of the 
chemotherapeutic agent. 
Since anthracyclines are interesting therapeutic agents being its cardiotoxicity a major limitation, 
efforts to circumvent this problem include: limiting dose exposure; encapsulated anthracyclines 
in liposomes to reduce myocardial uptake; administering concurrently with the iron chelator dex-
trazone to reduce free iron-catalyzed reactive oxygen species formation; and modify anthracy-
clines structure in an effort to reduce myocardial toxicity [11]. 
 Alternative formulations of DOX 
Doxorubicin plays an important role in cancer chemotherapeutic treatment, so its clinical unre-
sponsiveness is a major concern. Liposomal doxorubicin (Caelyx® in Europe, Doxil® in USA) is 
currently approved for cancer treatment and its formulation has the advantage of enhancing the 




antitumor effect, reducing toxicity, and improving pharmacokinetics, when compared to free 
DOX. These improvements are due to several factors: the polyethylene glycol (pegylated) coating 
reduces the uptake of liposomes by cells of the reticuloendothelial system (RES), thus prolonging 
the time of circulation; because normal blood vessels are not as fenestrated as tumor vessels, 
liposomes are confined to the intravascular space, reducing toxicity in normal tissues [12].  
 
Figure 7.2. Possible mechanisms by which anthracyclines causes cardiac toxicity. The formation of reactive 
species is induced by the quinone moiety of anthracyclines and by induction of nitric oxide synthase, lead-
ing to nitric oxide and peroxynitrite formation. Another method of anthracyclines cardiotoxicity is to inter-
calate into nucleic acids, causing suppression of DNA, RNA, and protein syntheses, as well as damaging 
some transcriptional regulatory proteins that seem important for regulation of cardiac-specific genes. An-
thracyclines also accelerate myofilament degradation, leading to a net negative balance of sarcomeric pro-
teins (“cardiac sarcopenia”) and induce changes in adrenergic function and adenylate cyclase as well as 
abnormalities in Ca2+ handling, functions that are critical for cardiac function. By last, anthracyclines also 
induce necrosis and apoptosis of myocyte cells. ROS – reactive oxygen species; JNK – c-Jun N-terminal 
kinases; bax – Bcl-2-associated X protein; NOS – nitric oxide synthase; GATA4 – gene name, member of 
GATA family of zinc-finger transcription factors; MHC – myosin heavy chain; CARP – cardiac ankyrin 
repeat protein and cardiac adriamycin-responsive protein [10]. 




Besides Caelyx®, another two liposomal formulations of anthracyclines have showed promising 
results: an uncoated formulation in which citrate is included for increasing DOX encapsulation 
above the levels predicted by the maintenance of a transmembranar pH gradient; and a liposomal 
DNR (DaunoXome) [5]. The first formulation is not as advantageous as the pegylated liposomal 
DOX, but still is better than free DOX and its main indication is treatment of metastatic breast 
cancer [13]. 
Tan et al. [14] produced an alternative drug delivery system composed by chitosan-dextran sulfate 
using a combinational coacervation method. DOX was successfully encapsulated into these mi-
croparticles and the in vitro studies demonstrated a reduction in SaOS-2 cell viability through 
various cell death mechanisms such as necrosis, and apoptosis. Treatment of mice bearing ortho-
tropic osteosarcoma with DOX microparticles decreased tumor volume, bone lysis, and reduced 
secondary metastasis to the lungs. In addition, the treated mice maintained their weight and did 
not appear to suffer from any visible side effects such as heart failure or dry skin. 
Another approach to decrease anthracyclines cardiotoxicity is by its encapsulation into nanopar-
ticles. Betancour et al. [15] reported acid-copped poly(lactic-coglycolic acid) nanoparticles as a 
carrier for DOX that deliver the drug into MDA-MB-21 breast cancer cells quickly and in higher 
quantity than free DOX. Janes et al. [16] showed similar results using chitosan nanoparticles in 
human melanoma A375 cells. Bisht et al. [17] reviewed the usage of dextran-DOX conjugates 
encapsulated in chitosan nanoparticles in solid tumors therapy and showed that nanoparticles in 
the range of 10-100 nm diameter are able to deliver chemotherapeutic drugs to solid tumor. Susa 
et al. [18] incorporated DOX into a lipid-modified dextran based polymeric nano-system and 
demonstrated improved anti-proliferative effects against osteosarcoma cell lines compared to free 
DOX. 
Wang et al. [19] demonstrated a way to overcome multidrug resistance in MCF-7/ADR cancer 
cells using a drug delivery system that tethers DOX onto the surface of gold nanoparticles with a 
poly(ethylene glycol) spacer via an acid-labile linkage (DOX-Hyd@AuNPs). These nanoparticles 
release DOX in response to pH of acidic organelles after endocytosis, inducing elevated apoptosis 
in cancer cells. This process may be monitored by the fluorescence of DOX from quenching due 
to the nanosurface energy transfer between the doxorubicinyl groups and the gold nanoparticles. 
However, cardiotoxicity is still observed in patients treated with Caelyx® [23] and its safety has 
constantly been under scrutiny due to the adverse side effects still experienced by patients. For 
instance, incidences of dermatological toxic reaction, palmar-plantar erythrodysesthesia, have 
been reported in up to 50% of all patients [20], while another 50% of patients suffered from 
various hematologic adverse reactions such as anemia, leucopenia, and neutropenia. Alternative 




formulations have been studied such as polymeric nanoparticles-based delivery systems that offer 
a significant advantage over other nanocarrier platforms. Since there is a tremendous versatility 
in choice of polymeric matrices that can be used it allows for the tailoring of nanoparticles prop-
erties to meet the specific needs they are intended to meet. Other advantages of these formulations 
are easy surface modification; greater encapsulation efficiency of the payload; payload protection; 
large surface area-to-volume ratio; and slow or fast polymer erosion for temporal control over the 
release of drugs. 
Furthermore, the development of nanostructured delivery systems that combine carriers with can-
cer-targeting molecules can potentially overcome the drawbacks presented by conventional ap-
proaches [21]. Salerno et al. [22] developed biodegradable, biocompatible nanoparticles made of 
a conjugate between poly (D, L lactide-co-glycolic) acid and alendronate, suitable for systemic 
administration and directly targeting the site of tumor induced osteolysis. These nanoparticles 
were loaded with doxorubicin and the in vitro and in vivo activity of the drug encapsulated in the 
carrier system was analyzed in a panel of human cell lines, representative for primary or meta-
static bone tumors, and in an orthotropic mouse model for breast cancer bone metastasis. Their 
results showed a significant dose-dependent growth inhibition of all cell lines. The use of poly-
meric nanocarriers allows the combination of various anti-cancer strategies. For example, some 
studies use magnetic nanoparticles loaded with chemotherapeutic agents [16, 23-26]. This com-
bination is suitable to use intracellular hyperthermia, a technique in which the particles are con-
centrated at the tumor site and are remotely heated using an applied magnetic field to the required 
hyperthermic temperatures (42-45 ºC), thus killing the cancer cells with the heat generated [27, 
28]. 
 Chitosan as a drug delivery system  
Chitosan (CS) is a polysaccharide obtained from deacetylation of chitin widely used as a drug 
delivery system for gene delivery, implants and nasal, oral, parental and transdermal administra-
tion [29]. Drug release from chitosan is dependent upon its swelling behavior and drug-chitosan 
interactions, which are influenced by pH of the medium [30]. Chitosan’s dependence upon pH of 
the medium may be used to achieve a controlled drug delivery for cancer treatment. It is known 
that the tumor microenvironment is characterized by an acidic pH (around 6.5) due to the increase 
production of lactate by the glycolytic pathway. The export of lactate for the poorly vascularized 
extracellular medium leads to a decrease in the pH of the tumor microenvironment [31]. Further-
more, intracellular organelles such as liposomes and endosomes have a more acidic pH, between 
3 and 5.5 [32]. 




 pH-sensitive swelling of CS 
Drug release from ionically cross-linked CS exhibits increased pH-sensitive swelling compared 
to covalently cross-linked CS. Swelling behavior of ionically cross-linked CS are influenced by 
ionic interactions between CS chains, which depend on the cross-linking density set during the 
formation of the network. An increased cross-linking density leads to a decreased swelling and 
decreased pH sensitivity, and consequently, decreased drug release from the polymeric chains. 
Since ionic cross-linking is reversible, it can be modified by the pH of the application medium. 
Therefore swelling occurs in both acidic and basic conditions, extending the range of application 
[33]. 
When the pH decreases, the charge density of the cross-linker also decreases, leading to a de-
creased cross-linking density and CS swelling. Thus, swelling is favored by protonation and re-
pulsion of CS from amino groups. If the pH decrease is too large it may lead to dissociation of 
ionic linkages and dissolution of the network. If the pH increases, the protonation of CS amino 
groups decrease, leading to a decrease in the cross-linking density and thus allowing swelling. 
However, if the pH increase is too large, amino groups of CS are neutralized and ionic cross-
linking is inhibited. Consequently, interactions are not strong enough to avoid dissolution and the 
ionic cross-linker is released [33].  
CS swelling depends not only upon pH, but is also influenced by other parameters. The presence 
of ions weakens ionic interactions through shielding effect, which increases swelling and drug 
delivery. Moreover, decrease of CS molecular weight (Mw) has proven to decrease CS swelling 
and thus favoring dissolution. Furthermore, drug release depends upon the solubility and Mw of 
the drug, and is influenced by its concentration inside the network [33]. 
 Mechanisms of drug release from CS NPs 
Drug release from CS NPs can occur through three different mechanisms: release from the surface 
of NPs, diffusion through the swollen rubbery matrix, and release due to polymer erosion [34]. In 
most of the cases, release occurs through more than one mechanism. 
Drug release from the surface of the NPs occurs when the drug immediately dissolves when it is 
exposed to the release medium. This kind of mechanism leads to a burst effect in the early stages 
of dissolution [35]. 
Drug diffusion through the swollen rubbery matrix is composed of three steps. The first step is 
the swelling of the polymer matrix due to water penetration into the system. In the second step, 




the conversion of glassy polymer into rubbery matrix occurs. Finally, drug diffuses from the swol-
len rubbery matrix of CS. Drug release through this mechanism is slow initially and later becomes 
faster. This type of release is more relevant in CS hydrogels [34].  
When considering drug diffusion from polymer swelling, two aspects must be taken into consid-
eration. In a swollen polymer, the length of the diffusion pathways increases, resulting in decreas-
ing drug concentration gradients (the driving forces from diffusion), potentially decreasing drug 
release rates. The second aspect is that the mobility of the polymer significantly increases, leading 
to increased drug release rates [36]. Consequently, in a swollen drug delivery system, there are 
two moving fronts: the swelling front and the diffusion front. The swelling front occurs when the 
polymer contacts with the release medium and water diffuses into the system. With increasing 
water content, the mobility of the polymer chains increases. Hence, the conversion of glassy pol-
ymer into rubbery matrix occurs. This is a moving boundary that separates the swollen from non-
swollen matrix. In this stage, dissolved and non-dissolved drug may co-exist in the polymer ma-
trix. At this stage, dissolved drug diffuse out of the swollen matrix into the release medium. The 
diffusion front separates the swollen matrix containing only dissolved drug from the swollen ma-
trix that contains both dissolved and non-dissolved drug. In some cases a third front can also be 
present, the erosion front, which separates the polymer matrix from the release medium [34, 36]. 
 DOX release profile from CS NPs 
Several investigators have studied DOX release profile from CS NPs. In most of the cases, the 
drug delivery system is placed into a dialysis bag, and drug release to the release medium is 
measured over time. The release medium may differ depending on the study purpose. 
Janes et al. [16] studied DOX release profile from CS-TPP NPs in acetate buffer (pH 4). The 
results showed a burst release of 4.5% during the first 2 h, which was maintained stable through 
the next 5 days. This result was explained by the interactions between DOX and CS, resulting in 
very stable bonding. DOX and CS show overwhelming charge repulsion between them. However, 
even then small quantities of DOX are able to complex with CS. This may be explained by the 
amphoteric property of this drug and due to the hydrophobic/hydrophilic interactions and reso-
nance effects. The authors concluded that drug release is caused by CS degradation or by release 
of DOX bonded to CS surface. Moreover, in vitro studies showed that CS NPs enter cells through 
endocytosis and are degraded intracellularly, thus causing DOX release. 
Yuan and co-workers [30] have studied chitosan-clay and chitosan-aluminosilicate clay nano-
composite as DOX delivery systems. DOX release was studied at 37 ºC and at pH 1.2 (gastric 
fluid), 5.3, and 7.4. Control experiments were performed by submitting free DOX to the same 




release conditions. In control experiments, DOX was completely release after 1 h, 5 h, and 12 h, 
at pH 1.2, 5.3 and 7.4, respectively. DOX release from the nanocarrier was slower, without 
achieving total drug release. 
DOX release from CS NPs incorporated with iron oxide NPs (Fe3O4) was studied by Javid el al. 
[37]. The authors tested different release mediums with pH from 1.5 to 7.0 during a period of 48 
h. The results showed that pH increase lead to smaller amount of drug released. Maximization of 
DOX release was achieved at pH between 4.5 and 6.4, corresponding to internalization and en-
docytosis of DOX-loaded NPs in tumor cells. In a more recent research, Unsoy and co-workers 
[32] studied DOX release from CS Fe3O4 NPs with different sizes. Release profiles were studied 
at pH 4.2 and 5 at 37ºC, during a maximum period of 30 h, with the purpose to simulate endosomal 
environment. A burst release in the first half hour was observed, followed by a slower release rate 
after 7 h of experiment. Reduction of particle size only cause an increase of drug release of about 
10%. Moreover, increased DOX release was observed at pH 4.2. Furthermore, DOX-loaded CS 
Fe3O4 NPs have a higher cross-linking density, thus leading to decreased swelling. 
 Mathematical modelling for drug delivery systems 
Mathematical modelling can be very helpful to better understand drug release profiles from dif-
ferent systems such as nanoparticles. Moreover, these models can predict the system performance. 
The use of mathematical models applied to drug delivery systems can help to improve the sys-
tem’s effectiveness and easiness of application. It also has the advantage of reducing time and 
costs, since the number of experiments made are reduced, and the procedures are optimized. 
In 1961, Higuchi was the first to publish a mathematical model of drug delivery. His famous 
equation provides a simple description of drug release from an ointment base exhibiting a con-
siderable initial excess of non-dissolved drug within and inert matrix with film geometry [38]. 
Since then, numerous mathematical models have been developed for different kinds of systems. 
These models can be divided into empirical/semi-empirical and mechanistic realistic ones. In the 
first case, the predictable power is usually low since the mathematical treatment (at least partially) 
is purely descriptive and not based on real physical, chemical, and/or biological phenomena. Con-
sequently, great caution must be paid when making quantitative predictions or mechanistic con-
clusions. This type of models is very useful when comparing different release profiles [36]. On 
the other hand, mechanistic realistic models are based on real phenomena, such as diffusion, dis-
solution, swelling, erosion, precipitation, and/or degradation [39, 40]. As such, these models al-
low prediction of different processes that are involved in the studied system, offering a deeper 
insight into the underlying drug release mechanisms [36]. However, some divergences have been 




found between theories and experimental data, mainly because several driving forces can be pre-
sent in a single transport process [41]. In these cases, the initial and boundary conditions must be 
known, such as drug distribution through the system before it contacts with the release medium. 
The solutions of these equations may be analytical or numerical, according to the complexity of 
the resulting set of mathematical equations that represent the system. Usually some approxima-
tions and simplifications are needed to achieve a relatively simple mathematical system [36]. In 
some cases, simplifications of the mechanistic models derived into empiric or semi-empirical 
models. 
Controlled release systems can be divided by their mechanisms of drug release into: diffusion-
controlled, chemically controlled, and swelling-controlled. Ordinary diffusion occurs in each of 
these mechanisms to a certain degree. Furthermore, most of the models used are based on diffu-
sion equations [42]. 
 Fundamentals of ordinary diffusion  
Diffusion in defined by the release of an active agent from a polymeric carrier by the movement 
of the drug through the bulk of the polymer. This phenomenon is mainly controlled by the mass 
transfer limitations at the boundary between the polymeric carries and its surroundings. Fick’s 
law of diffusion describes the diffusion of drug molecules through a polymeric carrier on a mac-










 Equation 7.2 
Where the concentration and mass flux of the species, i, are designated as ci and ji, respectively; 
Dip is the diffusion coefficient of species, i, in the polymer matrix, and x and t stand for the inde-
pendent variables of position and time, respectively [42].  
These equations describe the release of a drug from a carrier of a thin planar geometry. Moreover, 
in the above written form of Fick’s law, the diffusion coefficient is assumed independent of con-
centration. As such, initial and boundary conditions, which are necessary for solving Equation 
7.1 and Equation 7.2, allow for the appropriate description of the experimental conditions im-
posed upon the drug release device. Several solutions of the above-mentioned equation have been 
obtained to be applied to various in vitro and ex vivo experiments [42]. 




 Zero-order kinetics 
Zero-order kinetics model are present when the drug is released from carriers that do not dis-
aggregate. Drug release is slow and no equilibrium conditions are reached.  
This kinetic can be used to describe drug release from several types of carriers, such as transder-
mal systems, matrix tablets with low soluble drugs, coated forms, osmotic systems, among others 
[43, 44]. 
 First-order kinetics 
First-order kinetics modulates dissolutions profiles where the quantity of drug released is propor-
tional to the amount that is still in the dosage form that decreases by unit of time.  
It is usually used for porous dosage forms containing water-soluble drugs, in which drug release 
is proportional to the amount of drug remaining in the interior, in such a way that the amount of 
drug released per unit of time diminishes.  
In some cases, this model has also been used to describe absorption and/or elimination of some 
drugs, although it is difficult to conceptualize this mechanism in a theoretical basis [43, 44]. 
 Higuchi model 
As above mentioned, Higuchi [38] was the first author to develop a mathematical model describ-
ing water soluble and low soluble drug release from semi-solid and/or solid matrix systems. Hi-
guchi model describes the release based on Fick’s law for diffusion, and dependent of the square 
root of time. Initially was applied for planar systems, but after several modifications it was ex-
tended to different geometries and porous systems [43, 44].  
Higuchi model is based on the following assumptions: a) initial drug concentration in the matrix 
is much higher than drug solubility; b) drug diffusion takes places only in one dimension; c) drug 
particles are much smaller than system thickness; d) swelling and dissolution of the matrix are 
negligible; e) drug diffusion is constant; and f) perfect sink conditions are always attained in the 
release environment [43]. 
Higuchi model is more precise in systems of unidimensional matrixes with low solubility, in 
which drug diffuses in only one direction and without swelling behavior. It is usually used for 
matrix tablets with soluble drugs or transdermal systems [44]. 




 Hixson-Crowell model 
Hixson and Crowell (1931) described a model where the cubic root of the unreleased drug fraction 
versus time is linear if the equilibrium conditions are not reached and if the geometrical shape of 
the dosage form diminishes proportional over time. For the application of this model, it must be 
assumed a release rate limited by the drug particles dissolution rate and not by the diffusion that 
might occur through the polymeric matrix [43, 44]. 
Hixson-Crowell model is used to pharmaceutical dosage forms such as tablets, where the disso-
lution occurs in planes that are parallel to the drug surface if the table dimensions diminish pro-
portionally [44]. 
 Korsmeyer-Peppas model 
Korsmeyer and Peppas [45] developed a simple, semi-empirical model based on the power law, 
which relates exponentially the drug released to the elapsed time. The most used and simple equa-
tion is derived from a mechanistic model that describes drug diffusion from a controlled release 
polymeric system with the form of a plane sheet. Application of some assumptions and boundaries 
lead to the simplification of the initially proposed equation, which facilitates its application to 
experimental data. 
Korsmeyer-Peppas mathematical model is also applicable to polymeric systems with swelling 
ability and its constants assume different values depending on the release mechanism, with dif-
ferent boundary values according to the geometry of the device.  
Considering chitosan nanoparticles, there is only interest in the release from spheres [46]. This 
model is applicable to experimental data by doing the approximation to the first 60% of release, 
which means that Mt/M∞ < 0.6, where Mt is the amount of drug released at time t and M∞ is the 
cumulative quantity of drug released when time approaches infinite (equilibrium state of release) 
[44, 46, 47]. Depending on the value of the diffusional exponent n, different types of release 
profile can be identified. For spherical particles, n ≤ 0.43 correspond to Case I or Fickian diffusion 
where the diffusion contributes more than the relaxation mechanism. When n = 0.85, it is Case II 
transport or also called relaxation-controlled transport where the relaxation contribution is higher 
than diffusion. When n is between these values it is called anomalous or non-Fickian diffusion, 
where there is a similarity between diffusion and relaxation contribution [48]. Another category 
of release profile, when n > 0.85, is called Super Case II transport [44]. In this model K is related 
to the shape and structure of the polymer [36]. These two constants allow the comparison of 




experimental data of systems with different characteristics and the understanding of release mech-
anism.  
 Hopfenberg model 
Hopfenberg studied the release of drugs from surface-eroding devices with several geometries 
and have proposed a general mathematical equation describing drug release from slabs, spheres, 
and infinite cylinders displaying heterogeneous erosion [49].  
This model assumes erosion of the matrix as rate-limiting step for drug release. Moreover, time 
dependent diffusional resistances internal or external to the eroding matrix do not influence drug 
release [44]. 
 Peppas-Sahlin model 
In 1989, Peppas and Sahlin [50] described a modification of the previously published Korsmeyer-
Peppas semi-empirical equation by decoupling diffusion and Case-II transport. The resultant 
equation has two parcels; the first one represents Fickian diffusional contribution and the second 
one is related to dissolution and relaxation of polymeric chains contribution to release. The expo-
nent, m, of the equation is related with n exponent of Korsmeyer-Peppas model, and its values 
closely related [51]. 
 Weibull model 
In 1951, Weibull described a general empirical equation which was later adapted to the dissolu-
tion/release process. This equation fits most of the drug release profiles, and similarly to 
Korsmeyer-Peppas model, describes the initial 60% of drug release. However, it lacks kinetic 
basis and none of its parameters are related with the intrinsic dissolution rate of the drug [44, 52]. 
This equation has two constants: a, a time scale parameter, and constant b, a shape parameter. 
The shape parameter, b, characterizes the curve as either exponential (b = 1), sigmoid (b > 1) or 
parabolic (b < 1) [44].  
In 2006, Papadopoulou et al. [52] have correlate parameter b of Weibull model with exponent n 
of Korsmeyer-Peppas model. In this way, b can be used as an indicator for the mechanism of drug 
release as for b ≤ 0.75 it is a Fickian diffusion, while for 0.75 < b < 1 is a mixed mechanism, 
between Fickian diffusion and Case II transport, and when b > 1 drug is released through a com-
plex release mechanism. 
 




Table 7.1 summarizes the overall mathematical models above described. 
Table 7.1. Summary of the most used mathematical models for drug delivery systems  
Model Equation Application Ref. 
Zero-order1 𝑄𝑡 = 𝑄0 + 𝐾0𝑡 
Systems where release rate is independ-
ent of the concentration of dissolved 
substance. 
[43, 44] 
First-order2 log 𝑄𝑡 = log 𝑄0 + 𝐾1𝑡 
Systems where release rate is dependent 
on the concentration. 
[43, 44] 
Higuchi3 𝑄𝑡 = 𝑄0 + 𝐾𝐻𝑡





3 = 𝐾𝐻𝐶𝑡 
Release by dissolution where the surface 
area and diameter particles change; re-






Fickian (n ≤ 0.43); 
Case II transport (n = 0.85); 
Non-Fickian (0.43< n <0.85); 
Super Case II: n >0.85. 
[44, 45, 48] 





 Surface eroding polymer matrices. [44, 49] 
Peppas-Sahlin 𝑄𝑡 = 𝑘1𝑡
𝑚 + 𝑘2𝑡
2𝑚 
k1 – Fickian contribution;  
k2 – relaxation contribution;  
m - correspondent to exponent n of 
Korsmeyer-Peppas model. 
[50, 51] 




Fickian diffusion (b≤0.75); 
Combined mechanism of Fickian and 
Case II (0.75<b<1); 
Complex mechanism (b>1). 
[44, 52] 
1Q0, Initial amount of drug in solution; Qt, amount of drug released at time t; K0, zero-order release constant. 
2𝐾1, first-order release constant. 3𝐾𝐻, Higuchi dissolution constant. 4𝐾𝐻𝐶, Hixson-Crowell constant. 5n, em-
pirical release exponent; k, related to polymer structure and geometry. 6𝑐0 - uniform initial drug concentra-
tion in the system; 𝑎, radius of a sphere; 𝑘0, rate constant; n- shape factor. 




7.2. Materials and methods 
All the chemical reagents used in this research work were of analytical grade and used without 
further purification. 
 Preparation of buffer solutions 
Phosphate buffer solution with pH 7.4 (PBS 7.4) was prepared as followed: to 800 ml of distilled 
water were added 4 g of sodium chloride (NaCl, Sigma-Aldrich), 0.1 g of potassium chloride 
(KCl, Sigma-Aldrich), 0.72 g of disodium hydrogen phosphate (Na2HPO4, Sigma-Aldrich ) and 
0.12 g of potassium dihydrogen phosphate (KH2PO4, Sigma-Aldrich). After complete dissolution 
of the salts, pH was adjusted to 7.4 using HCl. Finally, the volume was adjusted to 1000 ml.  
Phosphate buffer solution with pH 6.5 (PBS 6.5) was prepared as followed: to 800 ml of distilled 
water were added 8 g of NaCl, 0.2 g of KCl, 0.61 g of Na2HPO4 and 0.19 g of KH2PO4. After 
complete dissolution of the salts, pH was adjusted to 6.5 using HCl. Finally, the volume was 
adjusted to 1000 ml.  
0.2 M acetic acid (Panreac) and 0.1 M sodium acetate (Scharlau) was used as a pH 4.5 buffer. 
 DOX calibration curves 
To determine DOX concentration through the further assays, DOX calibration curves were con-
structed by measuring the absorbance by ultraviolet visible spectrophotometer (UV-Vis, T90+ 
PG Instruments) in a range of concentrations between 5 and 50 μg.ml-1 of doxorubicin hydrochlo-
ride (Fluka). The maximum absorbance at 480 nm, DOX maximum absorbance peak [32, 53], 
was determined at different DOX concentrations, as represented in Figure 7.3.  
DOX calibration curves were performed for all solvents used in the experiments: water, PBS 7.4, 
PBS 6.5 and HAc/NaAc (pH 4.5). These measures to obtain the calibration curves were made in 
quadruplicates. 
 Selection of DOX carriers 
Different types of DOX loaded NPs were prepared: DOX-loaded Fe3O4 NPs, DOX-loaded poly-
meric NPs, and DOX loaded polymeric-Fe3O4 NPs.  





Figure 7.3. Example of the evolution of the maximum absorbance peak (480 nm) of DOX at different 
concentrations. 
Iron oxide NPs (Fe3O4) were prepared according to the procedure described in Chapter 3. The 
NPs used were: iron oxide NPs prepared by chemical precipitation technique without further 
treatment (Pristine Fe3O4 NPs), and stabilized with either a concentration of 10 mM of tri-sodium 
citrate (Fe3O4 TC 10 mM) or a concentration of 64 mM of oleic acid (Fe3O4 OA 64 mM); and 
finally, iron oxide NPs prepared by thermal decomposition technique (Fe3O4 TD).  
Regarding DOX-loaded polymeric NPs, was used chitosan (CS) and O-HTCC, a chitosan deriv-
ative synthetized in Chapter 4. Four molecular weights of each polymer were tested for drug 
delivery studies. Polymeric nanoparticles were produced through ionotropic gelation using tripol-
yphosphate (TPP) and a similar procedure was employed to produce polymeric NPs incorporated 
with Fe3O4 NPs. Detailed procedures for the preparation of these NPs are described in Chapter 4. 
 DOX encapsulation efficiency studies 
DOX-loaded Fe3O4 NPs were prepared as followed: 2 ml of DOX solution with different concen-
trations (2 mg.ml-1, 1 mg.ml-1 and 0.5 mg.ml-1) was added to 1 ml of an aqueous suspension of 10 
mg.ml-1 Fe3O4 NPs. A magnet was used to separate DOX-loaded NPs from free DOX and the 
supernatant was removed. The absorbance of the supernatant at 480 nm was measured by UV-
VIS spectroscopy. 




DOX-loaded CS and O-HTCC NPs, were prepared with different DOX concentrations added to 
polymer acidic solution (1.2% w/v in acetic acid at 1% v/v) being magnetic stirred for 10 min. 
After adding TPP (0.25% w/v) to 0.5 ml of DOX+polymer solution, the solution was centrifuged 
(Sigma 1-13 centrifuge) for 5 min at 10000 rpm. Supernatant was removed and added 1 ml of 
distilled water to the pellet and was centrifuged again under the same conditions. The absorbance 
of the obtained supernatants was measured by UV-VIS spectroscopy at wavelength of 480 nm. 
This procedure was repeated for the following tests. 
Different weight ratios CS:DOX were tested: 1 ml of CS solution and 2 ml of DOX with four 
different concentrations (2 mg.ml-1, 1 mg.ml-1, 0.5 mg.ml-1, and 0.25 mg.ml-1); 0.5 ml of these 
samples with 1.5 ml of TPP added. 
Different ratios of CS:TPP and O-HTCC:TPP were also tested: 1 ml of polymer solution with 1 
ml of DOX solution at 2 mg.ml-1; 0.5 ml of this solution and different amounts of TPP solution 
(0.5 ml, 1 ml, and 1.5 ml). 
DOX-loaded CS and O-HTCC NPs incorporated with Fe3O4 NPs were produced by adding a 
known amount of Fe3O4 NPs added to the polymer solution before addition of DOX. 
 DOX release studies 
DOX release profiles were determined using three different buffers: PBS 7.4, PBS 6.5 and 
HAc/NaAc buffer at pH 4.5, which represent the pH of the blood flow, pH of the tumor microen-
vironment, and the pH of lysosomes and endosomes, respectively [54, 55]. All release studies 
started with 1 mg of DOX and a total volume of 1 ml. 
Release studies from not freeze-dried CS NPs were prepared as following: 1 ml of CS+DOX was 
added to 4.5 ml of TPP (0.25% w/v), stirred in ULTRA-TURRAX for 5 min. This solution was 
then centrifuged (Heraeus Multifuge X1R centrifuge – Thermo Scientific) for 10 min at 12000 
rpm. The resultant supernatant was stored and 3 ml of water were added to the pellet; the solution 
was centrifuged again in the same conditions and this resultant supernatant was stored. The re-
sultant pellet was resuspended in 1 ml of PBS 7.4 and dialyzed (Spectrum Laboratories, cut off 
Mw = 10-12 KDa) in 10 ml of release buffer at 37 ºC for 72 h. Periodically, 3 ml of release medium 
was removed and the same volume of new buffer was added. The absorbance of all samples was 
measured at 480 nm, including the two supernatants resultant from the two initials centrifugations. 
These values of absorbance and with the help of DOX calibration curves, allowed the determina-
tion of DOX concentration and the calculation of the percentage of released drug during a period 
of time.  




Controls were made by dialyzing 1 ml of free DOX and varying the pH of the release medium 
(4.5, 6.5 and 7.4). 
Release studies from DOX-loaded Fe3O4 NPs were performed as following: 5 mg of Fe3O4 NPs 
and 1 mg of DOX in PBS 7.4 were placed in a dialysis bag. The following procedure was the 
same as the described above. 
For the preparation of freeze-dried samples, 1 ml of polymer (CS and O-HTCC)+DOX or Poly-
mer+Fe3O4+DOX was added to 4.5 ml of TPP (0.25% w/v), stirred in ULTRA-TURRAX for 5 
min, and then freeze-dried for 24 h (VaCo2 ZIRBUS technology; -45 ºC and 0.07 mbar). The 
resultant powder of DOX-loaded polymer nanoparticles was then resuspended in 1 ml of PBS 
7.4, and dialyzed. The remaining procedure was the same as the above described. 
All drug release experiments were performed in triplets. 
 Characterization 
 Fourier Transform Infrared (FTIR) spectrometry 
FTIR spectra of the samples were obtained to investigate changes in the chemical bound of the 
samples in a Nicolet 6700 – Thermo Electron Corporation Attenuated Total Reflectance-Fourier 
Transform Infrared spectrometer (ATR-FTIR). Measurements were performed in freeze-dried 
samples in the range of 480 to 4500 cm-1. 
 Thermogravimetric analysis (TGA) 
Thermogravimetric analysis and differential thermal analysis (DTA) studies were carried out us-
ing a Thermal Analyzer NETZSCH STA 449 F3 Jupiter® at a rate of 10 ºC.min-1 in a N2 atmos-
phere. 
 Iron content determination 
The iron content of the samples was determined using the 1,10-phenantroline colorimetric method 
[56], similarly to the description in Chapter 3 by the formula [Fe] = 0.7 x [NPs]. 




7.3. Results and discussion 
 Characterization of DOX loaded polymeric NPs 
Figure 7.4 displays the FTIR spectra of doxorubicin-loaded CS and O-HTCC nanoparticles. Dox-
orubicin spectrum shows multiple bands typical of this compound: two single vibration modes of 
O-H stretching at 3525 cm-1 and 3314 cm-1; a multiple band at 2890 cm-1 of C-H stretching vibra-
tion mode; at 1729 cm-1 the C=O stretching vibration band; the multiple bands at 1620 cm-1 and 
1578 cm-1 are attributed to the N-H bending vibration mode of a primary amine; the aromatic 
rings of DOX are identified by a multiple band at 1414 cm-1 of stretching vibration in-ring; at 
1276 cm-1, 1114 cm-1 and 1068 cm-1 are the C-O stretching vibration mode; and at 867 cm-1 is C-
H out-of-plane vibration mode in the aromatic ring [32]. 
The chitosan nanoparticles and DOX-loaded chitosan nanoparticles spectra are different in the 
bands at 1414 cm-1 and 877 cm-1 that identify the presence of the aromatic rings of doxorubicin, 
only present in the DOX-loaded chitosan NPs. The band at 1068 cm-1 of C-O stretching vibration 
is more pronounced. Similar behavior is observed in DOX-loaded O-HTCC NPs. The presence 
of these bands confirms the DOX encapsulation in the polymeric nanoparticles. The molecular 
weight does not influence the chemical bonds between chitosan and doxorubicin or O-HTCC, 
since the spectra are similar. 
  
Figure 7.4. FTIR spectra of doxorubicin loaded chitosan nanoparticles (A) and doxorubicin loaded O-
HTCC nanoparticles (B). Comparison was performed with DOX alone (DOX), and two molecular weights 
of CS, 38 and 469 kDa, and O-HTCC, 48 and 469 kDa.  
Thermogravimetric curves (sample weight % as a function of temperature) and its derivative 
(DTA) are displayed in Figure 7.5.  




Comparison was performed using polymeric NPs and DOX-loaded polymeric NPs. The results 
confirm that DOX does not enhance the degradation of polymer; in both cases, the remaining 
amount of product at 900 ºC is superior when polymeric NPs are loaded with DOX. According 
to Manocha et al. [57] most of the DOX do not decompose to vapor state. A slight weight loss is 
observed around DOX melting peak at 195ºC. As such, most of the mass loss observed is at-




Figure 7.5. TGA (A, C) and DTA (B, D) of DOX-loaded chitosan and O-HTCC nanoparticles, respectively. 
 Encapsulation efficiency 
To evaluate the encapsulation efficiency of DOX, the initial concentration of DOX was varied, 
keeping the remaining parameters fixed. The results are shown in Figure 7.6 A, expressed by the 
percentage of drug encapsulated as a function of chitosan molecular weight, for different CS:DOX 
ratios. Encapsulation efficiency (EE) was determined indirectly by measuring DOX concentration 
in the supernatant after centrifugation of DOX-loaded CS NPs [16, 55, 58]: 





(𝑇𝑜𝑡𝑎𝑙 𝐷𝑂𝑋 − 𝐷𝑂𝑋 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑢𝑝𝑒𝑟𝑛𝑎𝑡𝑎𝑛𝑡)
𝑇𝑜𝑡𝑎𝑙 𝐷𝑂𝑋
× 100 Equation 7.3 
In general, the encapsulation efficiency increases with the increase of DOX initial concentration. 
No significant differences were found between the four molecular weights tested. Considering 
these results, the mass ratio of CS:DOX 1:3 was chosen for the following tests, which correspond 
to an initial DOX amount of 1 mg. 
Using this amount of DOX as a reference, the ratio of CS:TPP or O-HTCC:TPP was changed to 
achieve the maximum encapsulation. Figure 7.6 displays the results for chitosan (B) and O-HTCC 
(C) nanoparticles loaded with DOX. In both cases, the ratio 1:0.625 was not suitable to encapsu-
late DOX, probably due to an amount of TPP not enough to produce polymeric nanoparticles. It 
is known that a critical number of cross-links (TPP) per chain is required to allow the formation 
of a network, in this case, a nanoparticle [33].  
 
  
Figure 7.6. A) Effect of doxorubicin amount in its encapsulation efficiency in chitosan nanoparticles, as a 
function of chitosan molecular weight; B) Encapsulation efficiency of chitosan nanoparticles as a function 
of molecular weight, for different CS:TPP ratios; C) Encapsulation efficiency of O-HTCC nanoparticles as 
a function of molecular weight, for different O-HTCC:TPP ratio. The results are expressed as average ± 
standard deviation for three independent experiments. 




Recalling that CS:TPP ratio of 1:0.5 produced polymeric nanoparticles with smaller hydrody-
namic diameters (Chapter 4). However, in this case it is important to consider the presence of 
DOX, a positively charged molecule that can ionically interact with TPP negatively charged phos-
phate groups, therefore preventing chitosan interaction with TPP, and consequently the formation 
of nanoparticles. As such, the amount of TPP was increased, confirming an effective encapsula-
tion of DOX into the polymeric nanoparticles. The higher amount of TPP contributed to enhance 
the encapsulation efficiency of both chitosan and O-HTCC nanoparticles. 
The encapsulation efficiency was also evaluated for three types of Fe3O4 NPs (pristine Fe3O4, 
Fe3O4 TC 10 mM, and Fe3O4 OA 64 mM) by using a fixed amount of NPs and varying the initial 
concentration of DOX. The results in Figure 7.7 A show that DOX initial concentration does not 
have a high influence in encapsulation efficiency by pristine Fe3O4 NPs. However, surfactant 
coated Fe3O4 NPs show a different behavior. For both Fe3O4 TC 10 mM and OA 64 mM the 
encapsulation efficiency increases with the decrease of DOX initial concentration. In general, the 
encapsulation efficiency is lower for oleic acid coated Fe3O4 NPs. 
The three types of Fe3O4 NPs were coated with low molecular weight chitosan, 38 kDa. Similarly 
to the previous analysis, the initial concentration of DOX was varied, changing the CS:DOX ratio. 
The obtained results are similar to previous ones: with the decrease in DOX initial concentration, 
the efficiency encapsulation decreases. For polymeric nanoparticles alone, the better ratio 
CS:DOX was 3:1. The same was found in CS-coated Fe3O4 NPs. As such, chitosan determines 
the encapsulation efficiency of DOX. 
  
Figure 7.7. Effect of DOX concentration in its encapsulation efficiency in 10 mg of pristine Fe3O4, Fe3O4 
TC 10 mM and OA 64 mM uncoated (A) and coated with chitosan (B) of low molecular weight (38 kDa). 
The results are expressed as average ± standard deviation for three independent experiments. 




The encapsulation efficiency of DOX into polymer-coated Fe3O4 TD NPs was studied using the 
best parameters found in the previous encapsulation tests. The polymer (CS or O-HTCC):TPP 
ratio was 1:1.875 and the polymer:DOX ratio 6:1, the encapsulation efficiency is around 50-60% 
(Figure 7.8) and is similar to both CS and O-HTCC alone. Therefore, the presence of Fe3O4 TD 
does not influence the encapsulation efficiency of DOX into polymeric nanoparticles. 
 
Figure 7.8. Encapsulation efficiency of doxorubicin in Fe3O4 TD NPs coated with either chitosan or O-
HTCC. The results are expressed as average ± standard deviation for three independent experiments. 
The overall obtained results for DOX encapsulation efficiency in either single polymeric NPs or 
polymer-Fe3O4 NPs are within the obtained range described in literature, in some cases even bet-
ter. For CS NPs, Janes et al. [16] obtained a DOX encapsulation efficiency around 9%. Higher 
entrapment efficiency, of about 60%, was obtained by Mitra el al. [58] as they conjugated dextran 
with doxorubicin when producing DOX loaded CS NPs. For CS coated magnetic NPs Unsoy et 
al. [32] achieved 99% of DOX loading efficiency to 150 g.ml-1 and 81% to 600 g.ml-1, differ-
ence justified by DOX saturation. 
The influence of pH on DOX release studies was performed at pH 4.5, 6.5, and 7.4. The procedure 
was similar for all the experiments: 1 ml of a suspension of DOX-loaded nanoparticles in PBS 
7.4 was placed inside a dialysis membrane with a cut-off of 10-12 kDa. The membrane was 
emerged in 10 ml of the buffer with the desired pH. Samples of the release medium (3 ml) were 
collected at specific times and replaced with fresh medium. 




The optimal conditions determined in the encapsulation efficiency studies were used for the prep-
aration of DOX-loaded nanoparticles. However, the polymer:DOX weight ratio used was not the 
optimal one; instead, the weight ratio was 6:1 (polymer:DOX). Although the encapsulation effi-
ciency is lower using this ratio, this was the one used due to DOX amount limitation. The used 
conditions for each type of DOX-loaded nanoparticles are summarized in Table 7.2. 
Table 7.2. Amount of polymer, iron oxide nanoparticles (Fe3O4 NPs), doxorubicin (DOX) and sodium 
tripolyphosphate (TPP) used for the preparation of DOX-loaded NPs. 
DOX-loaded NP type 
Weight amount (mg) 
Polymer Fe3O4 NPs DOX TPP 
CS 6 - 1 11.25 
O-HTCC 6 - 1 11.25 
Fe3O4 - 10 1 - 






O-HTCC + Fe3O4 
 DOX release studies from CS and O-HTCC nanoparticles 
DOX release from chitosan nanoparticles at pH 4.5 and 7.4 at 25 ºC and 37 ºC (Figure 7.9). The 
results of this preliminary experiment show that DOX release saturates at 60-70% for all the tests 
between 10 h and 20 h. The initial release is however dependent of medium pH and temperature. 
The DOX release from CS NPs is faster at physiological temperature, 37 ºC. Although a slow 
drug release is desired, the studied drug delivery system is to be applied in physiological condi-
tion. Therefore, the experiments were performed at 37 ºC.  
Due to chitosan hydrophilicity, at pH 4.5 a huge initial boost is observed, similar to control ex-
periments. Consequently, at 37ºC even in pH 7.4 chitosan reaches easily its complete swollen 
state, therefore having a release profile similar to pH 4.5. Another control experiment was per-
formed at 37ºC using 1 mg of free DOX placed inside a dialysis bag and emerged in three different 
mediums: pH 4.5, 6.5 and 7.4 (Figure 7.10). The results show that after 8 h of experiment a plateau 
is achieved for the pH mediums tested. At pH 4.5 total DOX amount is released from the dialysis 




bag, while around 90% is released at pH 6.5 and at pH 7.4 only 60% of DOX is released. Conse-
quently, these thresholds were considered as the maximum DOX release in the following experi-
ments. 
  
Figure 7.9. DOX release profile from chitosan nanoparticles with a molecular weight of 469 kDa, at pH 4.5 
and pH 7.4 at 25 ºC (A) and 37 ºC (B). Insets correspond to a magnification of the burst release in the first 
8 h of the experiment. The results are expressed as average ± standard deviation for three independent 
experiments. 
 
Figure 7.10. Free DOX release profile from a dialysis bag at 37 ºC at three mediums with different pH: 4.5, 
6.5, and 7.4. Inset corresponds to a magnification of the burst release in the first 8 h of the experiment. The 
results are expressed as average ± standard deviation for three independent experiments. 




DOX-loaded chitosan NPs were freeze-dried previously to drug release experiments with the pur-
pose to investigate whether DOX release profile was affected by this step. It is important to con-
sider that freeze-drying is an employed technique to prevent polymer degradation and drug leak-
age and desorption. Moreover, nanoparticles are more easily redispersible when freeze-dried [59]. 
Freeze dried sample was resuspended in 1 ml of PBS 7.4 and placed inside the dialysis bag. Figure 
7.11 shows the DOX release from chitosan nanoparticles after freeze-drying. Comparing Figure 
7.9 B and Figure 7.11, i.e., not freeze-dried and freeze-dried samples, respectively, is observed a 
slower release in the first hours of experiment for freeze-dried samples. Chitosan is already in its 
swollen state in not freeze-dried samples; therefore, the initial boost observed, which is similar to 
control experiments, is caused by the absence of the CS initial swelling stage. At pH 7.4 freeze-
dried samples lead to a more controlled drug release (around 20% of DOX released), while not 
freeze-dried samples released around 60% of DOX. 
 
Figure 7.11. DOX release profile from freeze-dried chitosan nanoparticles with a molecular weight of 469 
kDa, at pH 4.5, 6.5, and 7.4 at 37 ºC. The results are expressed as average ± standard deviation for three 
independent experiments. 
The influence of the polymer molecular weight and the differences between chitosan and O-
HTCC were analyzed. The DOX release profile from CS and O-HTCC NPs with low and high 
molecular weight is shown in Figure 7.12 at pH 4.5 (A), 6.5 (B) and 7.4 (C). At pH 4.5 the four 
samples show a similar drug release profile. The lowest and highest molecular weight samples of 
CS NPs show a similar drug release profile, but the higher molecular weight enhances the total 




DOX release by about 5%. In O-HTCC NPs, the same difference can be observed and even though 
the final amount of drug released is different, the drug release profile is similar in all cases. At 
pH 6.5, the transition pH of CS solubility (pKa around 6-6.5), the DOX-loaded CS NPs show 
identical drug release profile, but the influence of molecular weight is the opposite. In this case, 
CS NPs with 469 kDa at pH 6.5 caused a reduction of the total amount of DOX released in about 
20%, comparing to pH 4.5. In DOX-loaded O-HTCC NPs for the lowest molecular weights, there 
is a reduction in the total amount of DOX released at pH 6.5. The exception is for O-HTCC NPs 
with the highest molecular weight, were no significant differences are found between pH 4.5 and 
6.5. Overall, the release profiles are similar at pH 4.5 and 6.5. 
 
  
Figure 7.12. DOX release profile from freeze-dried chitosan and O-HTCC nanoparticles with a molecular 
weight of 39 KDa and 469 KDa or 48 KDa and 469 KDa, respectively, at pH 4.5 (A), pH 6.5 (B) and pH 
7.4 (C) at 37 ºC. The results are expressed as average ± standard deviation for three independent experi-
ments. 
At pH 7.4 the amount of DOX released from both types of polymeric NPs is much smaller, being 
the maximum obtained of about 25% for both polymers. In this case, since the total amount of 
DOX released is so small, no significant differences were found by changing the molecular weight 
of the polymers. 




 DOX release studies from iron oxide nanoparticles 
Figure 7.13 displays the DOX release of pristine Fe3O4 NPs (A), and coated with TC 10 mM (B) 
and OA 64 mM (C). A strong influence of pH on the DOX release is observed for the iron oxide 
NPs. At pH 4.5, DOX is nearly all (about 98%) released within 10 h. The value of DOX release 
decreases to 50% reached also in 10 h when pH is 6.5. If pH is 7.4 DOX is released within 8 hours 
of experiment being the maximum value 20%. The Fe3O4 TC 10 mM NPs and Fe3O4 OA 64 mM 
NPs have similar drug release profiles and DOX retention at pH 4.5. Interestingly Fe3O4 NPs 
stabilized with oleic acid (Figure 7.13 (C)) at pH 6.5 retains more 20% to 30% of DOX than the 
other iron oxide NPs tested. The formation of the oleic acid bilayer, described in Chapter 3, is 
maybe the main cause for this difference. 
 
  
Figure 7.13. DOX release profile from pristine Fe3O4 NPs (A), and Fe3O4 NPs stabilized with tri-sodium 
citrate 10 mM (B) and oleic acid 64 mM (C) at pH 4.5, pH 6.5, and pH 7.4 at 37 ºC. The results are expressed 
as average ± standard deviation for three independent experiments. 
 DOX release studies from polymer-coated Fe3O4 NPs 
Concerning DOX release studies from chitosan coated pristine Fe3O4 and Fe3O4 TC 10 mM and 
OA 64 mM the obtained results are shown in Figure 7.14. 




The amount of DOX release from DOX-loaded CS NPs with and without Fe3O4 NPs is higher in 
the presence of Fe3O4 NPs, although the influence of pH is quite similar to all particles. At pH 
4.5 and 6.5 the maximum release is 60-70% obtained within 10 h, while at pH 7.4 the total re-
leased is lower than 20% in CS and around 30% for coated Fe3O4 NPs. CS Fe3O4 OA 64 mM has 




Figure 7.14. DOX release profile from CS NPs (A), CS-coated pristine Fe3O4 NPs (B), CS Fe3O4 NPs 
stabilized with tri-sodium citrate 10 mM (C) and oleic acid 64 mM (D), and CS Fe3O4 TD NPs (E) at pH 
4.5, pH 6.5, and pH 7.4 at 37 ºC. The results are expressed as average ± standard deviation for three inde-
pendent experiments. 




Finally, DOX release from chitosan-coated Fe3O4 TD NPs is displayed in Figure 7.14 E. These 
Fe3O4 NPs are obtained from thermal decomposition technique and therefore are more stable in 
aqueous solution than pristine Fe3O4 NPs. The incorporation of this type of iron oxide nanoparti-
cles in chitosan strongly decreases for all the pH studied, even though the increase of pH reduces 
the overall release as observed for the other NPs. 
Comparison of DOX release from CS pristine Fe3O4 and CS Fe3O4 TD shows a decrease of around 
40% and 30% of total DOX release at pH 4.5 and pH 6.5, respectively. At physiological pH the 
decrease is not so marked, about 10 %. 
The amount of Fe3O4 incorporated in CS NPs was also varied from 0.5 mg to 1.5 mg and 6 mg. 
Figure 7.15 shows the obtained DOX release profiles for CS-coated pristine Fe3O4 NPs varying 
the amount of Fe3O4 NPs added to chitosan. DOX release studies performed at pH 4.5 are not 
influenced by the increase of Fe3O4 amount from 0.5 to 1.5 mg.  
 
  
Figure 7.15. DOX release profile from CS NPs with 0.5 mg (A), 1.5 mg (B) and 6 mg (C) of pristine Fe3O4 
NPs at pH 4.5, pH 6.5, and pH 7.4 at 37 ºC. The results are expressed as average ± standard deviation for 
three independent experiments. 




When the Fe3O4 amount is increased up to 6 mg, DOX release decreases from about 60% to 20%. 
At physiological pH (7.4) the total DOX release is almost linear with the increase in Fe3O4 
amount, decreasing from around 40% to 30 % and 10 % for 0.5 mg, 1.5 mg, and 6 mg, respec-
tively. Again, at pH 6.5 DOX has an abnormal release profile, apparently not related to Fe3O4 
weight. Since this is a transition pH of CS solubility, the drug release mechanism is always com-
plex at this pH. However, for most cases, the increase in Fe3O4 amount leads to a decrease in total 
DOX release. 
DOX release studies were also performed from Fe3O4 NPs incorporated in O-HTCC NPs. Figure 
7.16 shows the DOX release profile of O-HTCC NPs with and without Fe3O4 at pH 4.5, 6.5, and 
7.4. Some differences can be observed at the most acidic pH (4.5). Although in all cases the total 
DOX released achieves the same value (around 60%), the release is slower and more controlled 
for O-HTCC with pristine Fe3O4, TC 10 mM and Fe3O4 TD. The presence of Fe3O4 OA 64 mM 
does not seem to influence DOX release from O-HTCC NPs. At physiological pH (7.4) although 
some differences in the total DOX released, no significant differences in DOX release profile can 
be observed between the analyzed samples. Finally, at pH 6.5 an increase in total DOX released 
in some cases and no shift in another. However, in all the analyzed cases the incorporation of 
Fe3O4 in O-HTCC appears to fasten the DOX release, compared to O-HTCC alone. 
Similar to what was performed with chitosan, different amounts of pristine Fe3O4 NPs were in-
corporated into O-HTCC NPs to access its influence in DOX release profile. DOX release profile 
from O-HTCC with 0.5 mg, 1.5 mg, and 6 mg of pristine Fe3O4 NPs at pH 4.5, 6.5, and 7.4 is 
represented in Figure 7.17.  
The increase of Fe3O4 weight from 0.5 to 1.5 and 6 slightly decreases the total DOX released from 
O-HTCC NPs. At pH 4.5, the difference observed is of about 15% when the Fe3O4 weight in-
creases from 0.5 to 1.5 mg. However, when the amount of Fe3O4 is 6 mg, no significant differ-
ences are observed, compared to 1.5 mg. Moreover, at this acidic pH, DOX release is slower with 
the increase of Fe3O4 amount. A similar behavior is found at pH 6.5.  
When the Fe3O4 weight increases from 0.5 mg to 1.5 mg, a decrease in about 15% is observed in 
total DOX released. However, when Fe3O4 weight increases up to 6 mg, no significant differences 
are observed. Finally, at pH 7.4 a slight decrease in total DOX release is observed for a higher 
weight of Fe3O4 (6 mg) incorporated, although DOX release profile from O-HTCC NPs is not 
altered. 







Figure 7.16. DOX release profile from O-HTCC NPs (A), O-HTCC-coated pristine Fe3O4 NPs (B), O-
HTCC Fe3O4 NPs stabilized with tri-sodium citrate 10 mM (C) and oleic acid 64 mM (D), and O-HTCC 
Fe3O4 TD NPs (E) at pH 4.5, pH 6.5, and pH 7.4 at 37 ºC. The results are expressed as average ± standard 
deviation for three independent experiments. 






Figure 7.17. DOX release profile from O-HTCC NPs with 0.5 mg (A), 1.5 mg (B) and 6 mg (C) of pristine 
Fe3O4 NPs at pH 4.5, pH 6.5, and pH 7.4 at 37 ºC. The results are expressed as average ± standard deviation 
for three independent experiments. 
 Mathematical modeling of DOX release profiles 
A wide variety of mathematical models is available to fit drug release data, most of which are 
presented as nonlinear equations. However fitting these nonlinear equations to drug release data 
is not easy to be done by hand. Zhang and coworkers developed a freely available add-in program 
called DDSolver. This program can be used to facilitate modeling of dissolution data using non-
linear optimization methods based in a build-in model library containing several dissolution mod-
els. Furthermore, this program speeds up the calculation and reduces errors of calculation [60]. 
The fitting of the drug release data was performed using DDSolver, in which the desired model 
is selected, experimental data is chosen (time intervals and drug percentage), and the software 
provides the results from the specific modelling. An example of the obtained results can be seen 
in Figure 7.18. The software not only provides the adjusted data but also the “goodness of fit” 
where several parameters are calculated to determine in the selected model fits to experimental 
data.  





Figure 7.18. Example of the data sheet obtained using DDSolver program in fitting the Korsmeyer-Peppas 
model to DOX release from CS 38 kDa NPs at pH 7.4. 
When fitting a mathematical model to drug release experimental data it is important to correctly 
select the mathematical models suitable for the drug release data in study. Taking into consider-
ation the studied drug “containers”, chitosan and O-HTCC are both hydrophilic polymers. More-
over, DOX is a cationic amphiphilic drug. Thus, mathematical models such as zero-order, first-
order, Higuchi, Hixson-Crowell, and Hopfenberg are not applicable in these cases. Zero-order 
kinetics is used for drugs with low solubility in matrix tables, while first-order kinetics describes 
drug absorption and is used for water-soluble drugs in porous materials. Chitosan is considered 
to be a swelling matrix, which means that Higuchi model cannot be applied since it describes drug 
diffusion from a non-swelling matrix, typically used for matrix tablets [61]. Moreover, Hixson-




Crowell model is applicable for systems where the surface are and diameter of the “carrier” is 
maintained constant, which is not the case. Finally, Hopfenberg model describes drug release 
from eroding polymers, which do not fit chitosan profile, within the studied conditions. 
Consequently, the mathematical models that best fit experimental data of DOX release from both 
chitosan and O-HTCC NPs are Korsmeyer-Peppas, Weibull, and Peppas-Sahlin. The three math-
ematical models were applied to all experimental data of DOX release from CS and O-HTCC 
NPs with and without Fe3O4 NPs incorporated. To determine the most appropriate model, the 
adjusted coefficient of determination (R2adj) was used, which is calculated by: 
𝑅2𝑎𝑑𝑗 = 1 −
𝑛 − 1
𝑛 − 𝑝
(1 − 𝑅2) Equation 7.4 
where n is the number of data points and p is the number of parameters in the model. Therefore, 
the best model to fit the experimental data is the one with highest R2adj [60]. 
Although an extensive description of the mathematical models in available in the introduction 
section of this chapter, a brief summary will be presented here. 
Peppas and Sahlin model is described by an equation with two parcels; each parcel has a constant 
k. Using the constant values, the percentage of Fickian and relaxational drug release can be de-
termined [50]. The exponent m can be related to the exponent n of Korsmeyer-Peppas model, 
since the value should be the same. Exponent n of Korsmeyer-Peppas model gives information 
about the release mechanism. If n ≤ 0.43 it is a Fickian diffusion, if n = 0.85 it is a case II transport, 
which is related to polymer matrix relaxation and swelling. If n is between 0.43 and 0.85 it cor-
responds to an anomalous transport, resultant from the combination of Fickian diffusion and case 
II transport. Exceptionally, if n > 0.85 it is super case II transport [43]. Weibull model also has 
two constants, a and b. a is a time factor, and b is related to the shape of release curve and can be 
correlated to exponent n of Korsmeyer-Peppas model. If b ≤ 0.75 it is a Fickian diffusion, for b 
between 0.75 and 1 is a combined mechanism, and for b > 1 drug is released through a complex 
mechanism [52]. 
 Chitosan and O-HTCC NPs 
For the application of the chosen mathematical model it was taken into account that chitosan has 
a swelling behavior. As such, fitting was performed for freeze-dried samples. However, an ex-
ception was made for not freeze-dried chitosan nanoparticles with the purpose to better under-
stand the differences between freeze-dried and not freeze-dried samples. Korsmeyer-Peppas, 
Weibull, and Peppas-Sahlin models were applied to experimental data of DOX release from not 




freeze-dried chitosan nanoparticles with four different molecular weights: 38 kDa, 170 kDa, 215 
kDa, and 469 kDa. The obtained results from DDSolver program are represented in Table 7.3. 
Parameters values of each mathematical model as well as R2adj are described. Moreover, the higher 
R2adj of each sample is highlighted at bold and green. 
Almost all experimental data is well fitted by Weibull model, although small deviations are found 
from Korsmeyer-Peppas adjusted coefficient of determination. Parameter b of Weibull model is 
not equal to all samples. For higher molecular weights, b is between 0.75 and 1, indicating a 
mixed mechanism between Fickian and Case II. For the remaining molecular weights, b is below 
0.75, indicating Fickian diffusion. To understand these differences, parameters from the other two 
models were also analyzed. Exponent n from Korsmeyer-Peppas model presents a value below 
0.85 for most cases, indicating an anomalous or non-Fickian diffusion. However, for most cases 
the value approaches 0.5, which is close to the established limit between Fickian and non-Fickian 
diffusion. On the other hand, exponent m from Peppas-Sahlin model has an average value of 0.35 
for all cases, which indicates a Fickian diffusion mechanism of release. In Peppas-Sahlin model, 
constant k1 is much higher than k2, meaning that Fickian diffusion is the predominant mechanism. 
At higher molecular weight, since the polymer network is much denser, the relaxation rate has 
some contribution to DOX release. However, as the molecular weight decreases, the polymer’ 
network becomes thinner, facilitating drug release. DOX release is predominated by Fickian’ dif-
fusion mechanism since chitosan is already in its swollen state. 
In the case of freeze-dried chitosan NPs (Table 7.4), experimental data from all samples at pH 4.5 
and 7.4 are well fitted by Weibull model, while experimental data from samples at pH 6.5 are 
fitted by Korsmeyer-Peppas model. However, the adjusted coefficient of determination is very 
similar between both models. It should be noticed that these two models are only applicable for 
the first 60% of drug release, where it has a straight profile. First, considering the Weibull model’ 
parameters, constant b is higher than 1 at pH 4.5 and 7.4, which indicates a complex release 
mechanism. At pH 6.5, b value is below 0.85, corresponding to a Fickian release mechanism. 
Exponent n from Korsmeyer-Peppas model is higher than 0.85 at pH 4.5 and 7.4, and below 0.85 
at pH 6.5 in the four molecular weights, indicating an anomalous mechanism and a complex drug 
release or super case II transport, respectively. Regarding Peppas-Sahlin parameters, exponent m 
is between 0.5 and 0.6 for all samples which indicates an anomalous transport, while k1 although 
is higher that k2, is much smaller than the one obtained for not freeze-dried samples. Moreover, 
k1 values decreases with the increase of pH, indicating that the Fickian contribution also de-
creases.  




Table 7.3. DOX release profile from not freeze-dried chitosan nanoparticles at different molecular weights 
(Mv): parameters values and R
2




Korsmeyer-Peppas Weibull Peppas-Sahlin 






















































































































































Consequently, in freeze-dried samples the contribution of Fickian diffusion for DOX release is 
much smaller. In this case, both Fickian diffusion and relaxation-controlled transport contribute 
to DOX release from CS NPs. Furthermore, at pH 4.5 and 7.4 the release mechanisms are clearer. 
Again at pH 6.5, which is the transitory pH of chitosan due to its own pKa (6.0 – 6-5), DOX 
release occurs through a mixed mechanism between Fickian diffusion and Super-Case II 
transport, where both diffusion rate and relaxation rate play an important role. 
 




Table 7.4. DOX release profile from freeze-dried chitosan nanoparticles at different molecular weights 
(Mv): parameters values and R
2




Korsmeyer-Peppas Weibull Peppas-Sahlin 

































































































































































































































Table 7.5. DOX release profile from freeze-dried O-HTCC nanoparticles at different molecular weights 
(Mv): parameters values and R
2




Korsmeyer-Peppas Weibull Peppas-Sahlin 






























































































































































































































DOX release from O-HTCC NPs was expected to show a similar profile to chitosan due to the 
similarity between both polymer structures. However, the presence of the ammonium quaternary 
group in O-HTCC may affect not only its behavior to pH but also its interaction with DOX and 




consequently its release. Table 7.5 shows the obtained data from fitting experimental results of 
DOX release from O-HTCC NPs. In a first analysis, some differences can be found with the 
increase of molecular weight, although b constant is below 1 for all cases, indicating a mixture 
between Fickian diffusion and Case II mechanism. The higher and lower molecular weights show 
similar DOX release profiles to chitosan in the same molecular weights. In both cases, either 
Weibull or Korsmeyer-Peppas models are well fitted, will almost no differences between both 
adjusted coefficients of determination. Moreover, exponent n from Korsmeyer-Peppas model is 
below 0.85 for all cases, indicating anomalous or non-Fickian diffusion where the diffusion rate 
is equal to the relaxation rate. This is correlated to the values of exponent m, which is higher than 
0.43. The intermediate molecular weights show some different release profiles. In these cases, 
Peppas-Sahlin is the model with the best fitting. At pH 4.5 an inversion of the k1 and k2 constants 
occur, i.e., k2 is higher than k1, indicating that DOX release occurs mainly due to the relaxation of 
the polymer chains rather than by Fickian diffusion. In these intermediate molecular weights the 
presence of the ammonium quaternary group in O-HTCC appears to affect DOX release, greater 
than in the higher and lower molecular weights. 
 DOX release from CS Fe3O4 and O-HTCC Fe3O4 NPs 
After analyzing the mechanism of DOX release from chitosan and O-HTCC nanoparticles, it is 
important to access the influence that the presence of Fe3O4 nanoparticles have in the mechanism 
of DOX release from CS Fe3O4 NPs.  
Table 7.6 shows the obtained results from fitting the selected mathematical models to DOX re-
lease from CS NPs of 38 kDa incorporated with four types of Fe3O4 NPs: pristine Fe3O4, Fe3O4 
TC 10 mM, Fe3O4 OA 64 mM, and Fe3O4 TD. Starting with CS pristine Fe3O4 NPs, the experi-
mental data is well fitted by the three models since the adjusted coefficient of determination is 
very similar between the three models. For Korsmeyer-Peppas model, exponent n is between 0.43 
and 0.85, indicating a combinatory mechanism of release between Fickian diffusion and relaxa-
tion of the polymer chain. Constant b of Weibull model shows some differences between different 
pH. At pH 4.5 and 6.5, constant b has a value below 0.75, corresponding to a drug release by 
Fickian diffusion. As the pH increases to 7.4, the Case II mechanism also plays an important role 
in drug release. Finally, Peppas-Sahlin parameters corroborate with the other models’ parameters. 
Exponent m has a value around 0.53, indicating an anomalous transport. Similarly to what hap-
pened to chitosan nanoparticles alone, k1 constant is much higher than k2.  




Table 7.6. DOX release profile from freeze-dried CS NPs (38 kDa) with pristine Fe3O4, Fe3O4 TC 10 mM, 
Fe3O4 OA 64 mM and Fe3O4 TD: parameters values and R
2
adjobtained from fitting the mathematical models 




Korsmeyer-Peppas Weibull Peppas-Sahlin 








































































































































































































































Moreover, k1 is lower at pH 7.4, indicating a lower contribution of Fickian diffusion at this pH. 
Taking these results into consideration, the incorporation of pristine Fe3O4 in chitosan nanoparti-
cles does not clearly affects DOX releasing mechanism. Similar to what was observed in the DOX 
release curves, incorporation of Fe3O4 TC 10 mM, Fe3O4 OA 64 mM and Fe3O4 TD NPs into CS 
NPs has the same effect as the incorporation of pristine Fe3O4. Consequently, drug release mech-
anisms are similar between the three samples. As such, it can be concluded that the stabilization 
of iron oxide nanoparticles with tri-sodium citrate and oleic acid does not influence the drug re-
lease application of DOX-loaded CS Fe3O4 NPs. Moreover, the method of iron oxide nanoparti-
cles synthesis also does not influence the mechanism of DOX release. 
Succeeding, the amount of pristine Fe3O4 NPs incorporated into CS NPs will be further analyzed. 
In the drug release curves, the total amount of DOX released decreases with the increase of Fe3O4 
amount. Table 7.7 show the results of fitting experimental data of DOX release from CS NPs of 
469 kDa incorporated with 0.5 mg, 1.5 mg and 6 mg of pristine Fe3O4, at pH 4.5, 6.5 and 7.4. All 
the samples are well fitted by both Korsmeyer-Peppas and Weibull mode, with slight differences 
between the adjusted coefficients of determination. In Korsmeyer-Peppas model, exponent n in-
creases with the increase of pH, crossing the boundary of 0.85 at pH 7.4 from an anomalous 
transport to Super-case II. The same happens with constant b from Weibull model, which increase 
with the increase of pH. At pH 4.5 and 6.5 it indicates a mixed mechanism between Fickian and 
case II. At pH 7.4 constant b is higher than 1, indicating a complex release mechanism. Peppas-
Sahlin parameters have the same profile as for DOX release from CS NPs. Comparison between 
different amounts of Fe3O4 NPs shows no significant differences between 0.5 mg, 1.5 mg and 6 
mg. As such, the amount of pristine Fe3O4 NPs incorporated into CS NPs does not affect the 
mechanism of DOX release, although it significantly reduces the total amount of released DOX. 
Similar to chitosan, the effect on DOX release of the incorporation of Fe3O4 NPs into O-HTCC 
NPs was also accessed.  
Table 7.8 displays the results of fitting the three selected models to DOX release experimental 
data from O-HTCC NPs incorporated with four types of Fe3O4 NPs: pristine Fe3O4, Fe3O4 TC 10 
mM, Fe3O4 OA 64 mM, and Fe3O4 TD. An overall analysis shows a small difference between the 
adjusted coefficients of determination, indicating that the three models fitted well to the experi-
mental data. Furthermore, DOX release from O-HTCC pristine Fe3O4 show similar results to O-
HTCC NPs. Exponent n from Korsmeyer-Peppas model has a value below 0.85, which correlates 
to the exponent m of Peppas-Sahlin model, which has an average value of 0.5. Both of them 
indicate an anomalous release mechanism. Moreover, constant k1 is higher than k2, similarly to 




O-HTCC NPs, indicating a predominance of Fickian diffusion. Finally, constant b correlates with 
the later mechanism, showing a value below 0.75 for almost all cases. 
Table 7.7. DOX release profile from freeze-dried CS NPs (469 kDa) with different amounts of pristine 
Fe3O4 NPs (0.5 mg, 1.5 mg, and 6 mg): parameters values and R
2
adj obtained from fitting the mathematical 
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Again, similarly to DOX release from CS NPs, the incorporation of pristine Fe3O4, Fe3O4 TC 10 
mM and Fe3O4 TD into O-HTCC NPs have the same effect in DOX release profile. This point 
out that DOX release profile from O-HTCC NPs is not influenced by the synthesis method nor 
by the stabilization with tri-sodium citrate. For O-HTCC Fe3O4 OA 64 mM NPs the only signifi-
cant difference is that constant b from Weibull model shows higher values, crossing the boundary 




of 0.75, and consequently shifting the predominant release mechanism from Fickian diffusion to 
a mixed mechanism between Fickian diffusion and Case II. 
Table 7.8. DOX release profile from freeze-dried O-HTCC NPs (48 kDa) with pristine Fe3O4, Fe3O4 TC 
10 mM and Fe3O4 OA 64 mM: parameters values and R
2
adj obtained from fitting the mathematical models 




Korsmeyer-Peppas Weibull Peppas-Sahlin 







































































































































































































































Table 7.9. DOX release profile from freeze-dried O-HTCC NPs (469 kDa) with different amounts of pris-
tine Fe3O4 NPs (0.5 mg, 1.5 mg and 6 mg): parameters values and R
2
adj obtained from fitting the mathe-




Korsmeyer-Peppas Weibull Peppas-Sahlin 








































































































































































Finally, the amount of pristine Fe3O4 NPs incorporated into O-HTCC NPs was also evaluated 
(Table 7.9). In the same way to the previous results, the adjusted coefficient of determination is 
analogous between the three models. Exponent n and exponent m have values between 0.43 and 
0.85 for almost all cases, indicating equilibrium between Fickian diffusion and relaxation rate of 
the polymer chain. In these exponents, no difference was found with the increase of Fe3O4 
amount. On the other hand, constant b decreases with the increase of Fe3O4 amount, shifting from 
values above 0.75 (mixed mechanism) to values below 0.75 (Fickian diffusion) at pH 4.5. At pH 




7.4 constant b values are fixed between 0.75 and 1, without variation with the increase in Fe3O4 
amount. The later correlates with the results of constant k1 from Peppas-Sahlin model, which 
decreases with the increase of Fe3O4 weight at pH 4.5, but no significant shift is observed at pH 
7.4. Accordingly, the amount of Fe3O4 weight incorporated into O-HTCC NPs only has effect at 
lower pH; at physiological pH (7.4) no significant effect was found. At pH 4.5 the increase of 
Fe3O4 amount seams to facilitate DOX release by Fickian diffusion, probably due to an increased 
relaxation in the polymer chains. 
7.4. Summary 
When constructing a drug delivery system the main purpose is to obtain a drug release in a pre-
dictable and controllable rate. Achieving such a drug delivery system, not only increases drug 
safety but also improves its performance. Doxorubicin is a perfect candidate to be incorporated 
in drug delivery systems, since it is a widely used drug for several types of cancer but has severe 
side effects, such as cardiotoxicity. 
Chitosan is a biopolymer widely used as a drug delivery system. Drug delivery from chitosan is 
dependent upon its swelling behavior and drug-chitosan interactions, which are influenced by pH 
of the medium. As such, drug release from chitosan’ structure may be highly controllable. Fur-
thermore, ionically cross-linked chitosan NPs are mainly used for drug delivery applications due 
to the higher versatility of cross-linking, leading to higher swelling, and consequently, higher pH-
sensitivity [33]. 
The main purpose of the present work was to develop DOX delivery systems based on chitosan. 
For that, the previously studied nanoparticles in Chapter 3 and Chapter 4 were used. As such, 
DOX was encapsulated in chitosan and O-HTCC nanoparticles with different molecular weights, 
with and without iron oxide nanoparticles. Furthermore, release profiles were studied at physio-
logical temperature at three different pH: 4.5 (lysosomal pH), 6.5 (tumor microenvironment) and 
7.4 (physiological pH). Finally, mathematical models suitable for drug release systems were ap-
plied to the experimental data. 
Optimization of DOX encapsulation into chitosan nanoparticles led to an encapsulation efficiency 
above 70%. DOX encapsulation into O-HTCC is not so effective, probably due to the increase of 
charge repulsion between polymer and drug. Still, an encapsulation efficiency of about 50 % was 
achieved. On the other hand, incorporation of Fe3O4 NPs into polymeric NPs did not significantly 




affected DOX encapsulation. Moreover, polymer molecular weight does not affect DOX encap-
sulation efficiency, within the tested range. 
DOX release profiles from chitosan nanoparticles show a pH-sensitive release. In more acidic 
pH, DOX release is enhanced. In contrast, at physiological pH drug release is minimal (around 
20% in most cases). However, in the majority of the studied samples, DOX release profile show 
a burst effect within the first hour of experiment, reaching a plateau after 8-10 h, in some cases 
extended to 24 h. The initial burst effect is often associated with release of hydrophilic molecules 
from polymeric carriers, followed by a phase of very slow drug release [51]. Burst effect may 
occur due to immediate dissolution of DOX present at the surface of the NPs. Incorporation of 
Fe3O4 NPs into polymeric NPs increases DOX release in the same experimental conditions. How-
ever, the incorporation of higher amounts of Fe3O4 NPs into polymeric NPs led to a negative 
effect, i.e., total amount of DOX release was smaller. 
To understand the underlying mechanisms of DOX release from CS and O-HTCC NPs, three 
mathematical models were fitted to the experimental data: Korsmeyer-Peppas, Weibull and Pep-
pas-Sahlin model. In the majority of the samples, both Korsmeyer-Peppas and Weibull fitted well 
to the experimental data, with slight differences between their adjusted coefficients of determina-
tion. These models lead to a concordant mechanism for most of the samples, indicating an anom-
alous release at pH 4.5 and 7.4 where both Fickian diffusion and polymer relaxation contributes 
to the drug release mechanism. These results are in concordance with chitosan swelling behavior 
described in literature [34, 35]. DOX release at pH 6.5 should be further analyzed, since it is a 
transitory pH of CS and more complex drug release mechanism may be present at this pH. 
The present work gives a great contribution in understanding the release of a widely used chemo-
therapeutic drug from a widely used polymeric drug delivery system. Knowledge of the mecha-
nisms of DOX release is a first step to the application of such drug delivery system in order to 
reduce DOX side effects and improve its effectiveness in treating several tumors. 
Moreover, the incorporation of iron oxide nanoparticles into this polymeric system extends its 
application. In this regard, these types of composite nanoparticles can be used for magnetic hy-
perthermia combined with drug release. Furthermore, the presence of iron oxide nanoparticles 
may also be useful to detect the composite inside the body by magnetic resonance image, thus 
allowing diagnostic and treatment simultaneously. Consequently, the studied polymeric nanopar-
ticles incorporated with inorganic ones have a huge potential as theranostic agents.  
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 Conclusions and Future 
Perspectives 
In this chapter, the main findings of this PhD thesis are presented, comparing the key results with 
the literature. Future work is also proposed and discussed. 
8.1. Thesis findings 
The main objective of this PhD thesis, as presented in Chapter 1, was to develop a theranostic 
system composed of a magnetic core and a chitosan-based coating. This system was expected to 
achieve several functions: act as a drug delivery platform for doxorubicin; sensitize and/or destroy 
cancer cells by magnetic hyperthermia; to allow diagnostic and/or treatment monitoring by mag-
netic resonance imaging; and finally, to do it all in a highly specific manner due to the presence 
of a monoclonal antibody specific for a transmembranar protein present in several solid tumors. 
To achieve these objectives, four tasks were proposed at the beginning of this PhD thesis: 
1. Production and characterization of superparamagnetic iron oxide nanoparticles with diameters 
in the nanometric range, stable in physiological conditions and able to generate heat by the appli-
cation of an alternating external magnetic field. 
2. Production and characterization of chitosan and O-HTCC nanoparticles with diameters in the 
nanometric range, stable in physiological conditions. Further, both polymers are used to coat iron 
oxide nanoparticles produced in task 1. 
3. Production of a highly specific monoclonal antibody for CA IX (a glycoprotein over expressed 
in osteosarcoma). 
4. Study the suitability of the produced nanoparticles for application in magnetic hyperthermia, 
as a contrast agent for magnetic resonance image, and as a drug delivery system. 




Accordingly, task 1 results are presented and discussed in Chapter 3, task 2 in Chapter 4, task 3 
in Chapter 5, and finally the results of task 4 are presented and discussed in Chapter 6 and Chapter 
7. The main conclusions of each task will be further presented. 
 Production and characterization of iron oxide nanoparticles 
The theranostic system developed in this PhD thesis is expected to have a magnetic core. Iron 
oxide nanoparticles were selected as the most advantageous magnetic nanoparticles for the re-
quired functions. There are several techniques available to synthetize this type of nanoparticles, 
from which chemical precipitation and thermal decomposition were selected. Iron oxide nanopar-
ticles produced by chemical precipitation were the main focus of this study due to the easiness of 
methodology and low cost production.  
The produced iron oxide nanoparticles by either chemical precipitation or thermal decomposition 
are composed of magnetite with an average crystallite size of 9 nm. However, the iron oxide 
nanoparticles produced by chemical precipitation are often unstable in aqueous suspensions, thus 
invalidating its application in the biomedical field. To remove this drawback, the stabilization 
effect of three surfactants was studied: tri-sodium citrate, oleic acid, and triton X-100. Both mor-
phological and physicochemical analysis revealed that none of the surfactants used affect the 
properties of the nanoparticles. Triton X-100 was the one with the worst performance for the 
stabilization of iron oxide nanoparticles. An optimal concentration for the stabilization effect was 
found for both oleic acid and tri-sodium citrate: 64 mM and 10 mM, respectively. Tri-sodium 
citrate showed the best performance for long-term stability (up to 8 weeks), while oleic acid was 
the best for short-term stability (24 hours). 
Magnetic characterization confirmed the superparamagnetic behavior of the produced iron oxide 
nanoparticles, even in the presence of the surfactants. The saturation magnetization of pristine 
iron oxide nanoparticles at 320 K obtained was 58 emu.g-1, which decreases to 45 emu.g-1 in the 
presence of oleic acid 64 mM. 
Oleic acid forms a bilayer on the iron oxide nanoparticles contributing to maximum stabilization 
in water solution. That was confirmed by a zeta potential of -120 mV at physiological pH. 
The produced iron oxide nanoparticles met the requirements for the magnetic core of the 
theranostic system proposed in this PhD thesis. 




 Production and characterization of chitosan and O-HTCC coating 
The development of the chitosan-based coating was first obtained by depolymerized of chitosan 
in a simple and rapid procedure. Five different molecular weight chitosan were successful ob-
tained. Using chitosan of different molecular weights, O-HTCC was synthesized. Then, both chi-
tosan and O-HTCC were used to produce polymeric nanoparticles. The optimized polymeric na-
noparticles obtained have an average hydrodynamic diameter within the range of 100-200 nm. 
This is ideal size for intravenous administration since it evades being retained in the spleen, or 
being removed from the circulation by extravasation and renal clearance, improving the blood 
circulation time. Zeta potential measurements confirmed that the produced polymeric nanoparti-
cles have a positive charge and are stable in aqueous solution.  
The incorporation of iron oxide nanoparticles in the polymeric ones demonstrated that the hydro-
dynamic diameter of coated nanoparticles increases, being dependent on the polymer molecular 
weight. Iron oxide nanoparticles coated with low molecular weight chitosan show an average 
hydrodynamic diameter of around 250 nm, which may cause the retention of these nanoparticles 
in the spleen. As such, the production of chitosan-coated iron oxide nanoparticles should be fur-
ther optimized. 
 Production of monoclonal antibody anti-CA IX 
This aimed the achievement of highly specific target theranostic system. The presence of CA IX 
was demonstrated in two cell lines of solid tumors: osteosarcoma and breast cancer. Although it 
is a preliminary conclusion, the developed multifunctional system is not only suitable for osteo-
sarcoma theranostic, but also for theranostic of other solid tumors such as breast cancer. 
At least one hybridoma producing monoclonal antibodies anti-CA IX from each immunization 
was obtained: whole protein, central peptide, and N-terminal peptide. Recloning and purification 
steps are still required before attaching the produced monoclonal antibody to the theranostic sys-
tem developed. 
 Suitability as theranostic agents 
The developed parts were tested for the functions that the theranostic system is expected to fulfil. 
As such, iron oxide nanoparticles with and without polymeric coating were tested as magnetic 
hyperthermia agents, and as contrast agents for magnetic resonance imaging. Polymeric nanopar-
ticles with and without iron oxide were studied as drug delivery systems for doxorubicin. Finally, 
cytotoxicity assays were performed for all samples. 




Magnetic hyperthermia tests revealed that pristine Fe3O4 NPs have a SAR of 100 W.g-1 for an 
iron concentration of 125 mM at 24 kA.m-1 of the AC magnetic field strength and frequency of 
418.5 kHz. Stabilization with tri-sodium citrate at 10 mM reduces SAR value to 50 W.g-1, while 
oleic acid at 64 mM causes a reduction even higher, to 20 W.g-1. To better understand these dif-
ferences, Brownian and Néel relaxation times were calculated in water and agar dispersions. The 
obtained conclusion is that both pristine and tri-sodium citrate stabilized Fe3O4 nanoparticles have 
a large contribution of the Brownian movements for the heat generation, when in water disper-
sions. Oleic acid forms a bilayer that entraps the iron oxide nanoparticles, thus limiting their 
movements. Consequently, the generated heat in the latter case is only due to the Néel relaxation, 
thus SAR value being smaller. The same behavior is observed when polymer-coated iron oxide 
nanoparticles are subjected to the AC magnetic field, leading to the conclusion that chitosan en-
traps the nanoparticles and limits their movements. 
NMR measurements where performed for the most stable iron oxide nanoparticles produced, the 
ones stabilized with 96% of oleic acid. The promising results showed that the longitudinal relax-
ation time is slightly altered, while the transverse relaxation time remarkably increases. As such, 
these nanoparticles have potential as negative contrast agents for magnetic resonance imaging, 
although further tests are required to define the working conditions and reliability. 
Drug delivery studies were performed in polymeric nanoparticles with and without iron oxide 
nanoparticles incorporated. Optimization of the experimental parameters led to a doxorubicin en-
capsulation above 70% in chitosan nanoparticles and 50% in O-HTCC nanoparticles. The incor-
poration of iron oxide nanoparticles in the polymeric ones did not change the encapsulation effi-
ciency of doxorubicin. The release of doxorubicin from polymeric nanoparticles has a burst effect 
in the first hours, reaching a plateau after 8 h-10 h, in some cases extended to 24 h. Moreover, 
doxorubicin release in pH-sensitive: at pH 4.5 doxorubicin release in enhanced, while at physio-
logical pH the release is slower. Incorporation of small amounts of iron oxide nanoparticles into 
polymeric ones enhances doxorubicin release; however, higher amounts (6 mg) of iron oxide 
nanoparticles have the opposite effect. 
Fitting mathematical models to experimental data of doxorubicin release some differences be-
tween samples were found. Doxorubicin release occurs by an anomalous release mechanism, alt-
hough the diffusion mechanism dominates in not freeze-dried polymeric samples. In freeze-dried 
samples of chitosan nanoparticles, both Fickian diffusion and polymer relaxation have an im-
portant contribution to DOX release mechanism. The incorporation of iron oxide nanoparticles 
does not clearly change the doxorubicin release mechanism. However, it has influence in the 
polymer relaxation, thus facilitating drug release by Fickian diffusion. The incorporation of a 




higher amount of iron oxide nanoparticles has an opposite effect, decreasing the contribution of 
Fickian diffusion for doxorubicin release from the polymer matrix. The protonation of chitosan’ 
amino groups at pH 4.5 (below its pka) also facilitate doxorubicin release by Fickian diffusion, 
although polymer relaxation also plays an important role in the release mechanism. 
Cytotoxic assays in vitro demonstrated that pristine and tri-sodium citrate iron oxide nanoparticles 
are not cytotoxic in the tested range of concentrations. Oleic acid-coated iron oxide nanoparticles 
cause a reduction in cell viability for concentrations above 250 g.ml-1. Polymeric nanoparticles 
also did not show significant cytotoxicity in the tested range of concentration, for both Vero and 
SaOs-2 cell lines. 
The integration of all components is the great novelty of this work. Overall, the results led to 
conclude that to construct a theranostic system for magnetic hyperthermia, magnetic resonance 
imaging, and drug delivery might contain: 
 Superparamagnetic iron oxide nanoparticles produced by either chemical precipitation or ther-
mal decomposition techniques with an average diameter of 9 nm and saturation magnetization 
of 58 emu.g-1; 
 Coating the iron oxide nanoparticles with either chitosan or O-HTCC, preferably of low mo-
lecular weight, having the coated nanoparticle an average hydrodynamic diameter of 250 nm; 
 Encapsulation of doxorubicin into polymer-coated iron oxide nanoparticles with a maximum 
encapsulation efficiency of about 95%. 
The theranostic system produced in the above-described conditions is able to release 31% of the 
encapsulated doxorubicin in physiological pH (e.g. blood), 74% in the tumor microenvironment 
(pH 6.5) and 82% if the system is internalized by tumor cells (pH 4.5, lysosomes). These condi-
tions are set using chitosan as the coating. If instead the coating chosen is O-HTCC, the released 
DOX is lower: 25% at pH 7.4, 67% at pH 6.5, and 59 % at pH 4.5. 
These theranostic systems are also able to generate heat by the application of an external alternat-
ing magnetic field. The efficiency of the system depends upon the used coating and the core. 
Thus, specific absorption rate (SAR) values vary from 6 to 86 W.g-1, using an iron concentration 
of 6.3 mM. 
Table 8.1 and Table 8.2 resume the optimal conditions obtained for the theranostic core, and for 
the theranostic system, respectively.  
To confirm the functionality and define precisely its working conditions future work needs to be 
performed. 




Table 8.1.Optimal conditions obtained from the experimental word during this PhD thesis for the 
theranostic core: average diameter measured by transmission electron microscopy (TEM), saturation mag-
netization (MS), total amount of doxorubicin (DOX) released over 72 h; specific absorption rate (SAR) 
obtained from magnetic hyperthermia measurements; and relaxation times T1 and T2 obtained from nuclear 








Fe3O4 TX Fe3O4 TD 
Average 
diameter 
TEM (nm) 8.5 9.1 8.5 8.6 8.0 
Magnetic 
properties 





(%, 72 h) 
pH 4.5 96 94 96 
N/A 
N/A pH 6.5 58 55 39 
pH 7.4 24 31 32 






T2 (mMs)-1 88.4 
N/A – data not available. 
1SAR values were obtained using the following conditions: field intensity of 24 kA.m-1; frequency of 418.5 
kHz; 10 minutes of field application; 1 ml of samples; and average iron concentration of 60 mM. 
2NMR measurements were performed in the most stable sample; iron oxide nanoparticles obtained from 
chemical precipitation technique and stabilized with 96% of oleic acid, with respect to Fe3O4 nanoparticles 
mass, at physiological pH, 7.4. 
  




Table 8.2. Optimal conditions obtained from the experimental word during this PhD thesis for the 
theranostic system: average hydrodynamic diameter (DH) measured by dynamic light scattering, total 
amount of doxorubicin (DOX) released over 72 h; and specific absorption rate (SAR) obtained from mag-
netic hyperthermia measurements. 
Coating 
composition 

































66 82 84 81 35 66 59 56 56 59 
pH 
6.5 
62 74 78 65 43 52 67 61 44 54 
pH 
7.4 
13 31 36 33 18 23 25 26 30 15 
SAR (W.g-1)1 N/A 41 52 63 6 N/A 77 86 14 35 
N/A – data not available. 
1SAR values were obtained using the following conditions: field intensity of 24 kA.m-1; frequency of 418.5 
kHz; 10 minutes of field application; 1 ml of samples; and iron concentration of 6.3 mM (the same iron 
concentration used in drug release studies). 
8.2. Future work 
The work presented in this PhD thesis is just the beginning of a larger amount of work that still 
has to be done defined the applicability and suitability of this technology in cancer treatment. This 
section will start with the future work related to each part of the theranostic system and ends with 
future to the final theranostic system. 
 Core of the theranostic system 
In this PhD thesis, iron oxide nanoparticles were synthetized and characterized as the core of the 
proposed theranostic system. However, some improvements can be performed in this regard: 




 Adoption and optimization of other synthesis methods of iron oxide nanoparticles. 
Several methods for the synthesis of iron oxide nanoparticles are described in the literature. In 
this PhD thesis, only two methods were used. Chemical precipitation technique was optimized to 
obtain stable and superparamagnetic nanoparticles, while thermal decomposition was not so ex-
tensively evaluated. The later one is very useful to produce monodisperse and highly stable na-
noparticles. Similarly, other available methods have been described to produce stable and super-
paramagnetic nanoparticles. 
 Incorporation of other materials in the core of the theranostic system. 
Magnetic nanoparticles may have different compositions other than iron oxide. Materials such as 
iron in combination to iron oxides have shown a remarkably similar spinel structure to magnetite, 
with similar or improved magnetic properties. 
On the other hand, non-magnetic materials can be incorporated into the theranostic system’ core 
to improve its performance. For example, conjugation of gadolinium with iron oxide has demon-
strated synergetic effects in magnetic resonance imaging 
 Chitosan-based coating 
The development of an ideal coating for a theranostic system needs to be adapted for the required 
applications. In this case, chitosan and O-HTCC were studied as possible coatings for iron oxide 
nanoparticles. Although the production of chitosan-based nanoparticles was optimized, additional 
studies need to be made: 
 Improve the core incorporation into the polymeric nanoparticle. 
Incorporation of iron oxide nanoparticles into chitosan-based nanoparticles was successful. How-
ever, in this work is lacking different characterizations to confirm this successful incorporation. 
Furthermore, the obtained coated nanoparticles have an average hydrodynamic diameter of at 
least 250 nm for the lowest molecular weight tested. Considering that this system still lacks the 
monoclonal antibody and the drug, the obtained size is too large for intravenous administration. 
As such, other methods should be tested to optimize the size of coated nanoparticles. 
 Study the feasibility of other chitosan-based coatings. 
In this work, only chitosan and O-HTCC were tested as coatings for the theranostic system. In 
Chapter 4 some chitosan derivatives were described, which have different properties than chitosan 




or O-HTCC. As such, some of these derivatives could be tested as alternative coatings for the 
theranostic system. 
In addition, chitosan is often used as a grafting into other polymers with specific properties. For 
example, chitosan has been used in combination with poly(N-isopropylacrylamide) (PNIPAAm) 
to incorporate iron oxide nanoparticles into PNIPAAm microgels. These microgels are able to 
maintain the thermosensitivity of PNIPAAm combined with the properties of magnetic proper-
ties, making them appropriate for magnetic hyperthermia or magnetic resonance imaging. 
 Theranostic system 
The proposed theranostic system in this PhD thesis is composed of four basic components: a 
magnetic core, a chitosan-based coating, a monoclonal antibody, and an incorporated drug. Alt-
hough each one of these parts was extensively studied and evaluated for the proposed functions, 
the complete system was not assembled. Still much work is needed in this regard. 
 Assemble the complete theranostic system and evaluate its functionality. 
The complete assemble of the theranostic system is by itself a challenge. Grafting the monoclonal 
antibody to the polymeric coating by covalent bonds while maintain the nanoparticle structure 
may be hard to accomplish. Furthermore, the complete assemble of the system can influence the 
properties of the individual parts. As such, after complete assembling, the most important prop-
erties such as hydrodynamic size, superparamagnetism, ability to generate heat by the application 
of an external magnetic fields or to enhance contrast in magnetic resonance imaging, must be 
evaluated.  
 Evaluate the in vitro lyse capacity of the theranostic system 
After complete assembling of the theranostic system and confirmation of its reliability, still is 
needed to confirm its functionality to kill cancer cells in vitro. For that, the interaction of the 
system with tumoral and non-tumoral cells has to be accessed before naming the system specific 
for cancer cells.  
Moreover, application of magnetic hyperthermia in vitro was performed in this PhD thesis as a 
preliminary study. As such, further studies need to be performed. 
 Evaluate the in vivo biodistribution and anti-tumoral activity 
When the theranostic system is fully characterized and proved to be effective in vitro, biodistri-
bution and in vivo anti-tumoral activity tests can be performed. In this final stage, the four main 




functionalities of the proposed theranostic systems are to be evaluated: high specificity for solid 
tumors such as breast cancer or osteosarcoma; drug delivery system; magnetic hyperthermia 
agents; and contrast agent for magnetic resonance imaging. Although this final task is still far of 
being concretized, it should be the main target of future work. 
8.3. Summary 
The development of theranostic systems has been a growing research topic due to its possible 
great ability to selectively kill cancer cells. The research developed during this PhD thesis aimed 
to contribute to a step forward in this field. The obtained results and the main conclusions provide 
the basis for the development of the final theranostic system. Furthermore, the suggested future 
work allows attaining the final theranostic construct for osteosarcoma theranostic. An important 
conclusion to retain from this PhD work is the multifunctionality of the developed theranostic 
system. Although the purpose was osteosarcoma, this system can be applied for other solid tumors 
with proper adjustments. 
Cancer theranostic is currently a hot topic and clinical application of these systems should be 
coming soon. 
